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SUMMARY
This document is the culmination of my work on antibody design. Primarily, my target
system is HIV with some work on Influenza. It is divided up into orthogonal publications,
with each publication having incorporated an aspect of antibody design. Here I use the
modeling suite ROSETTA whenever I mention in silico solutions to design problems. All
computational work was done by me as well as validation with the experimental character-
ization.
The introduction in chapter I outlines four pieces of background knowledge that must be
considered for the remaining chapters to become clear. I first detail antibodies in general, as
this document only considers immunoglobulins as the design target of interest. I detail their
purpose and how they are diversified to create an immunoglobulin repertoire. I next detailed
the pandemic of HIV, its structure, the current state of an efficacious vaccine, and describe
the broadly neutralizing antibodies that have been characterized to date. I also describe
the molecular modeling suite ROSETTA and briefly cover the ROSETTA energy function.
I detail a particular application in ROSETTA known as ROSETTADESIGN, which is the
focus of my thesis. I then describe how ROSETTADESIGN has been used in translational
medicine. Lastly I detail the current state of the field, the difficulties in molecular modeling,
the challenges in protein design, and how this work can be used to aid in these challenges.
Briefly, I describe how antibody design is used to answer questions about basic science to
implications for vaccine strategies. It is here that I tie antibody design with all aspects of
my research.
The beginning of my research starts in chapter II. This part of my research aims to
answer a basic question in immunology. Here I used ROSETTADESIGN to investigate the
molecular basis for polyspecificity. It is known that a finite set of antibodies is able to ac-
commodate a nearly limitless antigen space. Using design, I investigated which sequences
are ideal to bind multiple antigens or single antigens in a protocol I used called multi-state
v
design.
Using the strategies and principles built upon in chapter II, chapter III focuses on a
novel vaccine paradigm. Here I used antibody design to interrogate the HIV-naïve donor
antibody repertoire with a simple goal in mind: Does the HIV-naïve antibody repertoire
contain antibodies that resemble known broadly neutralizing antibodies? This paradigm
focuses on a structural mimicry rather than a sequence identity, which not only allows me
to use ROSETTADESIGN and homology modeling as a tool to investigate this hypothesis,
but mandates it, showing the necessity of molecular modeling. All antibodies found in this
chapter were made experimentally and characterized to corroborate computational findings.
In chapter IV, I used ROSETTADESIGN to show that the antibody PG9, which is known
to be one of the most broad and potent antibodies against HIV-1 characterized to date, still
has room for improvement. Mutations were returned from ROSETTADESIGN which were
predicted to enhance breadth and specificity. These mutations were tested experimentally
and did indeed corroborate our hypothesis that even the most broad and potent antibodies
could be improved with careful computational design and analysis.
Finally, chapter V details future directions I foresee for these project. These strategies
are generalizable and can be applied to any given antibody/antigen system and may even
extend to any given protein-protein interface. In addition, I consider reasons for design fail-
ures, imperfect sequence recovery, and antibodies that failed to corroborate in silico pre-
dictions. I give an idea of many future experiments that could be used to take of advantage
of the information detailed in this document. I also detail some of my other work on viral
escape assessed by computational modeling and broadly neutralizing mAbs to Influenza
which were in various stages of completion.
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CHAPTER I
Introduction
I.1 Antibody Overview
The lymphocytes that make up the adaptive immune system have evolved to recognize a
limitless number of antigens that constitute viruses, bacteria and all foreign material to a
hosts immune system (Murphy et al., 2007). The concern of this thesis is on the antigen-
recognition molecules of the B-cell known as immunoglobulins (Ig). These can exist either
as a membrane-anchored form on the B-cell known as the B-cell receptor (BCR) or as a
secreted form with a wide range of functionality known as antibodies. The main effector
function of antibodies is to bind foreign pathogens in the body, and this is the basis for the
adaptive immune response. Antibodies have two separate functions. One is to bind specif-
ically to molecules known as antigens. The other is to recruit other cells and molecules
to destroy the pathogens to which immunoglobulins are bound. There are two genetic do-
mains that make up the antibody structure and differentiate these processes (figure I.1).
One is the variable domain responsible for specificity. The other is the constant domain
that engages different effector functions such as complement recruitment and phagocytosis
of compromised cells. Structurally, antibodies consist of two identical heavy chains, that
are encoded by recombined gene segments of the heavy variable and constant domain gene
segments, and two identical light chains, that are encoded by recombined copies of light
chain variable and constant domains gene segments.
The variability of antibodies is what ensures that any individual with a functional im-
mune system can produce antibodies to recognize almost any structure. The mechanisms
of variability are discussed in further sections but are typically distributed to the tips of
the antibody. It is important to note that B-cell bound receptors and effector functions of
antibodies play important roles in the humoral immune system, but the remainder of this
1
Figure I.1: Overview of antibody structure. Heavy chain is shown in blue, light chain in
grey. The structure is divided into the variable portion responsible for recognition, and the
constant portion responsible for effector function. The tips of the antibodies are where anti-
gens typically bind and are therefore known as the antigen binding sites. Image reproduced
from http://crdd.osdd.net/raghava/absource/abasic.html.
document will focus on the diversity and specificity of secreted antibodies of the IgG class,
the most common circulating immunoglobulin.
I.1.1 Antibody Diversification
The antibody genes that encode heavy and light chains are located in three primary lo-
cations in the human genome: heavy chain genes (IGH) are located on chromosome 14,
light chain kappa genes (IGK) are located on chromosome 2, and light chain lambda genes
(IGK) are located on chromosome 22 (Brochet et al., 2008). Each of these loci consists
of multiple variable (V, not to be confused with the variable region of an antibody) and
joining (J) gene segments. In addition, the IGH locus also contains several diversity (D)
gene segments. Sequencing of the human IGH locus revealed 55 functional V genes, 23 D
genes, and six J genes (Matsuda et al., 1998; Lefranc et al., 2009).
The human variable genes (and, at the IGH locus, the diversity genes) can be grouped
phylogenetically into families based on sequence similarity. Heavy chain variable genes
are organized into seven families and homology within gene families is typically above
80%. The 23 functional human diversity genes are also organized into seven families. For
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an example variable gene, IGVH5-15*01, the standard IMGT nomenclature for human
V and D genes follows the following pattern: the chain and gene description (IGHV for
variable genes, IGHD for germline genes), the family (5 in this example), the gene number
(determined by position in the germline locus, 15 in this example), and the allele. The gene
number is separated from the family with a hyphen and the allele is separated from the gene
number with an asterisk.
I.1.1.1 Recombination to Enable Diversity
The tremendous sequence and structural diversity of antibodies can be attributed to two
immunologic processes that act on antibody germline gene segments. The first is the ini-
tial recombination initiated by the recombination activating gene machinery (RAG) (Brack
et al., 1978; Alt and Baltimore, 1982; Tonegawa, 1983; Schatz et al., 1989; Oettinger et al.,
1990). The RAG machinery is responsible for the recombination of V, D, and J gene for
the heavy chain, and the V and J gene for the light chain (figure I.2, left-panel). This pro-
cess takes place to make functional B-cell receptors in the bone marrow, before antigenic
stimuli. If a B-cell receptor is found to bind self-antigens of the host, it is eliminated. This
clonal selection and deletion is the fundamental process for which antibodies are able to
recognize foreign antigens while not attacking the host.
Recombination signal sequences (RSS), which flank V, D and J genes and are composed
of conserved AT-rich heptamer and nonamer sequences separated by spacers of either 12
or 23 nucleotides, are recognized and bound by recombination activating gene (RAG1 and
RAG2) encoded proteins at the initiation of the recombination process (Hesse et al., 1989;
Alt et al., 1992). Recombination typically occurs only between RSS elements of differ-
ent spacer lengths, in a model commonly referred to as the 12/23 rule of recombination
(Ramsden et al., 1996; Steen et al., 1996; van Gent et al., 1996; Schatz and Ji, 2011). After
binding to one 12-bp RSS and one 23-bp RSS, the RAG complex induces single-strand
DNA nicks between the coding sequence and the heptamer of each RSS, resulting in hair-
3
Figure I.2: Overview of Antibody Recombination. Diversity in the antigen-combining
site of the B-cell receptor repertoire (and thus also in the corresponding secreted antibody
repertoire) is mediated by three principal molecular mechanisms, illustrated in the three
panels, left, middle, and right. Figure adapted from (Finn and Crowe, 2013).
pin formation on each of the coding ends and a blunt double-stranded break on each signal
end (Roth et al., 1992; Schlissel et al., 1993; McBlane et al., 1995; Sadofsky, 2001). The
hairpins are opened with another components of the RAG mutation machinery known as
Artemis (Ma et al., 2002). Nucleotides may be added or removed from the coding ends,
and the double strand breaks at the coding ends are joined into a single coding strand with
DNA ligase IV (Lewis, 1994; Mahajan et al., 1999; Shockett and Schatz, 1999; Walker
et al., 2001; Mansilla-Soto and Cortes, 2003; Roth, 2003) (figure I.2, middle panel). The
newly recombined gene produces an antibody (figure I.2, right panel). Recombination of
the light chain is similar but the result of a single VLJL recombination. To establish a di-
verse naïve antibody repertoire, that is, antibodies that have not encountered antigens, these
events of RAG-mediated recombination produce an initial repertoire of 3 x 1011 different
recombinations. This process happens before antigen stimulus in the bone marrow leading
to the next form of antibody diversity, somatic hypermutation.
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I.1.1.2 Somatic Hypermutation to Enable Diversity
Maturation of the antibody repertoire to hone specificity is known as somatic hypermuta-
tion (SHM) and is initiated by the somatic hypermutation machinery (SHMM). Somatic
hypermutation is the response to antigen stimulus and occurs in various lymph tissues to
diversify the antibody repertoire (Tonegawa, 1983; Brenner and Milstein, 1966).
Naïve, antigen-inexperienced, B-cells undergo the SHM process upon recognition of an
infectious agent. It is through the SHM process, which occurs primarily in lymphoid tissue,
mutate the variable region of their antibody genes (figure I.3) (Li et al., 2004; MacLennan
et al., 1992). Many of these mutations have no effect on antigen recognition and many
have deleterious effects on either antigen recognition or proper folding of the antibody
protein. However, some mutations produce antibodies with improved affinity for the tar-
get pathogenic epitope (Casali et al., 2006). Thus, the SHM process provides a basis for
the positive selection of high affinity antibodies that are characteristic of a mature im-
mune response (MacLennan, 1994). SHM introduces point mutations at a frequency of
approximately 1 in 103 per base pair, which is 106-fold higher than the rate of spontaneous
mutation in other genes (Rajewsky et al., 1987). Activation-induced cytidine deaminase
(AID) is required for SHM and initiates the SHM process by the deamination of cytosine
nucleotides, which results in the conversion of cytosine to uracil (Muramatsu et al., 2000,
1999). Deamination thus produces a uracil-guanine mismatch, and several processes re-
sult in the error-prone repair of the mismatch. The precise mechanism(s) responsible for
error-prone repair during SHM are not known, although several DNA repair mechanisms
have been shown to be critical to the SHM process, including base excision repair and mis-
match repair (Phung et al., 1998; Rada et al., 1998; Wiesendanger et al., 2000; Di Noia and
Neuberger, 2002; Zheng et al., 2005).
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Figure I.3: Somatic mutations in response to antigen stimulus. The VH gene and VL gene
are shown for various VH and VL pairs represented by blue and green lines. The CDR loops
H1-H3 and L1-L3 are darkened. The pink dots represent mutations. The early response
has little to no somatic mutations recapitulating naïve repertoire. The late and response
starts developing mutations. A second challenge with the same antigen shows even more
mutations to hone specificity. Figure adapted from (Berek and Milstein, 1988), redrawn by
C., Scotti.
I.1.1.3 Implications for Antibody Structure
Antibody complementarity determining regions (CDRs, also referred to as hypervariable
regions, figure I.4) are the primary region of antigen recognition that lie in loop regions of
the antibody framework (figure I.4). They are preferentially targeted for affinity matura-
tion by the SHM machinery, making them the most variable regions of the antibody gene
(Padlan and Padlan, 1994). Structurally, the CDRs are largely loop-based, which makes
them sufficiently flexible to incorporate the substitutions without compromising structural
integrity. Framework regions (FRs) are highly structured and less able to accommodate
somatic mutations (Jimenez et al., 2003).
I.2 HIV Pandemic Overview
HIV-1 is an unprecedented health problem that continues to remain a worldwide pandemic.
Since the recognition of acquired immune deficiency syndrome (AIDS) in 1981 (Gottlieb
et al., 1981) followed by the discovery of its causative agent, human immunodeficiency
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Figure I.4: Antibody structure with CDRs.The light chain in green with the LCDRs not
pictured. The heavy chain is shown in yellow with the HCDRs shown in red. Figure
adapted from PDB: 1IGT (Harris et al., 1997).
virus (HIV) in 1983 (Barré-Sinoussi et al., 1983), an estimated 65 million have been in-
fected with over 25 million deaths (Hemelaar, 2012). The amount of people estimated
to living with HIV is 30 million, many of whom live in the developing world (UNAIDS,
2013).
More than 40 different non-human primate species harbor SIV infections, with each
species carrying a species-specific virus. Each independent zoonotic transmission can gen-
erate a different lineage. HIV type 1 (HIV-1), thought to be transmitted from chimpanzees
in the Congo around 1900 (Keele, 2006), is the most common and further is split into
groups M, N, O, and P. HIV-1 group M is responsible for the global pandemic and is fur-
ther split into subtypes clades A-D,F-H, J and K that are tropic to specific regions. Within
each subtype, variation of the amino acids vary as much as 30%. For example, clade B
is the most common in North America while clade C is the most common in Sub-Saharan
Africa (figure I.5). If full genome sequences are found that result from recombinations
of different HIV-1 group M subtypes, they are designated circulating recombinant forms
(CRFs). If they are epidemiologically linked or unique recombinant forms they are un-
linked recombinant form (URF) (Robertson et al., 2000).
A major contributing factor to HIV spread and defense is its potential for enormous ge-
netic diversity. This genetic diversity stems from the error rates of the reverse-transcription
7
Figure I.5: Global distributions of HIV-1 subtypes. In the main figure, pie charts represent-
ing the distribution of HIV-1 subtypes and recombinants from 2004 to 2007, colored by
HIV-1 subtype. Adapted from UNAIDS report 2013.
.
machinery which lacks proof-reading capabilities (Ho et al., 1995). This genetic diversity,
particularly in the envelope gene (Env), gives rise to sequence divergence of up to 10%
within a single individual (Korber et al., 2001). This is one of the many defense mecha-
nisms HIV uses to evade host response and contemporary vaccination strategies.
I.2.1 The HIV Virus Genome and Structure
HIV-1 is an enveloped virus containing a duplicate positive-strand RNA genome (figure
I.6, left panel). The functional spike on the surface of the virion is the envelope (Env)
glycoprotein and is coded by the Env gene (figure I.6, right panel). The Env glycoprotein
complex is originally produced as a single-chain glycoprotein precursor, gp160, which is
cleaved by a cellular protease. Cleavage of gp160 results in the cell-surface attachment
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protein gp120 and the membrane-spanning protein gp41. The gp160 cleavage products
are noncovalently linked and assembled into a trimer of gp120-gp41 heterodimers that are
expressed on the virion surface (Kowalski et al., 1987). Gp120 is heavily glycosylated, with
nearly half the total mass being the result of N-linked glycans (Poignard et al., 2001). It is
composed of five variable regions (V1-V5) interspersed with five constant regions (C1-C5)
(Starcich et al., 1986). The principal function of the glycoprotein spike is to facilitate cell
entry by binding to the primary cell-surface receptor, CD4, and one of the two common
co-receptors, CCR5 or CXCR4. Binding to the receptor and co-receptor is accomplished
by gp120, and fusion of the viral and cell membranes is mediated by gp41 (Zwick et al.,
2001).
The remaining genes for HIV-1 include viral enzymes such as the error-prone reverse
transcriptase, the integrase that allows integration of viral DNA to the host genome, and
protease, to allow cleavage of gene products into their functional subunits. There are also
structural proteins that lie below the envelope that make up the inner matrix and nucleo-
capsid. There are also several accessory proteins, vpu, vif, vpr, p6, nef, rev, and tat which
aid in combating host defense or enhancing viral fitness (Fields et al., 2007). All of these
proteins serve a significant purpose to the virulence and life cycle of the HIV-1 virus, but
will not be discussed further as they have low antigenicity for the induction of antibodies,
the primary focus of my research. However, a list of their genes and gene products can be
found in figure I.6.
I.2.2 The Viral Spike and Humoral Resistance
The failure of conventional experimental vaccine candidates to prime the immune system
for a broad response against HIV-1 challenge is partially explained thorough the structural
definition of the HIV-1 spike. Much of the surface is covered in carbohydrates that shield
neutralizing epitopes (Binley et al., 2010). The conserved CD4 binding site is recessed
and sits behind the hypervariable loops (Burton et al., 2005). The co-receptor binding
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Figure I.6: Simplified view of HIV structure and genome. The proteins that make up the
virus structure are displayed as a schematic. The virus is coded by a duplicated RNA
genome (pink) surrounding by a viral nucleocapsid proteins. The inner envelope is sup-
ported by gag protein with gp120 envelope shown as a trimer bound to gp41. These
trimeric “spike” are responsible for infectivity by binding CD4-binding sites (left panel).
Each gene is represented in a different color and localizes to either the nucleocapsid (green)
or the outer envelope (red). Figure adapted from (Murphy et al., 2007)
site is also recessed unless CD4 has triggered a conformational shift exposing this region
(Harris et al., 2011). Another defense is the relative lability of the trimeric complex (Wyatt
and Sodroski, 1998). The gp120 head often sheds creating “stumps” that serve as decoy
epitopes against the viral complex (Liu et al., 2008). In addition there are few functional
trimeric spikes on the surface of HIV, limiting immune response to a few locations on the
virion.
The biggest defense is sequence variability. Much of the antibody response is targeted
to the hypervariable loops that can easily change sequence without much consequence
to viral fitness. This is why the humoral response produces autologous or strain-specific
neutralizing antibodies that must catch up to a constantly evolving antigenic target (Albert
et al., 1990; Gray et al., 2007; Pilgrim et al., 1997; Richman et al., 2003; Sagar et al., 2006;
Wei et al., 2003).
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I.3 Broadly Neutralizing Antibodies to HIV
Given the major defenses of the HIV Env structure, there is a rather discouraging view for
vaccine development. In fact, only four modestly neutralizing antibodies were discovered
between 1991 and 2009 (Burton et al., 2005; Kwong and Mascola, 2012), two membrane
proximal extracellular region (MPER) binding mAbs 2F5 and 4E10 (Zwick et al., 2001;
Muster et al., 1994), a CD4 binding site neutralizing mAb b12 (Burton et al., 1994), and a
complex carbohydrate binding mAbs 2G12 (Trkola et al., 1996) (table I.1, figure I.7).
It was thought that the conventional vaccine strategies could not stimulate the immune
system to produce broadly neutralizing antibodies to HIV due to the extreme variability of
the viruses and the capability of the virus to escape antibody responses. Recently, technolo-
gies like high throughput neutralization assays were developed that could rapidly test sera
for neutralization capacity in vitro, allowing researchers to accurately quantify the neutral-
izing response of HIV infected patients (Binley et al., 2004; Blish et al., 2007; Li et al.,
2005; Mascola et al., 2005; Montefiori, 2005). Several groups found that there were mul-
tiple patients who could neutralize very genetically diverse panels of HIV variants, even
those variants that were not in that patients sub-type (Binley et al., 2008; Doria-Rose et al.,
2010; Simek et al., 2009; Wu et al., 2006). That led to longitudinal studies to show how
long it took for a broadly neutralizing response to develop. Researchers showed that this
generally took anywhere from 2-4 years (Gray et al., 2011; Mikell et al., 2011; Moore et al.,
2011), with earliest time points arising at 1 year (Doria-Rose et al., 2014). The question
still remained if those neutralizing responses were caused by few monoclonal antibody re-
sponses or just a large polyclonal response (Gray et al., 2007; Binley et al., 2008; Li et al.,
2007; Rong et al., 2009; Sather et al., 2009; Scheid et al., 2009; Tomaras et al., 2011;
Walker et al., 2010).
The question was answered by the recent explosion of newly discovered broadly neu-
tralizing antibodies isolated by multiple research groups (Corti and Lanzavecchia, 2013).
It started with two new isolates, PG9 and PG16, from an African donor that led to the dis-
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covery of a completely new neutralizing epitope, which is the focus of my research (figure
I.7) (Walker et al., 2009). Both PG9 and PG16 bind to a proteoglycan epitope through an
extended HCDR3 structure (McLellan et al., 2011).
The discovery of PG9 and PG16 led to newly characterized antibodies using similar
techniques such as microneutralization screening, high-throughput sequencing, and hy-
bridoma technology. The Haynes laboratory characterized additional long HCDR3 anti-
bodies that bound similarly as PG9 and PG16 but with less breadth (Bonsignori et al.,
2011). There are other classes of glycan-dependent antibodies isolated by the Poignard
group that bind the V3 and beta-strands that are higher potency than PG9 and PG16 (Walker
et al., 2011). Other MPER antibodies have also been characterized to by the Connors group
such as 10e8 that neutralizes 98% of viruses (Huang et al., 2012). Focused epitopes de-
signed computationally also can be used to identity some of the most potent antibodies
to date (the VRC series) (Wu et al., 2010a). These antibodies were identified using a de-
signed protein scaffold of gp120 that “knocked-out” non-neutralizing epitopes. Thus, only
neutralizing antibodies would be isolated upon binding. I will not elaborate further on all
of the antibodies characterized to date, their method of isolation and if any longitudinal
studies were used to determine their pathways of development. These characteristics are
summarized in table I.1 and figure I.7.
It is interesting to note, and important for the work that will be presented here, that the
broadly neutralizing antibodies to date share one of two characteristics. They are either
highly somatically mutated, indicative of years of chronic infection and selective pressure,
or have a very long HCDR3 (figure I.8). Both of these characteristics, long HCDRs or
highly mutated genes, make it difficult to elicit such antibodies in a vaccine attempt, but
will be discussed further in the upcoming chapters.
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Figure 2
Model of the HIV-1 Env trimeric glycoprotein bound to broadly neutralizing antibodies. The tridimensional model of the Env trimer
(Electron Microscopy Data Bank code EM-5019) with two of the three gp120 subunits highlighted in gray was positioned on a
modeled lipid bilayer (64). The left panel shows the major sites targeted by broadly neutralizing antibodies. The approximate
positioning of the V1/V2 and V3 loops is shown, and the CD4 footprint on the gp120 monomer is highlighted in blue. The right panel
shows the Fabs of broadly neutralizing antibodies VRC01 (3ngb), PG9 (3us2), and PGT128 (3tyg) bound to gp120. Carbohydrates
(oligomannose, red spheres) were modeled on the unliganded YU2 gp120 core (3tgq) using GlyProt, with the exception of the glycans
bound by PGT128 and PG9 (depicted with different colors), which were taken from the structures. The location of PG9 above the
trimeric gp120 is approximate; VRC01 and PGT128 Fabs were docked by superposition with the unliganded YU2 gp120 model. The
bottom panel shows in blue the footprints of CD4 (1gc1) and the CD4bs-specific antibodies PGV04 (3se9), NIH45-46 (3u7y), b12
(3dnl), and VRC01 (3ngb). Figures were made with PyMOL.
www.annualreviews.org • Broadly Neutralizing Antiviral Antibodies 711
An
nu
. R
ev
. Im
mu
no
l. 2
01
3.3
1:7
05
-74
2. 
Do
wn
loa
de
d f
rom
 w
ww
.an
nu
alr
ev
iew
s.o
rg
by
 V
an
de
rbi
lt U
niv
ers
ity
 on
 07
/30
/13
. F
or 
pe
rso
na
l u
se 
on
ly.
Figure I.7: Model of the HIV-1 Env trimeric glycoprotein bound to broadly neutralizing an-
tibodies. The left pa el shows the maj r sites targeted by broadly eutralizing antibodies.
The approximate positioning of the V1/V2 and V3 loops is shown, and the CD4 footprint on
the gp120 monomer is highlighted in blue. The right panel shows the Fabs of broadly neu-
tralizing antibo ies VRC01 (3NGB), PG9 (3US2), and PGT128 (3 YG) bound to gp120.
Carbohydrates (oligomannose, red spheres) were modeled on the unliganded YU2 gp120
core (3TGQ) using GlyProt, with the exception of the glycans bound by PGT128 and PG9
(depicted with different colors), which were taken from the structures. The location of
PG9 above the trimeric gp120 is approximate; VRC01 and PGT128 Fabs were manually
positioned by with the unliganded YU2 gp120 model (approximation). The bottom panel
shows in blue the footprints of CD4 (1GC1) and the CD4bs-specific antibodies PGV04
(3SE9), NIH45-46 (3U7Y), b12 (3DNL), and VRC01 (3NGB). Figure adapted from (Corti
and Lanzavecchia, 2013)
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Figure I.8: Trends of HIV bNAbs. Data from a representative panel of 30 antibodies is
shown. Plotted on the y-axis is the frequency of amino acid mutations of the currently
characterized bNAbs. On the x-axis is the length of the heavy chain CDR3 (HCDR3). A
negative correlation exists between the frequency of mutations and the HCDR3 length (r2
= 0.44, left panel). When long HCDR3s (>24 AA) are binned against canonical length
HCDR3s (<24AA), there is a statistical significance between the frequencies of amino acid
mutation (p = 0.0005, right panel).
I.4 ROSETTA
Many software packages exist for the specific tasks of threading, minimization, and design.
The ROSETTA software suite includes algorithms for all of these tasks and was developed
for computational modeling and analysis of protein structures; further, it is free for non-
commercial users. It has enabled notable scientific advances in computational biology,
including de novo protein prediction, protein design, enzyme design, ligand docking and
structure prediction of biological macromolecules and macromolecular complexes (Rohl
et al., 2004; Siegel et al., 2010; Kuhlman et al., 2003; Davis and Baker, 2009; Misura
et al., 2006; Davis et al., 2009; Das and Baker, 2008). The broad spectrum of applications
available through ROSETTA allows for multiple computational problems to be addressed
in one software framework. To aid in the understanding of ROSETTA-specific language, a
supplementary glossary has been provided in Appendix VI.1.
One of the most common applications of ROSETTA is protein structure prediction via de
novo folding and comparative modeling (Kaufmann et al., 2010; Rohl et al., 2004). De novo
15
folding can be used to predict a protein’s tertiary structure when only the primary sequence
of a protein is known. However, to date, ROSETTA has been shown to successfully fold only
small, soluble proteins (fewer than 150 amino acids), and it performs best if the proteins are
mainly composed of secondary structural elements (Meiler and Baker, 2003). Structures
of helical membrane proteins between 51 and 145 residues were predicted to within 4Å of
the native structure (Yarov-Yarovoy et al., 2006), but only very small proteins (up to 80
residues) have been predicted to atomic-detail accuracy (Bradley et al., 2005a,b; Das et al.,
2007). Accurate prediction of larger and/or more complex proteins can be achieved with
the addition of experimental data, such as NMR chemical shifts and electron tomography
maps (Rohl, 2005; Lange et al., 2012; Lange and Baker, 2012).
Another application, protein threading, refers to the tolerance of a tertiary fold given
PDB coordinates. The ROSETTA scoring function evaluates how well a sequence can “’tol-
erate” a structure. It is often referred to as the “inverse folding problem”. The known
template structure of which a sequence will be threaded reduces almost all-conformational
space by providing a protein backbone scaffold. Threading has played a major role in aiding
experimental design and the interpretation of experimental results. Results can be used to
help predict structure-function relationships (Kaufmann et al., 2009), and aid in designing
proteins for binding pathogens (Azoitei et al., 2011; Correia et al., 2010, 2011a,b; Schief
et al., 2009), determining thermostable proteins (Stranges and Kuhlman, 2013; Kuhlman
et al., 2002; Der and Kuhlman, 2011), and aid in the determination of target residues for
site-directed mutagenesis (Keeble et al., 2008; Fortenberry et al., 2011).
I.4.1 The ROSETTA Energy Function
All of the applications described above rely on a metric to score predictive models. This
metric in ROSETTA is referred to as the ROSETTA energy function. The scoring function
in ROSETTA is derived empirically through analysis of observed geometries of a subset
of proteins in the PDB. We call this scoring function a knowledge-based scoring function,
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since it relies on previous knowledge of observed structures. The measurements include,
but are not limited to, radius of gyration, packing density, distance/angle between hydrogen
bonds and distance between two polar atoms. The measurements are converted into an
energy function through Bayesian statistics (Simons et al., 1997; Metropolis et al., 1953).
The scoring function in ROSETTA can be separated into two main categories: centroid-
based scoring and all-atom scoring. The former is used for de novo folding and initial
rounds of loop building (Rohl, 2005; Simons et al., 1997, 1999b). The side chains are
represented as “super-atoms”, or “centroids”, which limit the degrees of freedom to be
sampled while preserving some of the chemical and physical properties of the side chain.
Although this centroid-based scoring function is important for de novo folding, the folding
protocol is not covered within the scope of this document.
The all-atom scoring function represents side chains in atomic detail. Similarly to the
centroid-based scoring function, the all-atom scoring function comprises weighted indi-
vidual terms that are summed to create a total energy for a protein. Most of the scoring
terms are derived from knowledge-based potentials. The scoring function contains New-
tonian physics based terms, including a 6-12 Lennard-Jones potential and a solvation po-
tential. The 6-12 Lennard-Jones potential is split into two terms, an attractive term (fa_-
atr) and a repulsive term (fa_rep), for all van der Waals interactions (Kuhlman and Baker,
2000; Neria et al., 1996). The solvation potential (fa_sol) models water implicitly and
penalizes the burial of polar atoms (Lazaridis and Karplus, 1999). Interatomic electro-
static interactions are captured through a pair potential (fa_pair) (Simons et al., 1999b),
and an orientation-dependent hydrogen bond potential for long-range and short-range hy-
drogen bonding (hbond_sc, hbond_lr_bb, hbond_sr_bb, and hbond_bb_sc, respectively)
(Gordon et al., 1999; Wedemeyer and Baker, 2003). In addition to the electrostatic terms,
the ROSETTA all-atom scoring function contains terms that dictate side chain conforma-
tions according to the Dunbrack rotamer library (fa_dun) (Dunbrack and Karplus, 1993;
Dunbrack and Cohen, 1997), preference for a specific amino acid given a pair of phi/psi
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angles (p_aa_pp), and preference for the phi/psi angles in a Ramachandran plot (rama)
(Rohl et al., 2004; Wedemeyer and Baker, 2003; Ramachandran et al., 1963).
I.4.2 ROSETTA Energy Minimization
When new sequences are threaded, or rebuilt onto target protein structures, it is often nec-
essary to go through a round of energetic minimization. The protein undergoes all-atom re-
finement using the ROSETTA all-atom scoring function to yield an a protein model (Bradley
et al., 2005a). Both threading and docking in ROSETTA involve an all-atom refinement of
the protein. The protocol used for structural refinement, visually described in figure I.9,
is often referred to as “relax”. The goal of the relax protocol is to explore the local con-
formational space and to energetically minimize the protein. During this process, local
interactions are improved by iterative side-chain repacking, in which new side chain con-
formations, or “rotamers”, are selected from the Dunbrack library (Dunbrack and Karplus,
1993); and by gradient-based minimization of the entire model, in which the energy of the
model is minimized as a function of the score. These small structural changes are eval-
uated according to the all-atom scoring function and are sampled in a Metropolis Monte
Carlo method (Metropolis et al., 1953). The “relax” protocol has been shown to markedly
lower the overall energy of the ROSETTA model and is essential to achieving atomic detail
accuracy (Das and Baker, 2008; Bradley et al., 2005b; Rohl, 2005).
I.4.3 ROSETTA Design
Protein design seeks to determine an amino acid sequence that folds into a given protein
structure or performs a given function. The ROSETTADESIGN algorithm is an iterative pro-
cess that energetically optimizes both the structure and sequence of a protein (Kuhlman
et al., 2003). ROSETTADESIGN alternates between rounds of fixed backbone sequence op-
timization and flexible backbone energy minimization. During the sequence optimization
step, a Monte Carlo simulated annealing search is used to sample the sequence space. Ev-
ery amino acid is considered at each position in the sequence, and rotamers are picked from
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Figure I.9: Refinement via Relax. Simplified energy landscape of a protein structure. The
relax protocol combines small backbone perturbations with side-chain repacking. The cou-
pling of Monte Carlo sampling with the Metropolis selection criterion allows for sampling
of diverse conformations on the energy landscape. The final step is a gradient-based mini-
mization of all torsion angles to move the model into the closest local energy minimum (A).
Comparison of structural perturbations introduced by the repack and minimization steps.
During repacking, the backbone of the input models fixed, whereas side-chain conforma-
tions from the rotamer library are sampled (Dunbrack and Karplus, 1993). Comparison
of the initial (transparent yellow) and final (light blue) models reveals conservation of the
R135 rotamer but changes to the R11 and E15 rotamers. Minimization affects all angles
and changes the backbone conformation (B).
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to the Dunbrack library (Dunbrack and Karplus, 1993). After each round of Monte Carlo
sequence optimization, the backbone is relaxed to accommodate the designed amino acids.
The practical uses of ROSETTADESIGN can be divided into five basic categories: design
of novel folds. Redesign of existing proteins, design to enhance knowledge of structure,
enzyme design, and design applied to translational medicine.
I.4.3.1 Design of Novel Folds
The ROSETTADESIGN method was implemented by Kuhlman and colleagues (Kuhlman
and Baker, 2000). The method has been used for the de novo design of a fold that was not
(yet) represented in the PDB (Kuhlman et al., 2003). A starting backbone model consisting
of a five-strand β -sheet and two packed helices was constructed with the ROSETTA de novo
protocol using distance constraints derived from a two-dimensional sketch. The sequence
was designed iteratively with five simulation trials of 15 cycles each. The final sequence
was expressed, and the structure was determined using X-ray crystallography. The experi-
mental structure has an all-atom deviation to the predicted structure of <1.1Å.
I.4.3.2 Redesign of Existing Proteins
When nine globular proteins were stripped of all side chains and then redesigned using
ROSETTADESIGN, the average sequence recovery was 35% for all residues (Dantas et al.,
2003). In four of nine cases, the protein stability improved as measured by chemical de-
naturation. The structure of a redesigned human protein was determined experimentally.
ROSETTADESIGN was then used to systematically identify mutations of carboxypeptidase
that would improve the stability of the protein. All of the tested mutants were more stable
than the wild-type protein, with the top-scoring mutant having a reduction of free energy
of 5.2 kcal/mol.
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I.4.3.3 Design to Enhance Knowledge of Structure
Protein design approaches have enhanced our knowledge of how protein sequence relates to
protein structure. For instance, the finding that designed protein sequences are highly simi-
lar to the native sequence suggests that native protein sequences are optimal for their struc-
ture (Kuhlman and Baker, 2000). Babor and Kortemme investigated the antibody sequence-
structure relationship using ROSETTADESIGN. They demonstrated that native sequences of
antibody HCDR3 loops are optimal for conformational flexibility (Babor and Kortemme,
2009). The authors collected pairs of unbound and antigen-bound antibody structures.
They used multiconstraint design to find low-scoring sequences that were consistent with
both unbound and bound structures. The sequences predicted by multi-constraint design
were more similar to the germline sequences than the sequences predicted to preferentially
bind either the unbound or bound conformations.
I.4.3.4 Enzyme Design
The ROSETTAMATCH algorithm starts from the protein backbone and attempts to build
toward the specified transition state geometry (Zanghellini et al., 2006). In this method,
all possible active site positions are defined for the protein scaffold, and rotamers from the
Dunbrack library are placed at each sequence position in the catalytic site. The sequence
of the area surrounding the catalytic site is then designed. Recently, the ROSETTAMATCH
algorithm was used to design enzymes that catalyze the retro-aldol reaction (Jiang et al.,
2008). The degrees of freedom in the transition state, the orientation of the active site side
chains, and the conformations of the active site side chains were simultaneously optimized.
Of 72 models tested, a total of 32 were found to have catalytic activity as much as four
orders of magnitude greater than that of an uncatalyzed reaction. Two of the active enzymes
were crystallized. The experimental structures shared a high degree of similarity with
the computational design although the loop regions surrounding the catalytic site showed
significant differences from the model.
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Computationally designed functional Kemp elimination catalysts using ROSETTAMATCH
have also been designed. Quantum chemical predictions were used to generate an idealized
transition state model, and ROSETTAMATCH was used to search for backbone configura-
tions that would support the predicted transition state (Röthlisberger et al., 2008).
I.4.3.5 Design Applied to Translational Medicine
The successes of the ROSETTADESIGN algorithm in predicting new sequences that opti-
mize binding and answer questions about protein structure led to its application to more
biomedical applications such as vaccine design and protein therapeutics. Fleishman et al.
used the paratope of an antibody to find hot-spot positions that neutralized influenza. Us-
ing these positions, they designed a protein that would properly present a mimic of the
paratope. The crystal structure of the designed protein structure indicated that it did indeed
present a functional paratope while functional studies confirmed its neutralization capacity
(Fleishman et al., 2011b).
The works of the Schief group have expanded design to explore novel scaffolding ap-
proaches to be used as immunogens. Using ROSETTADESIGN, they presented the epitope
to broadly neutralizing antibodies 2F5 and 4E10 to HIV, which elicited this class of anti-
body in animal models (Correia et al., 2010; Ofek et al., 2010). In addition, the research
group used ROSETTADESIGN to target potently neutralizing antibodies against the CD4
binding site while eliminating binding to non-neutralizing antibodies that bind to decoy
epitopes (Wu et al., 2010a). More recently, this group has used design to mimic an epitope
to respitory syncitial virus (RSV) that is now being tested in animal models (Correia et al.,
2014).
A current major challenge in protein design is the de novo design of a novel protein-
protein interface. So far, the most successful attempts at de novo interface design have
been relatively modest, focusing on small proteins and yielding micromolar affinity (Man-
dell et al., 2009; Huang et al., 2007). This small boost in affinity often requires display
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technology to increase potency and specificity. The ROSETTA community is well aware
of these limitations and work on increasing the accuracy of predicted interface mutations,
particularly around hydrogen bonding networks and explicit solvent models (Combs and
Meiler, 2012).
I.5 The State of the Field
Here I can describe the state of the field in molecular modeling and antibody design. I will
describe molecular modeling as the “folding-problem”, the solution of which, is considered
to be the holy-grail of computational modeling. In a related field which is more applicable
to my work, I describe the “inverse-folding problem.”
I.5.1 The Folding Problem
As described, there have been tremendous advances in computational modeling and it’s role
as a promising surrogate for costly experimentation. However, most work in computational
modeling serves as a proof-of-principle using known model systems as benchmarks. Most,
if not all computational studies at the time of writing require an experimental validation of
the model using the very experimentation for which they are trying to serve as a prediction.
However, experimental structures are only currently available for less than 1/1000th of
the proteins for which sequences are known and that number is expected to increase with
advances in high-throughput sequencing (Moult et al., 2014). To that end, computer-aided
structure prediction is expected to play a major role in helping solve the ever growing
number of structures. But, where is the state of the field?
Computational structure prediction and computational docking have been continually
evaluated in the Critical Assessment of Structure Prediction (CASP) and Critical Assess-
ment of Predicted Interactions (CAPRI) community-wide experiments. These experiments
have been invaluable to the field as they have served as a metric for evaluating the various
international groups attempts to tackle the unsolved problems of protein folding and pro-
tein docking. This has served as a “grand challenge” in computational biology. A physics
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based approach coupled with a knowledge of protein folding pathways were expected to
be the answer to this question, but as so far, knowledge-based approaches like those of
ROSETTA have been the front runners in these assessments. However, physics based meth-
ods are starting to bear fruit, especially for refinement stages of molecular modeling, where
the global fold is known, but full-atom placement is needed to optimize bond angles, dis-
tances and structure free energy.
For small proteins (<100 AA), ab initio methods where a template is not used have
been successful in predicting the overall topology of the structure. ROSETTA fairs par-
ticularly well in this task, as this application was what it was originally developed for
(Simons et al., 1999a). For larger proteins, the view is quite bleak, as an improvement
judged by CASP has only led to an increase of accurately predicted models by 24% in
two decades (Kryshtafovych et al., 2014). This figure is not surprising as the search space
increases exponentially as sequence space gets larger, and sampling methods like those of
ROSETTA eventually hit a computational limit.
Homology modeling appears to be the more suitable method for structure prediction
as it limits the search space to a certain folds. If the target and template sequence are
sufficiently aligned, then many methods have shown to be accurate (as evaluated by CASP).
The number of folds deposited is slowing down, which makes homology modeling a more
viable solution to structure prediction.
Often, a handful of mutations are made to a known structure and it is the desired goal
to model those mutations onto the existing structure and explain the effect at a molecular
level. This is becoming easier to do as refinement stages of modeling progress. A few
mutations often does not change the overall fold of protein molecules and their effects can
be modeled accurately. This type of minimal mutational modeling is now a credible form
of empirical science as it is appearing in more and more high-impact publications were a
full crystal structure or solution NMR structure is not needed. I use this method here to
explain observations to a traditional antibody known as PG9. This is detailed in chapter
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IV.
I.5.2 The Inverse-Folding Problem
The folding problem, which tries to accurately determine a protein structure given an amino
acid sequence must consider many poorly understood principles of folding kinetics and
thermodynamics. The problem is trying to find an accurate globular fold in which the
free energy of the folded structure is considerably more stable than the entropy cost of the
fold. However, this problem has created many all-atom “force fields” that are needed to
evaluate such folds. The all-atom nature of these modeling trajectories created a new class
of problems in the field that could be solved with these “force fields.” Rather than search
for the lowest-energy structure for a given amino acid sequence, researchers are searching
for the lowest-energy sequence for a given protein structure (Baker, 2014). This is known
as the “inverse-folding problem” and less formally known as protein design.
The problems that are relevant to the inverse-folding problem are related to the folding-
problem. They often both use the same scoring function or “force-field”, so a rapid and ac-
curate knowledge- or physics-based approach has been the focus of many research groups.
It is also a matter of exponential conformations that need to be sampled. In the protein-
folding problem, what is the conformations that fit a given sequence. If each the length
of the amino acid sequence, A, where each amino acid can sample N conformations, then
AN conformations are available to a complete sampling strategy. As cited in “Levinthal’s
Paradox”, this is clearly not how proteins fold, and complete computational sampling of
large proteins can’t be completed with current technology (Levinthal, 1969).
The sampling space needed for the inverse-protein is also similar. Instead of conforma-
tions, amino acid identities need to be sampled and scored. The same exponential sequence
space formula is also applied, were a protein of length A, has 20A sequence combinations
to choose from the 20 canonical amino acids in mammalian system. The problem is com-
pounded when several conformations or “rotamers” for each amino acid are considered,
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Figure I.10: Questions answered through antibody design. Vaccine applicability spans
from basic scientific questions using antibody design about specificity. These principles
can be used to enhance specificity. Finally, we can query the immunoglobulin repertoire
using antibody design.
where 20A, no longer constant, but defined by the amount of “rotamers” considered R as
RN . Regardless, protein-design has been far more successful at application driven research
than the ab initio methods. This is due to the reduced sequence space that needs to be sam-
pled. For instance, we can define far fewer positions to be “designed” rather than the entire
protein. We can also only consider certain amino acid identities (for instance, consider only
hydrophobics in a core and hydrophilics in solvent-space). The success of protein-design
is detailed in application driven research in section I.4.3.
I.5.3 Antibody Design Summary
The goal of this thesis exists in three main sections ranging from questions of basic science
to application driven antibody design. However, it is not entirely clear how these concepts
tie together. In figure I.10, I show how antibody design can be used to scale up to vaccine
applicability from answering basic immunologic questions. As the applicability progresses,
one step informs the other. First, I will use antibody design to interrogate a very basic
question about antibody specificity. That is, how does a finite set of antibody structures bind
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a near infinite antigen repertoire? Using principles derived from specificity, I can begin to
redesign known antibodies to enhance specificity, and increase breadth. Finally, I can use
antibody design and how it relates to specificity and breadth to interrogate the antibody
structural repertoire. This answers questions about vaccine applicability. What does a
normal structural repertoire look like? How close is it to forming a broadly neutralizing
antibody that confers protection against HIV? If it is not close, how many mutations are
necessary to achieving broad neutralization? All of these questions I aim to answer using
antibody design with the ROSETTADESIGN application and the model system HIV.
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CHAPTER II
Mechanisms of Polyspecificity
II.1 Introduction
Human antibodies are critical for eradication of viral and bacterial infections, while pro-
viding the basis for immunological memory. Antibody protein molecules are encoded by
several recombined germline gene segments prior to antigen exposure. The initial set of
antibodies that are generated by recombination in the bone marrow is the antigen-naïve
antibody repertoire. It is of great interest to know how a finite set of such germline gene-
encoded antibodies can recognize the large number of possible foreign antigens. A current
hypothesis in the field suggests that antibodies encoded by germline gene segments are
structurally flexible and therefore able to accommodate binding to many antigens, much
like one glove fitting the shape of many hands. The phenomenon of one structure binding
to many unrelated targets is known as polyspecificity. In this chapter, I will describe how I
further support this hypothesis using computational design by showing the entire antibody
protein variable region sequence is close to ideal for polyspecificity by mechanisms of flex-
ibility. I will detail the computational protocol I have developed and the results that suggest
how a finite set of antibody germline gene segments can encode antibodies that can engage
a large number of potential antigens. Computational design of antibodies capable of bind-
ing multiple antigens may allow the rational design of antibodies that retain polyspecificity
for diverse epitope binding, which will be an important to future vaccine design.
II.1.1 Three Models of Protein Binding
Antibodies are encoded by the rearrangement of variable (V), diversity (D), and joining (J)
gene segments into recombined genes that encode a large but ultimately finite number of
unmutated antibody structures, known as the germline repertoire (Tonegawa, 1983). There
are approximately 104 combinations of the V, D, and J heavy chain gene segments and an
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estimated 1011 possible combinations when junctional diversity is considered (Patten et al.,
1996). This number of potential antibodies is far less than the immeasurable number of
epitopes on foreign antigens to which one could be exposed. The germline gene repertoire
therefore encodes a finite number of starting structures in the germline repertoire that must
be capable of recognizing and binding a large and diverse array of antigens (Patten et al.,
1996; Schultz et al., 2002; Collins et al., 2003).
The classical protein binding mechanism was the “lock-and-key” model, where anti-
bodies acquired somatic mutations in order to rigidify a pre-bound structure that would
complement the shape of the epitope (figure II.1A). This mechanism dominated the field
for many years but has to assume that one antibody optimally binds to one particular anti-
gen (Notkins, 2004; James and Tawfik, 2003). The lock-and-key model has many short-
comings, as the “one paratope-one epitope” principle leaves little room to describe the
polyspecificity phenomenon, an antibody’s ability to recognize multiple unrelated antigens.
Polyspecificity has been demonstrated in a variety of biochemical and structural studies,
therefore the “lock-and-key” model cannot possibly describe all antibody-antigen interac-
tions without the existence of multiple paratopes per antibody (Schultz et al., 2002; Yin
et al., 2003; James et al., 2003; Foote and Milstein, 1994). In contrast to the “lock-and-
key” model, a degree of pre-bound structural flexibility are found in two models of antigen
binding, the “induced-fit” and the “conformational flexibility” models. In these models,
germline gene-coded antibodies retain a degree of structural plasticity in their backbone
in order to bind a number of different unrelated antigens. The induced-fit model hypothe-
sizes that upon binding conformational changes are induced to accommodate the interact-
ing structure (figure II.1B) (Notkins, 2004; James et al., 2003).
The conformational flexibility hypothesis in protein binding suggests that an unbound
protein assume a variety of conformations (conformational isomerism), a subset of which
is recognized by the interacting partner (figure II.1C). For antibodies, a large body of work
has attributed polyspecificity to the nature of their germline gene sequences. It has been
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Figure II.1: Three models of protein binding. The “lock-and-key” model assumes the
protein binding site in a pre-bound state is optimized for the shape of the ligand (A). The
“induced-fit” mechanism allows for conformational change after the ligand had bound to
optimize shape in a two-step isomerization (B). For the “conformational flexibility” model,
the pre-bound structure exists in several isomers which the ligand selects the conformation
that complements it’s structure (C). Figure adapted from (James and Tawfik, 2003)
reported that polyspecific antibodies often retain a larger proportion of germline gene se-
quences than more mature, specific antibodies (Notkins, 2004; Chen et al., 1991; Crouzier
et al., 1995; Harindranath et al., 1993).
II.1.2 Evidence for Conformational Flexibility
Conformational flexibility is emerging as an important hypothesis to explain both polyspeci-
ficity and changes in affinity between germline and mature antibody sequences (Schultz
et al., 2002; Notkins, 2004; James and Tawfik, 2003; Yin et al., 2003; James et al., 2003;
Foote and Milstein, 1994; Romesberg et al., 1998; Manivel et al., 2000; Yin et al., 2001;
Nair et al., 2002; Jimenez et al., 2003; Li et al., 2003; Mohan et al., 2009; Marlow et al.,
2010; Wong et al., 2011; Davies and Cohen, 1996; Mohan et al., 2003; Wedemayer et al.,
1997; Zimmermann et al., 2010). The first evidence for conformational isomerism in an-
tibodies was observed through kinetic experiments in which antibodies show a triphasic
distribution that, in some cases, appears to reflect the existence of multiple isomers of
the unbound antibody in solution, in the pre-equilibrium state (James et al., 2003). To
determine the dynamics of the binding process, James and colleagues examined the pre-
steady-state kinetics of complex formation between SPE7 and DNP-Ser, as well as between
SPE7 and the hapten cross-reactants. The kinetics confirmed the existence of an equilib-
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rium in solution between two preexisting isomers, only one of which bound the haptens.
Pre-steady-state binding kinetics were analyzed by monitoring changes in SPE7’s intrinsic
fluorescence upon rapid mixing with ligand.
In 1997, Wedemayer and colleagues found a structural basis for conformational flexi-
bility observed for germline antibodies (Wedemayer et al., 1997). They solved the crystal
structures for a germline antibody with and without its target hapten, and mature antibody
with six somatic mutations that bound the target hapten 30,000 times stronger than the
germline counterpart. They noticed that the rigid-body deviation in the crystal structure
was significant between the bound and unbound germline antibody structure indicating a
degree of flexibility. In contrast, the mature antibody had less structural deviation upon
hapten binding. They showed that the somatic mutations observed in the mature antibody
stabilize the binding sites either directly or indirectly by locking the structure into the pre-
bound conformation. This was the first indirect evidence showing that germline encoded
antibodies may be more flexible than the mature sequences due to the intrinsic properties
of the sequence.
More recently, structural studies along with computational tools have corroborated
these findings by showing direct evidence that antibodies encoded by germline gene se-
quences retain flexibility in their HCDR3 loops (Wong et al., 2011; Babor and Kortemme,
2009). For example, Babor et al. redesigned germline or mature HCDR3 loops in an-
tibodies that had been crystallized in free or antigen-bound states (Babor and Kortemme,
2009). These investigators found that germline gene-encoded HCDR3 sequences are nearly
optimal for conformational flexibility. The study, while exceptional in its concept, was lim-
ited as the dataset contained many antibody/hapten (non-protein) complexes, which may
not reflect the biology of interactions with larger protein targets that are more typical in
foreign pathogens. Some antibodies classified as “germline” in the study were not from
antigen-naïve cells. Further, that study exclusively analyzed the HCDR3 loop, not the en-
tire variable region.
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Schmidt et al. used molecular dynamics simulations and structural analysis to deter-
mine how mutations in the antibody variable domain enhance antigen binding to the in-
fluenza virus HA protein (Schmidt et al., 2013). In the study, they found two broadly
neutralizing antibodies that have branched in lineage from a common intermediate, and an
unmutated common ancestor (UCA) in which they obtained high-resolution crystal struc-
tures. They found that even though the UCA and mature antibodies have nearly identical
binding configurations, the affinity for influenza for the mature antibodies was 40-fold
greater than the UCA. Molecular dynamics simulations predicted that the paratope in un-
bound UCA was not in an optimal conformation for binding, while the mature antibodies
had a higher probability of being pre-configured for the influenza HA epitope.
II.1.3 Experimental Rationale
The VH-gene encodes the HCDR1, HCDR2, much of the immunoglobulin framework re-
gions and the beginning of the HCDR3 loop. I hypothesized that the conformational flex-
ibility mediating the polyspecificity of germline gene-encoded antibodies is determined at
least in part by the heavy chain variable region encoded by the VH-gene, considering it
makes up a large portion of the structure. The focus of my study was to test this hypoth-
esis using computational design. Specifically, I analyzed the somatic mutations in sets of
mature antibodies that derived from the same VH gene and for which co-crystal structures
with biologically relevant target proteins were available. Sets of mature antibody-antigen
complexes incorporating antibodies that derived from a common germline VH-gene were
input into the ROSETTA “multi-state” design algorithm that recovers the optimal single se-
quence for an antibody to bind all antigens simultaneously (Babor and Kortemme, 2009;
Humphris and Kortemme, 2007; Leaver-Fay et al., 2011a). The sequences recovered us-
ing this protocol would be considered inherently flexible and polyspecific, since they are
predicted to accommodate binding to diverse antigens using a structurally diverse set of an-
tibody conformational states. In contrast, I also tested monospecificity for each antibody by
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measuring which sequences are preferred during the design towards a single antigen. This
is known as the “single-state” design protocol. For any change between the preference
for sequence between the multi-state design protocol that considered polyspecificity and
the single-state design that considers monospecificity, recapitulates in silico, the process of
affinity maturation.
Fundamentally, our approach compares germline and mature antibody sequences opti-
mized in nature through evolution and maturation with sequences predicted to be optimal
based on ROSETTA’s energy function applied to a set of co-crystallized antibody/antigen
complexes. The power of the present approach is that I predicted germline and mature se-
quences in silico without any prior knowledge of either, which is an important step towards
rational antibody design. I would expect that results of this type of analysis will continue to
improve as the size of the collection of conformational ensembles available in the Protein
Data Bank (PDB) increases and as the accuracy of the ROSETTA energy function continues
to improve.
II.2 Multi- and Single-State Design of Antigen-Antibody Complexes
I compiled panels of antigen-antibody complexes from the Protein Data Bank (PDB) in
which the antibody heavy chain variable region were encoded by germline VH-genes, des-
ignated VH3-23, VH1-69, or VH5-51 (Wu et al., 2010b; Tian et al., 2008). Antigen-antibody
complexes were selected only if they contained Homo sapiens or humanized antibodies and
the binding partner was a protein antigen. The search of the PDB returns 10, 8 or 3 candi-
date complexes for VH1-69, VH3-23, or VH5-51 respectively (table II.1).
For each panel I compared the mature (somatically mutated) sequence to the inferred
germline gene sequence via a multiple sequence alignment (figure II.2A). The number of
mutations with respect to the germline sequence range from 4 to 23 mutations with an
average of 12.2. All HCDR1, HCDR2, and framework positions that differed from the
germline sequence of the common VH-gene sequence in at least one position in the multi-
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PDB ID VH* Germline Antibody Ligand VH* Mutations
2CMR 1-69*01 D5 gp41 6
3FKU 1-69*01 F10 HA 13
3GBM 1-69*01 CR6261 HA 15
3MA9 1-69*01 8066 gp41 4
3MAC 1-69*01 8062 gp120 7
3P30 1-69*01 1281 gp41 20
1G9M 1-69*02 17b gp120 21
2DD8 1-69*05 M396 SARS-RBD 5
2XRA 1-69*05 HK20 gp41 14
2XTJ 1-69*10 1D05 PCSK9 4
2QQN 3-23*01 anti-Nrps-1 Nrps-1 10
2R56 3-23*01 IgE BLG 23
2VYR 3-23*01 VH9 MDM4 10
3KR3 3-23*01 DX-2647 IGF-II 8
1S78 3-23*04 Pertiuzimab ErbB2 22
2FJG 3-23*04 G6 VEGF 15
3DVN 3-23*04 Apu2.16 Ubiquitin 18
3BN9 3-23*04 E2 MT-SP1 5
2B1A 5-51*01 2219 UG1033 17
2XWT 5-51*01 K1-70 TSHR 8
3HMX 5-51*01 Ustekinumab IL-12 12
Table II.1: Antibody-antigen test set. Details of the 10, 8, and 3 complexes for VH1-69,
VH3-23, and VH 5-51 respectively. The antibodies bind a diverse set of antigens but each
share a common germline across a test set. The VH mutation count of amino acid mutations
away from their inferred germline gene. *Predicted from IMGT
ple sequence alignment were included in the computational design simulations as “variable
positions”. Note that my study explicitly excluded positions that remained unchanged as
no claims can be made with respect to the relevance of these positions for conformational
flexibility or polyspecificity. My analysis is limited to antibody regions encoded by the
VH-gene as only this region can be unambiguously aligned within each set of antibodies.
Therefore, I excluded D-gene and J-gene that encode HCDRH3, and antibody light chain
positions. The identity and conformation in all variable positions to identify the sequence
and conformation that return minimal energy for the given protein backbone of the anti-
body/antigen complex (Kuhlman and Baker, 2000). In this work, I used multi-state design
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(Leaver-Fay et al., 2011a) to find a single sequence that minimized energy with all antigens
within each VH gene-encoded group. To reduce noise in the outcome of the computations,
100 simulations were executed, and results are displayed using WebLogo representation
(Crooks et al., 2004) (figure II.2 C).
For a concrete example, consider position 31 (PDB numbering, boxed in II.2 C). This
position, encoded by VH5-51, diverged from a germline serine residue in the sequence
for all three complexes. Complexes 2B1A and 2XWT (PDB code) possess an aspartate
residue in this position acquired by somatic mutation, while 3HMX has a threonine in the
same position. The multi-state design protocol selected the germline residue serine as the
energetically most favorable residue out of all 20 possible genetically encoded amino acids
when interaction with all three structurally diverse antigens is required. The experiment
was repeated as three separate “single-state design” experiments (figure II.2B, right side)
to predict the sequences and conformations that minimized interaction energy for each
antigen individually. The resulting sequences were compared to both the inferred germline
and the mature sequence (figure II.2C). In this experiment position 31 is predicted as an
aspartate for complexes 2B1A and 2XWT, and as a threonine for 3HMX, the mature amino
acid sequence (data not shown).
For this work, it was important to convert the outcome to a statistical quantitative anal-
ysis. Each design outcome is compared to the mature or germline sequence, by computing
a bit-score “recovery” measure. The results can either recover towards germline, mature or
neither sequences. The bit-score computation I used is described in the methods of the ap-
pendix section. The advantage of the bit-score measure in comparison to a more simplistic
percentage-recovery is that it analyzes the relative probabilities of all twenty amino acids in
a particular sequence position, not just the probability of the correct one. It thereby arrives
at an accurate measure of “surprise” of seeing a certain outcome, a normalized measure in
information theory that can be readily compared between different experiments. In our ex-
periment high bit-score for the germline sequence indicated that among the 100 designed
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sequences, germline gene-encoded residues were chosen in a large number of instances
(figure II.2D). To facilitate comparison across complexes that have a different number of
designed entities considered, I determined the sum bit-scores over all designed positions
and normalized the score to fall between 0 and 1 by division with the maximum bit-score
that could be achieved, i.e., every amino acid position designed towards a germline or ma-
ture sequence.
II.3 Specificity Inferred by Sequence Design
The results of the multi-state design simulations returned sequences that resembled germline
gene-encoded sequences more often than mature sequences. This finding was remarkable
as no information about germline sequences was input into the simulation. I found that the
designed sequences gave normalized bit-scores of 0.54, 0.60, and 0.43 for germline genes
VH1-69, VH3-23, or VH5-51, respectively. In contrast, statistically significant reduced bit-
scores of 0.48, 0.45, or 0.26 (p < 0.0001) were observed when comparing the designed
sequences with the mature genes (figure II.3A). The single-state redesign of mature an-
tibodies for binding to their associated antigen gave normalized bit-scores of 0.47, 0.43,
or 0.28 for comparison with germline gene-encoded sequences and 0.57, 0.54, or 0.53 for
comparison with mature sequences of VH1-69, VH3-23 or VH5-51, respectively. In this
design experiment, a proclivity to recover the somatically mutated mature sequences was
observed (figure II.3A). Given that a normalized bit-score is the preference for each de-
sign experiment to match a certain sequence profile, a high bit-score to germline sequence
indicates the output matching the germline profile, while a high bit-score to the mature
sequence indicates a preference for the mature profile, each design experiment outcome
can be measured as a difference in bit-scores (mature - germline). With this definition, a
preference for mature sequence gave a positive ∆bit-score, while a preference for germline
residues gave a negative ∆bit-score for a given complex - i.e., the ∆bit-score provided an
in silico predicted metric for antibody optimization for affinity to a specific antigen versus
36
2XWT 3HMX 2B1A
Single State DesignMulti-State Design
100X Designs 100X Designs
VH5-51 Derived Antibodies
A
B
C
D
Ge
rm
lin
e
Ma
tur
e
0.2
0.3
0.4
0.5
0.6
2XWT  EVQLVQSGAEVKKPGQSLKISCKASGYSLTDNWIGWVRQKPGKGLEWMGIIYPGDSDTRY
3HMX  EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRY
2B1A  EIQLEQSGAEVKKSGESLKISCQTSGYSFSDYWIGWVRQMPGKGLEWMGIFYPGDSDSRY
5-51  EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRY 
      *:** ********.*:******: ****::  *:***** *****:*:**: * *** **
2XWT  SPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCVG
3HMX  SPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCAR
2B1A  SPSFEGQVTMSADRSTNTAHLQWSSLKPSDTALYYCAR
5-51  SPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCAR
      ****:****:*.*:* .**:***.***.****:***.
PDB ID FR 1 CDR 1 FR 2 CDR 2
FR 3
2B1A
3HMX
2XWT 2B1A
Ge
rm
lin
e
Ma
tur
e
0.5
0.2
0.3
0.4
0.6
B
it 
S
co
re
 
N
or
m
al
iz
ed
B
it 
S
co
re
 
N
or
m
al
iz
ed
VPEKGFTSYIMEMIYGTQIAKISYSAMAR 50.9Score
ESEQTFSDYIMEMFYGSEMARTNHSPLAR 27.72XWT VPQKALTDNIKEMIYGTQIAKINYSAIVG 34.93HMX VPEKGFTTYLMDIMSVIQMVKITYNAMAR 29.8
VPEKGFTSYIMEMIYGTQIAKISYSAMAR Score
ESEQTFSDYIMEMFYGSEMARTNHSPLAR 59.4
30.6
Seq =                                 
E_min(
2XWT+           
3HMX+
2B1A)  
Seq =
E_min(2B1A) 
VH5-51 Multi-State 
Design
VH5-51 Single-State 
Design
2B1A
5-51
Figure II.2: Multi-state and single-state design methodology. Position candidates were
chosen for design if the position differed from the germline sequence in at least one mature
complex (A). Co-crystal structures for each complex are shown with designed positions
highlighted in gold. Single- and multi-state design schemes are shown (B) Each position
in the sequence logo corresponds to a position conserved for design (C). Bit-scores were
determined quantitatively by measuring the frequency of a letter at each position (D).
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polyspecificty. I observed positive values for single-state design and negative values for
multi-state design, indicating a preference for the mature or germline sequences, respec-
tively (figure II.3B, p < 0.0001).
II.4 Affinity Maturation Correlates with Predicted Affinity
The number of somatic mutations can be used as a measure of the maturity of an anti-
body (Briney et al., 2012). Hence, I asked the question if the ∆bit-score, the change in
proclivity for a germline or mature sequence, correlated with affinity, i.e., if tendency to
recover mature versus germline sequences increased as antibody maturation progressed.
Such a correlation would indicate that as antibodies mature, features of the germline se-
quence critical for polyspecificity are replaced with features critical to recognize one target
antigen. Figure II.3 C shows the somatic mutation percentage of antibodies in each com-
plex as a metric for “in vivo maturation” correlated with the ∆bit-score as a metric for “in
silico predicted optimization for affinity versus polyspecificty”. For positive ∆bit-scores,
the mature sequence was preferred, indicating a preference for specificity. For negative
values, the germline sequence, and hence polyspecificity was preferred. The correlation
coefficient for the “in vivo affinity maturation” and “in silico predicted optimization for
affinity vs. polyspecificity” was 0.83.
II.5 Backbone Conformational Space for Germline Sequences
Torsional phi-psi angles in the protein backbone were compared across the sets of experi-
mental structures for positions that recovered to germline sequence for multi-state design
and those positions that recovered to a non-germline sequence. I found that positions that
converted back to germline in multi-state design, i.e., positions critical for conformational
flexibility according to the simulation, had a deviation of 19.6◦ ± 2.0◦ across beta-sheet
phi-psi torsion angles. Sequence positions that did not recover to a germline gene-encoded
amino acid had a reduced deviation 15.5◦ ± 1.5◦ for beta-sheet backbone torsion angles (p
= 0.099) (figure II.4 A-C). Considering the limited range for beta-sheet backbone torsion
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Figure II.3: Multi-state designs to-
ward the germline sequence. An-
tibodies encoded by the same in-
ferred germline VH gene preferred
germline sequences when considered
in the multi-state design, inferring a
more flexible combining site. The bar
graph shows the bit-score for each of
the three different inferred germline
groups and then the sum of the scores
in a grouped bar. A perfect design
would have a normalized bit-score of
1.0, and summated score of 3.0 for
three germline groups. Multi-state
design preferred germline sequences
for all complexes, while in contrast
single-state design preferred mature
sequences (A, p<0.0001). The change
in bit-score is determined to be the
proclivity to either the mature (positive
score) or the germline (negative score)
sequence. Each complex was assigned
a change in bit-score. The change
in proclivity between design proto-
cols was significant (B, p< 0.0001).
Each complex was scored against ma-
ture and germline sequences and a
difference was calculated (∆bit-score).
Positive numbers returned showed a
proclivity towards mature sequences,
while a negative score suggested a de-
sign toward germline. A tight cor-
relation was observed (r2=0.8263) for
the in silico predicted optimization
for specificity versus polyspecificity
(∆bit-score) and the in vivo matura-
tion process (C, plotted as the muta-
tion percentage away from VH gene
sequence).
39
angles, I don’t expect large deviations. For reference, all framework residue beta-sheets in
antibody-antigen complexes across my dataset have an average phi-psi deviation of 18.7◦
± 0.9◦.
II.6 Impact of Residue Environment on Specificity
Figure II.5 maps each amino acid position encoded by the VH gene segment onto the im-
munoglobulin fold using a custom Collier de Perles representation, as described by Ruiz
and Lefranc (Ruiz and Lefranc, 2002). I modified the output to distinguish positions by
location in the interface with the antigen and the degree of burial. I correlated these metrics
to the bit-score at a per-residue level. Each residue given is in IMGT numbering.
For multi-state design (figure II.5 A-C), 33 out of a possible 46 of the designed interface
residues (72%) contributed to polyspecificity, i.e., recovered to germline sequence with a
normalized bit-score > 0. Remarkably, also 41 out of 77 residues outside the interface
(53%) recovered to germline. Residues 25, 40 and 105, far removed from the interface,
recovered perfectly (normalized bit-score = 1) in at least two of the three germline gene
test sets. These residues are highly buried, with a neighbor count score of 13.3 ± 0.5. The
intermediately packed residues 17, 51, 70, and 71, with an average neighbor score of 8.6
± 2.2 neighbors, were predicted to contribute to polyspecificity, even though they lie in
distal positions from the antigen-binding site. The interface residues 35, 63, 64, and 82
were found to contribute to polyspecificity in two out of the three germline gene test sets.
A conserved serine, which was found in all three germline sequences at position 36 in the
CDR1, was the only residue identified as critical for polyspecificity in all three germline
genes.
In contrast, for single-state design, it is more difficult to deduce overall trends for any
specific position as the paratope is altered in each antibody and the recognized epitopes
cover diverse structural space. Generally, when each complex was considered individu-
ally, 214 designed interface residues recovered to their mature sequence out of a possible
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Figure II.4: Phi-psi variances for frame-
work residues. The degree of structural
variation of the framework residues were
measured as the standard deviation of
the phi and psi angles over each residue
position. Side view of immunoglobu-
lin fold for VH5-51 complexes aligned
by framework residues. Beta-sheets in-
cluded in the analysis are shown as a
cartoon representation, while loop re-
gions are in a transparent ribbon rep-
resentation. Framework 1 is shown in
brown, HCDR1 in green, framework 2 in
black, HCDR 2 in magenta, and frame-
work 3 in cyan (A). Same as (A) but
top down view (B). The standard de-
viations of the phi-psi angles of each
framework position were binned into
either a residue that was found to be
critical for polyspecificity (recovered to
germline) or a residue that was not re-
covered to germline in multi-state de-
sign. For each position, the phi-psi an-
gles were averaged, and the standard er-
ror of the mean was calculated. An aver-
age of 19.6◦ ± 2.0◦ for germline recov-
ered residues and 15.47◦ ± 1.5◦ for non-
germline recovered residues support-
ing our hypothesis that residues which
enable polyspecificity alter beta-sheet
packing to a greater degree than residues
that do not. The axis is normalized to
18.7◦ ± 0.9◦, the average deviation for
all beta-sheet framework positions (C).
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340 designed amino acids, indicating their importance for recognition of, and affinity for
binding to, the specific antigen (63%, figure II.5 D-F). When non-interface residues were
considered, 411 out of a possible 699 designed residues recovered to their mature sequence
(59%).
Residues that were found to be critical for polyspecificity, i.e., reverted to germline in
multi-state design, differed substantially for each germline gene test set considered. For
the VH1-69 gene derived antibodies, all of the residues in the HCDR2 loop contributed
to binding interactions in the single-state but not the multi-state design. In contrast only
G63 and T64 residues contributed in the multi-state case but not in single-state designs.
Residue L50 was recovered in all single-state complexes but was not critical for multi-state
design. For the VH3-23 gene, residues A55 and Y66 were not recovered in multi-state
design but were found to be important for high affinity in single-state design. For the VH5-
51 complexes, non-interface residues P15, M53 and A80 were not recovered in multi-state
design but were found to be critical in single-state design. HCDR2 was found to be critical
in single-state design for all VH5-51 complexes.
II.7 Mature Sequence Bias
To understand some of the trends described above more quantitatively, I determined for
each residue in each antibody/antigen complex if it was part of the interface, i.e., directly
engaging the antigen. For this purpose the change in neighbor count between unbound
antibody and bound antibody/antigen complex score was measured, and positions with a
change larger than 1.0 were classified as “interacting residues”. Next, I counted how often
a residue position appeared in the interface within each set of antibody/antigen complexes.
Positions were binned as occurring in the ensemble interface never, once, two-four times, or
more than four times and average bit-scores were compared (figure II.6). I found a general
trend for interface ensemble size correlating with interface ensembles sampled. For the set
of structures derived from VH3-23, which contained a total of 8 complexes, I found that
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Figure II.5: Colliers de Perles reepresentation of VH gene segments. The 98 amino acids
present in VH1-69, VH3-23, or VH5-51 are shown in a Collier de Perles two-dimensional
representation and numbered according to the IMGT numbering scheme 37. Hatched cir-
cles are missing residues according to the IMGT numbering scheme and are shown to
make graphs consistent. Square boxes represent the boundary between framework and
CDR loops. A dashed line is shown for the interface. Interface residues are colored with
a blue-pink gradient indicating a numerical antigen contact score defined by a change in
neighbors between the free and bound complex. Non-interface residues are colored with a
green-orange gradient according to their degree of burial defined through a neighbor count.
A, B, C show the germline sequence represented in the immunoglobulin fold with the thick-
ness of each line representing the design bit-score for that position relative to the germline
sequence for multi-state design. D, E, F the thickness of the line corresponds to the mature
sequence bit-score averaged over each complex.
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residue positions that are never found in the interface gave an average bit-score of 2.3 ±
0.4. If a residue position was found only in one interface, the average bit-score dropped to
1.2± 1.1. As residues were found more frequently at the interface between 2-4 complexes,
and 5-8 complexes, the average bit-score increased to 2.5 ± 0.8 and 3.6 ± 0.7 respectively.
For the 10 VH1-69 complexes, an average bit-score of 2.3 ± 0.3 was observed for residues
that were never found in the interface. If a residue was only found in the interface once,
the average bit-score dropped to 1.9 ± 1.0. For interface occurrences between 2-4 and 5-8,
I found the average bit-score to increase to 2.6 ± 0.7 and drop to 0.8 ± 0.4 respectively.
Due to the limited number of residues occurring in multiple interfaces, a significant change
in bit-score between each grouping was not observed for VH1-69 (p= 0.1844) and VH3-23
residue positions (p=0.2007).
II.8 Evolutionary Sequence Bias
I expected the result of multi-state design to deviate from germline in cases where alternate
amino acids are compatible with the conformational space and binding modes observed in
the ensemble of structures. Alternative amino acids might be tolerated but are not observed
in evolution - “evolutionary sequence bias”. To test this hypothesis, I reverted each position
back to germline and compared the energetic change with the favored residue returned by
multi-state design. Using reference energies, ROSETTA facilitates the direct comparison
for energies between different residue types (Kuhlman et al., 2003). For complexes derived
from VH5-51, all positions in which the germline residue were not chosen in at least 10%
of the 100 simulated models were forced into the germline identity (figure II.7 A, x-axis).
The difference in average energy of the germline sequence at that position from the aver-
age energy of the residue returned by multi-state design was calculated (y-axis). For each
position, if positive values were returned for all three complexes, ROSETTADESIGN would
most likely place a non-germline amino acid at that position. If negative values were re-
turned for all three complexes, ROSETTA would most likely place a germline amino acid at
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Figure II.6: Interface occurrences affect germline sequence recovery. For VH3-23 (A) and
VH1-69 complexes (B), I binned each residue position into how many times it occurred in
an interface (interface ensembles). Most designed positions never occurred in an interface.
As their occurrences became more frequent, I observed a trend for increasing the recovered
germline residue. This trend fell off for VH1-69 complexes (B) for positional occurrences
between 5-8 interfaces.
that position. I found that, in most cases, the energetic contribution of the designed amino
acid is not significantly more stabilizing than the germline amino acid, i.e. the germline
sequence is tolerated as well. Only positions 52, 76, 88, and 98 gave a significant energy
increase for the germline sequence in at least one complex. Changes in energy were classi-
fied as significant if larger than 0.7 ROSETTA energy units (REU, horizontal dashed line).
This threshold was derived from the average difference in energy between the germline and
mature residue (0.7 ± 0.2 REU, data not shown). For Figure II.7B, a multiple sequence
alignment is given as a reference, where each position that was considered in multi-state de-
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Figure II.7: ROSETTA multi-state design solutions. I evaluated a complete germline rever-
sion of VH5-51 sequence versus the sequences output by multi-state design. (A) Considera-
tion of positions in which the multi-state design algorithm chose a non-germline amino acid
for at least 10% of the models where evaluated. The difference in energy of the germline se-
quence and the multi-state design solution sequence is shown for each position. Bars above
0 represent the multi-state design sequence preferred while bars below the line represent
the germline amino acid preference. The horizontal dashed line at 0.7 ROSETTA energy
units (REU) shows the average energy difference between the germline and mature se-
quence and is represented as a marker for sequence tolerance. (B) The multiple sequence
alignment for each VH5-51 complex is shown and compared with the germline sequence.
Sequences highlighted in bold were considered for design. Sequences highlighted in green
are positions in which the multi-state design algorithm chose the germline amino acid as
the design solution. The numbers in the bottom row are the alignment-numbering scheme
of each position and correspond to the position numbers in (A).
sign is highlighted in bold while each position that recovered well to the germline sequence
is highlighted in green.
II.9 Discussion
II.9.1 Limitations of Computation
I recognize several important limitations of my study:
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1. I assumed that the ROSETTADESIGN protocol determined the optimal sequence for
any given design challenge. While it has been demonstrated that ROSETTADESIGN typ-
ically recovers close-to-optimal sequences (Kuhlman and Baker, 2000), inaccuracies
in the scoring function and limitations in the sampling algorithm will introduce er-
rors. In the future, this limitation could be reduced by improvements applied to
the energy function and comparing the results obtained with complementary energy
functions. I assumed that the finite and small set of antibody conformations observed
in the set of co-crystallized mature antibodies completely describes the conforma-
tional flexibility of the germline gene-encoded antibody (finite ensemble bias). While
I used the largest ensembles available (10, 8, and 3 antigen-antibody complexes), this
assumption must be wrong, introducing a bias. For example, assume there is a se-
quence position that is part of the paratope in only one of the n complexes. In this
antibody, a somatic mutation occurred at this position greatly increasing affinity to
the antigen. The somatically mutated amino acid is however compatible with all
other n-1 complex structures. In such a scenario the multi-state design algorithm will
recover the somatically mutated instead of the germline amino acid. Here, I found
that as a residue was more often part of the paratope, it became more likely to be re-
covered to the germline sequence. This finding might be due to the fact that a critical
conformation that the germline antibody needs to adopt was not represented in the
ensemble (for framework residues) or the epitope needed for recognition by a critical
germline amino acid represented in the ensemble.
2. I assumed that the germline gene-encoded antibodies were able to adopt the con-
formations of each of the mature antibodies derived from it. This assumption is
important, as crystal structures of the “true” germline antibody in complex with the
antigen are generally not available. While this assumption is expected to be correct
for the majority of cases, notable exceptions are discussed in the literature (Yin et al.,
2003; Li et al., 2003; Wedemayer et al., 1997; Sethi et al., 2006).
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3. It is not guaranteed that only the germline amino acid is compatible with all con-
formations adopted by mature antibodies. Rather, it is likely that for some positions
alternative amino acids are plausible or even better in realizing the conformational
flexibility needed. The germline sequence observed in nature is optimized in evo-
lution and clearly works, but does not need to be perfect in all positions. In such
a scenario, multi-state design could return amino acids that deviate from germline
(evolutionary sequence bias). Conversely, the mature sequences observed in the co-
crystal structures are not guaranteed to be the perfect sequence for high affinity. In
some positions a somatic mutation might have introduced a better amino acid but is
not the “true” best option. Some somatic mutations might have occurred by chance
and do not contribute to affinity maturation. Some positions might not have experi-
enced somatic mutations but still favorable mutations exist. In all these cases I expect
the single-state design to deviate from the mature sequence observed in the co-crystal
structure (evolutionary sequence bias).
4. The imperfect nature of the ROSETTA scoring function will not yield 100% agree-
ment with natural phenomenon (Kuhlman and Baker, 2000). Importantly, water
coordination can often be important in antibody-antigen binding sites. However,
ROSETTA is currently being developed to include tools with explicit solvent models
(Lemmon et al., 2012).
It is important to understand these biases and limitations to arrive at an accurate interpre-
tation of the results. Given these known limitations, I expected imperfect agreement of
in silico predicted and natively observed mature and germline gene-encoded antibody se-
quences. Nevertheless, I found a remarkably high correspondence of residues designed for
polyspecificity in a blinded fashion and the amino acids encoded by germline genes.
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II.9.2 Interpretation
Germline gene-encoded sequences for commonly used VH segments are hypothesized to
possess high conformational flexibility making them ideal for binding diverse antigens,
i.e., being polyspecific. During antibody maturation, somatic mutations are introduced
that increase affinity for a specific target in part by adding attractive interaction to the
antigen (increasing enthalpic gain) and in part by locking the conformation critical for
interaction with the specific antigen (reducing entropic cost). Here I tested this hypothesis
by analyzing three sets of antibodies, each derived from a commonly used VH gene and
each co-crystallized with a protein target in its antigen-specific binding conformation.
I chose to not directly compare conformational flexibility for germline and mature an-
tibodies. While this approach may be feasible in general through predicting the accessi-
ble conformational space using molecular dynamics (Wong et al., 2011), it is challeng-
ing to achieve complete sampling of large conformational spaces that include the entire
immunoglobulin framework. To circumvent this problem, I chose to solve the inversely
related protein design problem, which was to study amino acid sequences that are con-
sistent with the conformational space seen in antibody/antigen co-crystal structures. This
approach is complementary and potentially superior as it replaces sampling of the large
conformational space in antibody backbone regions with solving the better understood
ranking of amino acid sequences, given a certain antibody/antigen complex conformation.
Specifically, I employed multi-state design to find single amino acid sequences that were
compatible with the multiple conformations of antigen combining sites.
Computational tools to design multi-specific proteins were first described by pioneering
work in the Kortemme laboratory (Babor and Kortemme, 2009; Humphris and Kortemme,
2007). In parallel, Leaver-Fay and colleagues developed a general algorithm for multi-
state design in the ROSETTA framework, in which they designed one protein to interact
with non-native targets (Leaver-Fay et al., 2011a). I used the latter tool to design antibody
sequences that are optimal for facilitating interactions to:
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1. Multiple and diverse antigens, or
2. A single specific antigen.
In the absence of a priori knowledge of the germline or mature sequences or the mecha-
nism of antibody maturation through somatic mutations, multi-state design of one antibody
to recognize several target proteins recovered sequences similar to those encoded by the
inferred germline gene segment. When designing the same antibody to recognize one spe-
cific target, the sequence recapitulated the mature antibody sequence. This trend correlated
tightly with the divergence of the mature sequence from the inferred germline sequence,
i.e., the more somatic mutations an antibody contained, the more reversions to germline
needed in order to facilitate interactions to multiple antigens.
Use of a computational tool to approach questions regarding polyspecificity as a func-
tion of protein sequence is advantageous, as the ROSETTADESIGN algorithm is able to
rapidly enumerate the effect of multiple simultaneous mutations in sequence space for the
entire heavy chain variable region. This task is quite difficult if not impossible to complete
experimentally at this scale. In this manner, conformational flexibility in the framework
regions, HCDR1, and HCDR2 can be tested in a holistic model. All mutated positions
in the VH gene segment were considered simultaneously, including the effect of interac-
tions between different domains in the antibody, thus revealing the role of interface and
non-interface residues in both poly- and monospecificity. Because this approach considers
multiple antibodies of variable conformation at once, each with a distinct binding mode,
the multi-state design algorithm predicts sequences that are inherently flexible and capable
of adopting the diverse set of conformations needed to bind to multiple antigens.
Harindranath and colleagues demonstrated that polyspecific antibodies were encoded
largely by germline gene sequences (Harindranath et al., 1993). Romesberg and Spiller
presented structural evidence for flexibility in germline gene-encoded sequences (Romes-
berg et al., 1998). In addition, Schmidt et al. correlated mature sequence to rigidity of the
paratope (Schmidt et al., 2013). Taken together, these data suggest conformational flexi-
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bility coupled with pre-sampled conformations of the target binding site as the underlying
mechanism for polyspecificity (Wedemayer et al., 1997). Here, I used a multi-state design
algorithm to assess the contribution of the VH gene segment to specifying an antibody with
conformational flexibility, preorganization, and polyspecificity. I found that this property is
largely attributed to antibody sequences in the germline gene repertoire, since designing an-
tibodies for polyspecificity, sequences recovered germline gene-encoded sequences, while
designing antibodies for monospecificity to a single target, returned sequences similar to
the mature antibody. This trend increased in strength the higher the number of somatic
mutations that had accumulated, i.e., the further optimized the antibody had become. Im-
portantly, the effect is not limited to the HCDR3, which often contributes much to antibody
specificity. I obtained the same finding to be clearly measurable throughout HCDRs 1 and
2 as well as the immunoglobulin frameworks. I found each germline VH gene to encode
a set of amino acids that enabled polyspecificity in a distinct manner. These positions
were present not only in the paratope, but also in the buried or semi-buried positions of
the immunoglobulin frameworks (figure II.5). I expect, that with an increasing number of
antibody-antigen complexes in the PDB it will become easier to discern general trends.
I conclude that conformational flexibility in the beta-sheet framework is critical for
changing critical regulators of the conformation of the paratope - i.e., the takeoff and land-
ing angles of HCDR loops, thereby enabling the paratope of germline antibodies to as-
sume multiple conformations. Accordingly, I find that residues that contribute the most to
polyspecificity contain larger deviations of their phi-psi torsion angles (figure II.4). During
antibody maturation, mutations in these positions likely lock in the target-specific frame-
work conformation, reducing the entropic cost of target binding. Somatic mutations in the
paratope, for example within HCDR1 and HCDR2, can directly increase affinity to a target
(enthalpic contribution to free energy), or lock in a conformation that recognizes the tar-
get (entropic contribution to free energy). I found that on average 62% of residues in the
paratope and 42% of residues in the framework were important for changing the binding
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pattern of the antibody from polyspecificity to recognition of one specific target (figure
II.5).
I identified at least four specific scenarios in which current datasets are limiting for
informing design efforts:
The first scenario involves a framework position that does not interact with the epitope
in any of our tested complexes. For this position, the germline residue, and only the
germline residue, is capable of adopting the phi-psi angles in order to accommodate
the flexibility needed for the binding site. Multi-state design likely designs in the
germline residue for each simulation. I then observe agreement between in silico
design and natively observed sequence for a majority of the designed positions (figure
II.3).
The second scenario involves a framework position that also lies distal from the epitope.
In this scenario, the germline residue but also other amino acids are compatible with
the observed conformations since they both contain properties to adopt the phi-psi
angles necessary to accommodate the flexible binding site. For this scenario, I ex-
pect ROSETTA’s multi-state design algorithm to pick one of the compatible amino
acids, not necessarily the germline gene-encoded one. This outcome can occur either
because the conformational ensemble is incomplete or because of the evolutionary
sequence bias. I find that both biases contribute to ambiguity. Residues that are never
found in the interface give modest recovery to germline sequences being either “hit-
or-miss” (finite ensemble bias, figure II.6), and residues that are reverted to an amino
acid different from that encoded in the germline are not significantly better in energy
score than the germline encoded amino acid (evolutionary sequence bias, figure II.7)
The third scenario concerns residues that are at part of the paratope in only one instance.
If the mature residue forms critical interactions that minimize the free energy of
binding in this one complex, while in all other complexes the residue is not part of
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the paratope and the mature amino acid seen for the one complex is compatible with
the backbone confirmation, ROSETTA will choose the mature residues from the first
complex also in multi-state design mode. I observed this trend, especially for VH3-
23 complexes. If a residue was found in only one interface (figure II.6), that position
tended to have a low recovery to the germline sequence.
The last scenario deals with positions that are part of the paratope multiple times and
that experience frequent somatic mutations. As positions are found to be more fre-
quently in interface ensembles, the germline recovery increases as these positions
become more important to facilitating direct interactions with their antigen (figure
II.6). These residues contribute to polyspecificity by being the preferred residue in
interaction with multiple antigens, rather than facilitating binding by altering beta-
sheet packing.
II.10 Conclusions and Future Directions
These results suggest that the naturally occurring antibody maturation process can be reca-
pitulated or reversed at least partially in silico, opening exciting new avenues for antibody
engineering work. Further, my results suggest the applicability of multi-state design to en-
gineer polyspecific antibodies, exploring another important strategy for designing broadly
neutralizing antibody therapeutics. Traditional antibody engineering approaches empha-
size isolating monoclonal antibodies that are highly specific for a given antigen, relying
on display techniques in which emphasis typically is placed only on HCDR loop design.
The method described here considers the entire antibody variable region during design,
including critical framework residues that allow for conformational flexibility and con-
tribute to polyspecificity. Considering that I found that up to 64% of framework and HCDR
residues may contribute to binding and specificity, computational design will be invaluable
to rapidly enumerate the large sequence and structural space of residues that can contribute
to breadth of binding diverse targets.
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CHAPTER III
HIV Neutralizing Antibodies in HIV-Naïve Donors
III.1 Introduction
The induction of broadly neutralizing HIV-specific antibodies is likely to be a critical com-
ponent of the mechanisms of protection for an effective HIV vaccine. In the work presented
here, I used a novel approach for examining the heavy chain complementarity determining
region 3 (HCDR3) repertoire of HIV-naïve donors to interrogate the structural properties
of long HCDR3 loops. Some broadly neutralizing HIV-neutralizing human antibodies pos-
sess long HCDR3 regions, which typically are created at the time of original antibody gene
recombination rather than during somatic hypermutation. I sought to determine if antibod-
ies with long, structured HCDR3s that are present in the naïve B-cell repertoire of HIV-
naïve donors confer neutralizing properties to those antibodies similar to that of previously
isolated HIV-neutralizing antibodies such as PG9 and PG16, which target the HIV envelope
protein variable loops 1 and 2. Using ultra-deep nucleotide sequence analysis of HCDR3
regions in antibody gene replicons for 64 different HIV-naïve donors, I obtained approx-
imately 25,000 unique sequences that encoded HCDR3s of 30 amino acids in length, the
same size as broadly neutralizing antibody PG9. The modeling suite ROSETTA was used
to assess the ability of these 30 amino acid length HCDR3 sequences to form a loop with
structure similar to that of antibody PG9. The PG9 backbone template then was threaded
rapidly with sequences from HIV-naïve donors to evaluate the energetic state of naturally
occurring long HCDR3s when tested in a PG9-like conformation. The sequences encoding
HCDR3s with the most favorable predicted energy states in this conformation then were
redesigned in silico to optimize binding with minimal changes, simulating the process of
somatic hypermutation. The sequences that were found to mimic the binding energy and
HCDR3 structure of PG9 were synthesized and characterized experimentally for ability
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to bind to HIV envelope (Env) protein and neutralize HIV infectious virions. I found 12
unique antibodies that present PG9 HCDR3 mimicry with 0 to 7 mutations away from their
respective HIV-naïve wild-type sequence. This work, using a robust new bioinformatics
and modeling pipeline, suggests that HIV-naïve donors may possess naïve B-cells encod-
ing antibodies with long HCDR3s that can neutralize HIV prior to infection. Expanding
and preserving these unique naïve B-cells from the naïve repertoire may represent an im-
portant new strategy for HIV vaccine priming.
III.1.1 Potential Paradigm Shifts in Vaccinology
Elicitation of broadly neutralizing antibodies (bNAbs) against human immunodeficiency
virus type 1 (HIV-1) has been one of the greatest challenges in modern vaccinology (Ack-
erman and Alter, 2013). A bNAb response occurs in 10-30% of those infected, with about
1% of those possessing “elite” neutralization breadth (Simek et al., 2009). These antibodies
typically arise 1 year after infection at the earliest and peak at approximately 3-4 years after
infection (van Gils et al., 2009). Recent advances in donor selection from cohorts of chron-
ically infected patients, novel screening methods, and antibody isolation technologies, have
allowed identification of dozens of new antibodies to the envelope protein gp120/gp41 of
HIV-1 (Kwong and Mascola, 2012). These antibodies bind at least five major epitopes on
gp120 including the CD4 binding site (Wu et al., 2011), the gp120 outer domain (Trkola
et al., 1996), the V3 loop and V3 complex glycans (Mouquet et al., 2012), the V1/V2 loop
and surrounding glycans (Walker et al., 2009), or the membrane proximal region (MPER)
on gp41 (Huang et al., 2012). While the various bNAbs of interest were isolated using
different strategies, they often share certain unusual and distinctive genetic features, such
as very large numbers of somatic mutations or very long heavy chain complimentarity de-
termining region 3 (HCDR3) structures (Corti and Lanzavecchia, 2013).
Although studies based on bNAb isolation have revealed new targets for immunogen
design and have been useful for experimental therapeutic efficacy (Klein et al., 2012), the
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design of a vaccine against HIV-1 that induces sterilizing or protective immunity has re-
mained elusive (McCoy and Weiss, 2013). For example, the RV144 trial that tested a
vaccine strategy using priming immunization with a recombinant canarypox vector fol-
lowed by a bivalent gp120 protein boosting immunization revealed 31% efficacy in the first
year for this regimen (Rerks-Ngarm et al., 2009). While the RV144 trial results did sug-
gest modest efficacy, the waning of protection after one year suggested major improvement
in immunogenicity is still needed. An obstacle in vaccine development for elicitation of
bNAbs is the limited understanding of the maturation process from germline to hypermu-
tated variable gene segments or the process for eliciting secretion of antibodies with long
HCDR3s, which are characteristic of a number of mature bNAbs (Haynes et al., 2012b).
One recent study conducted by Doria-Rose and colleagues at the Vaccine Research
Center (VRC) structurally characterized twelve somatically related V1/V2 binding mAbs
that share characteristics with PG9 and PG16, including a long protruding HCDR3 loop
(Doria-Rose et al., 2014). They found that the unmutated common ancestor was present at
30-38 weeks post-infection and was able to weakly neutralize superinfecting virus. This
finding is a great step in corroborating my rationale for eliciting these types of V1/V2
binding mAbs as a strategy for vaccine development.
Here, I attempted to study the occurrence of antibodies in the naïve B-cell repertoire
with long HCDR3s that might mediate neutralization of HIV, prior to exposure to HIV
antigens. I examined the HCDR3 repertoire of a large number of HIV-naïve donors in
context of the HCDR3 structure of the V2/V3-binding antibody PG9. This antibody was
isolated initially from a donor in the IAVI African Protocol G cohort using high-throughput
B-Cell microneutralization assays to identify functional B-Cell clones (Walker et al., 2009).
These antibodies possess unusual HCDR3 structures characterized by a 30 amino acid long
(IMGT numbering) hammerhead-structured HCDR3 region that protrudes about 20/AA
from the surface of the rest of the combining site (Pancera et al., 2010; Pejchal et al.,
2010; McLellan et al., 2011). Initial studies using point mutations identified the HCDR3 as
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the primary structural feature that mediated neutralization (Pancera et al., 2010), and this
finding was confirmed later by atomic-resolution structural studies of the mAbs in complex
with V1/V2 scaffolds (McLellan et al., 2011; Pancera et al., 2013).
Using ultra-deep sequencing technology along with a robust molecular modeling pipeline,
I identified long HCDR3 sequences from the B-cells of HIV-naïve donors that were pre-
dicted to mimic the unusual structure of mAb PG9. First, I identified 30 amino acid
length HCDR3 sequences, which matched the amino length of the PG9 HCDR3. Using
pilot comparative modeling experiments in the software package ROSETTA (Leaver-Fay
et al., 2011b; Kaufmann et al., 2010), I created position specific structure scoring matrices
(P3SMs) to score the large number of HCDR3 sequences returned from HCDR3 sequenc-
ing rapidly without the need for a full molecular modeling trajectory to assess the ability
of the sequences to achieve a PG9-like loop structure. The sequences were ranked by
predicted tolerance for assuming the structure of the HCDR3 of PG9 in the PG9/CAP45
complex. Sequences that returned scores close to those of PG9 were characterized exper-
imentally by synthesis and expression of recombinant antibodies, followed by testing for
binding to HIV antigens and neutralization of HIV. I found 12 antibodies that mimics the
function of PG9 with at least one mAb that neutralized HIV.
Here, I used a structural convergence paradigm, as I found the sequences that mimicked
PG9 function by searching for antibodies with the ability to form a similar structure, rather
than clones with a high level of genetic identity or homology. The results suggest that a
vaccine strategy based on elicitation of PG9-like antibodies may provide several advantages
in rational vaccine design for HIV, since PG9-like HCDR3 loops are found in the HCDR3
repertoire of HIV-naïve individuals. Furthermore, the number of somatic mutations nec-
essary to achieve broad and potent neutralization is less than the extraordinary number of
mutations typical of many conventional bNAbs (Klein et al., 2013). Taken together, the
targeting of B-Cell receptors with sequences that encode PG9-like HCDR3 structures in
the repertoire of HIV-naïve individuals may provide a critical target in immunogen design
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Figure III.1: Current sequencing technologies. On the x-axis is the current read length for
each sequencing platform. The y-axis is the bases per run. Each point is a new iteration
of that platforms sequencing read length and coverage. HiSeq has the most coverage with
relatively short read lengths. Figure adapted from (Nederbragt, 2012)
for HIV vaccine development.
III.1.2 Ultra High-Throughput Sequencing
Through the remainder of this section I will refer to next-generation sequencing as high-
throughput sequencing (HTS). These can be divided into technologies that often produce
a smaller number of reads but allow a much longer read length. This approach includes
Roche 454-pyrosequencing ©, Illumina MiSeq ©, IonTorrent ©, and PacBio © platforms.
These high-throughput sequencing technologies give a throughput from 0.7 to 95 gigabases
(figure III.1 and table III.1) (Nederbragt, 2012). In contrast, some platforms fall into what
I call ultra high-throughput sequencing (UHTS), including those of the Illumina HiSeq ©
and SoLiD © platform, which tends to give shorter reads but achieves higher number of
reads, from 320-600 gigabases (figure III.1, table III.1). The advances in HTS spurred an
initial investigation to examine the healthy donor repertoire in my laboratory.
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Platform Instrument Year Reads per run Read length (mode or average) Bases per run (gigabases)
Sanger 3730xl ND 96 800 0.0000768
454 GS20 2005 200,000 100 0.02
454 GS FLX 2007 400,000 250 0.1
454 GS FLX Titanium 2009 1,000,000 500 0.45
454 GS FLX+ 2011 1,000,000 700 0.7
454 GS Junior 2010 100,000 400 0.04
IonTorrent PGM 314 chip 2011 100,000 100 0.01
IonTorrent PGM 316 chip 2011 1,000,000 100 0.1
IonTorrent PGM 318 chip 2011 5,000,000 100 0.5
IonTorrent PGM 318 chip 2012 5,000,000 200 1.0
IonTorrent PGM 318 chip V2 2013 5,000,000 400 2.0
IonTorrent Proton PI 2012 50,000,000 200 10.0
Illumina GA 2008 28,000,000 35 1.0
Illumina GA II ND 100,000,000 50 5.0
Illumina GAIIx 2009 440,000,000 75 33.0
Illumina GAIIx 2011 640,000,000 75 48.0
Illumina GAIIx 2012 640,000,000 150 95.0
Illumina HiSeq 2000 2010 2,000,000,000 100 200.0
Illumina HiSeq 2000 2011 3,000,000,000 100 600.0
Illumina HiSeq 2500 RR 2012 600,000,000 150 180.0
Illumina MiSeq 2011 30,000,000 150 4.5
Illumina MiSeq 2012 30,000,000 250 8.5
Illumina MiSeq 2013 30,000,000 300 15.0
SOLiD 3 ND 320,000,000 50 16.0
SOLiD 4 ND 2,000,000,000 50 100.0
SOLiD 5500xl 2011 3,000,000,000 60 180.0
SOLiD 5500xl W 2013 3,000,000,000 75 320.0
PacBio RS C1 2011 36,000 1,300 0.045
PacBio RS C2 2012 36,000 2,500 0.090
PacBio RS C2 XL 2012 36,000 4,300 0.155
PacBio RS II C2 XL 2013 47,000 4,600 0.216
Table III.1: Figure adapted from (Nederbragt, 2012)
III.1.3 Long HCDR3s are Established at Original Recombination
Using first generation HTS technology, we first observed long HCDR3 sequences in the
healthy HIV-naïve repertoire (Briney et al., 2012). Although long HCDR3s were known
to exist (Zemlin et al., 2003; Ivanov et al., 2005) they are primarily found in chronically
HIV-infected subjects (Walker et al., 2009; Spurrier et al., 2011; Choe et al., 2003; Walker
et al., 2011). This led to a multiple hypothesis model about the origin of long HCDR3s
in chronically infected patients (figure III.2). Given that long HCDR3 antibodies against
HIV are highly mutated relative to other antibodies, it could be hypothesized that insertions
and deletions (indels) due to somatic mutations could be responsible for the ‘elongation’
of HCDR3s. These antibodies could be elicited by a chronic infection or heterogeneous
prime-boost vaccine strategy, both of which will exhibit selective pressure for antibody
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maturation from germline sequence (figure III.2). This long HCDR3 origin model was
known as the ‘mutational’ model. The alternate hypothesis was that long HCDR3s were
established in the bone marrow at the time of original recombination and were found in
the circulating repertoire at low frequency, or were selected against due to known issues
associated with autoimmunity (Aguilera et al., 2001; Wardemann et al., 2003; Ichiyoshi
and Casali, 1994; Crouzier et al., 1995). This is known as the “original recombination”
model.
These two models for the origin of long HCDR3s were the original focus for this project
and are detailed in specific aims of the 2012 thesis of Bryan Briney from the Crowe Lab-
oratory. The models were tested by comparing immunoglobulin sequence repertoires for
long HCDR3s to those of canonical length HCDR3s (Briney, 2012). I can further test these
models based on two main assumptions about antibody maturation process. One, all anti-
bodies are generated in the bone marrow from the germline repertoire and affinity mature
in the lymph tissue (Tonegawa, 1983; Murphy et al., 2007). Thus, an antibody that is re-
cently recombined in the bone marrow would have fewer mutations than antibodies that
have gone through multiple rounds of affinity maturation. Figure III.4 A (top panel) shows
an analysis of peripheral B-cell mean number of mutations as a function of HCDR3 length.
Longer HCDR3s tend to have lower levels of somatic mutations. Figure III.3 B (top panel)
specifically shows the correlation for IgM and IgG class types that have undergone positive
and negative selection.
The second assumption is that the affinity maturation process is associated with in-
sertion and deletion events that are likely to be caused by somatic hypermutation associ-
ated proteins (Reason and Zhou, 2006; Wilson et al., 1998a,b). Figure III.4 A and III.4 B
(lower panels) show a negative correlation to insertion-deletion associated (indel) percent-
age, suggesting further evidence supporting the ‘original recombination’ model. Finally,
a statistically significant change in long HCDR3 percentage between naïve B-cells and
class switched IgM and IgG B-cells indicates that these antibody sequences are present at
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Mutation Model Original Recombination Model
Figure III.2: Origins of long HCDR3 models. Two models are proposed to explain the
origin of HCDR3s. In the mutation model (left), B-cells (yellow) with canonical length
HCDR3s are ‘elongated’ through selective pressure on B-cells (blue) by chronic infection
or repeated rounds of vaccine boosts to trigger affinity maturation to an evolving antigen.
This repeated round of exposure creates insertions into the long HCDR3. The original
recombination model (left) assumes the long HCDR3 is in low frequency in the naïve pop-
ulation (yellow). Antigens from a vaccine or chronic infection select the infrequent B-cell
and expand its clonal population and refine affinity.
original recombination and are selected against during maturation.
Although the original goal for the work done by Bryan Briney was to determine the
genetic origin of HCDR3s, it confirmed a population, albeit a very small one, of very long
HCDR3 sequences that are the same length as many of the exceptional broadly neutral-
izing antibodies against HIV-1. This fortuitous conclusion, along with rapidly advancing
throughput of HTS technology, led to the experimental rationale.
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III.1.4 Rationale and Experimental Design
My conclusions from examining the HIV-naïve donor repertoires made me consider vari-
ous existing approaches to HIV vaccine design. Traditional vaccinology assumes that one
can make a germline antibody into a broadly neutralizing antibody by a series of prime-
boost steps to achieve an optimal level of mutations to produce a protective response to
HIV challenge. Indeed, many great strides have been made in the field (Liao et al., 2013;
Javier Guenaga and Wyatt, 2011; Kwong and Wilson, 2009; Doria-Rose et al., 2012). How-
ever, the other unusual characteristics about broadly neutralizing antibodies to HIV is many
of them possess very long HCDR3s, where almost all of the contact and therefore mecha-
nism of neutralization, stem from the long HCDR3 (McLellan et al., 2011; Pejchal et al.,
2010; Klein et al., 2013; Zhou et al., 2007).
With knowledge that long HCDR3s are present in HIV-naïve donors, and that they
are established at the time or recombination, I hypothesized that it was possible for these
long HCDR3 sequences to mimic some of the long HCDR3-driven broadly neutralizing
antibodies. I choose the complex of PG9 and a scaffolded epitope V1/V2 to be my template
(McLellan et al., 2011). The goal was to see if I could mimic the 30-length HCDR3 in PG9
to neutralize HIV (PG9 mimicry). I chose PG9 with the following rationale:
1. The co-crystal structure had recently been elucidated (figure III.3) (McLellan et al.,
2011).
2. The long HCDR3 accounts for neutralization and functionality with few contact
residues in other regions of the antibody (Pancera et al., 2010; Pejchal et al., 2010).
3. Variants with germline reversions of the framework still retains neutralization ability
(Klein et al., 2013).
4. The RV144 trial, the first trial to show substantial vaccine efficacy, revealed an
increase in V1/V2 binding antibodies (the binding region of PG9) (Haynes et al.,
2012a).
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5. Interactions with the V1/V2 region are structure-dependent and sequence indepen-
dent, i.e. backbone-backbone hydrogen bonding across beta-sheets (McLellan et al.,
2011).
6. There is a 9 mutation difference between PG9 and its sister antibody PG16 at the
HCDR3 paratope, showing a structural as well as functional convergence irrespective
of sequence similarity (Walker et al., 2009; Pancera et al., 2010; Pejchal et al., 2010).
Bryan Briney’s work with first generation high-throughput sequencing yielded a low
frequency of sequences with a length of 30 amino acids (0.4%). Building on this observa-
tion, figure III.5 proposes an experimental plan that could test a large number of sequences
for PG9 mimicry. In order to make the proposal feasible, I needed to increase the number
of donors sequenced and the amount of B-cell coverage in a new round of next-generation
high-throughput sequencing. I also knew that the coverage necessary was going to produce
500 million to 1 billion sequences, far more data than could be supported on my existing
data analysis architecture.
In collaboration with Jessica Finn who did the sequencing, I planned to implement
custom databases and search algorithms to collect the sequences into a functional anti-
bodyome. For prediction of PG9 mimicry, I also needed to develop a structural prediction
scheme based on the package ROSETTA that would rapidly be able to predict whether a
sequence could tolerate the PG9 configuration. I also planned for a reasonable number
of recombinant antibodies to be made in the laboratory to test for experimental validation
using binding and neutralization analysis.
III.2 Ultra High-Throughput Sequencing of HCDR3s
As explained in the rationale, it was necessary to obtain many more sequences than were
available using the coverage of 454-pyrosequencing. I decided to use the HiSeq platform,
as the throughput at the time was 109 reads of 150 base pairs (bp). Although, the sequenc-
ing read of 150 bp was not long enough to cover the entire antibody variable gene, it would
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transfected 293F cells when scaffolded with V1/V2 (Supplementary
Table 2), but it behaved poorly in solution. We identified 11 smaller
proteins of 36–87 amino acids in size and designed chimaeric proteins
encoding V1/V2 from the YU2 strain of HIV-1 (Supplementary Fig. 2
and Supplementary Table 3). The expressed chimaeric glycoproteins
from these smaller scaffolds were mostly soluble, permitting us to
characterize them antigenically against a panel of six YU2-specific
V1/V2 antibodies (Supplementary Tables 4 and 5). Three of the
smaller scaffolded YU2 V1/V2 chimaeras showed reactivity with all
six YU2-specific antibodies, and two (Protein Data Bank (PDB)
accessions 1FD6 (ref. 23) and 1JO8 (ref. 24)) were also recognized
by the a4b7 integrin25, suggesting that they retained biological
integrity (Supplementary Table 5 and Supplementary Fig. 3).We next
identified strains of gp120 that retained PG9 recognition in the gp120
monomer context, including clade B strain TRJO and clade C strains
16055, CAP45, ZM53 and ZM109 (Supplementary Table 6). We
placed V1/V2 sequences (residues 126–196) from these strains into
the 1FD6 and 1JO8 scaffolds, and assessed PG9 binding. Notably,
affinities of PG9 for 1FD6-ZM109 and 1JO8-ZM109 were only 50-
fold and threefold lower than wild-type ZM109 gp120, respectively
(Supplementary Fig. 4). Scaffold-V1/V2 heterogeneity was apparent
after expression inGnTI2/2 cells26 as was sulphation heterogeneity on
antibody PG9 (ref. 27) (Supplementary Fig. 5). We therefore used an
on-column selection procedure coupled to on-column protease cleav-
age of Fab to obtain homogeneous complexes of scaffold-V1/V2 with
PG9 (Supplementary Fig. 6).
Two 1FD6-V1/V2 scaffolds were crystallized in complex with PG9.
One scaffold contained the V1/V2 region from the gp120 of the
CAP45 strain of HIV-1 with five sites of potentialN-linked glycosyla-
tion. Crystals of this CAP45 construct with the Fab of PG9 diffracted
to 2.19 A˚, and the structure was refined to an Rcryst of 18.2%
(Rfree5 23.4%) (Fig. 1 and Supplementary Table 7). A second scaffold
included the V1/V2 region from the gp120 of the ZM109 strain of
HIV-1 withN-linked glycans at positions 160 and 173, and asparagine
to alanine substitutions at four other potentialN-linked sites. Crystals
of this ZM109 construct with the Fab of PG9 diffracted to 1.80 A˚, and
the structure was refined to an Rcryst of 17.8% (Rfree5 20.5%) (Sup-
plementary Fig. 7 and Supplementary Table 7).
Structure of V1/V2
The V1/V2 structure, in the context of scaffold and PG9, folds as four
anti-parallel b-strands (labelled A, B, C, D) arranged in (21,21,13)
topology28 (Fig. 2a–d and Supplementary Table 8). Important struc-
tural elements, such as a hydrophobic core, connecting loops and
disulphide bonds, cross between each of the four strands, indicating
that, structurally, the V1/V2 domain should be considered a single
topological entity.
Overall, the four-stranded V1/V2 sheet presents an elegant solution
for maintaining a common fold while accommodating V1/V2 diversity
and glycosylation. The strands contain mostly conserved residues and
are welded in place by inter-strand disulphide bonds (between strandA
and neighbouring strands B and D) and extensive hydrogen bonding
(between strands A andD and between strands B andC). The two faces
of the sheet—concave and convex—have very different characters. The
concave face of the sheet is glycan-free andhydrophobic (Fig. 2e),with a
cluster of aliphatic and aromatic side chains surrounding the disulphide
bond that links strands A and B. This conserved hydrophobic cluster
continues onto strand D at the sheet edge, to form a half-exposed
hydrophobic core for this domain. The convex face of the sheet is
cationic (Fig. 2f), with the main-chain atoms of the conserved strands
of the sheet forming stripes on the V1/V2 surface (Fig. 2g) and the
N-linked glycan 160 situated at its centre (Fig. 2h). In contrast, two
strand-connecting loops—emanating from the same end of the
sheet—are highly glycosylated and variable in sequence (Fig. 2i). We
can now redefine the ‘V1 loop’ as the residues connecting strands A
and B, and the ‘V2 loop’ as those residues between strands C and D
(Fig. 2h, i).Of these, theV1 loop ismost variable, ranging in length from
,10–30 residues. The V2 loop is less variable and contains at its start
the tripeptide motif recognized by integrin a4b7, the gut homing
receptor for HIV-1 (ref. 25).
PG9–V1/V2 interactions
The most prominent interaction between antibody PG9 and V1/V2
occurs with N-linked glycan (Fig. 3, Supplementary Fig. 8 and
Supplementary Tables 9 and 10). PG9 grasps the entire ZM109 160
glycan (Fig. 3a). Its protruding third complementarity-determining
region of the heavy chain (CDRH3) reaches through the glycan shield
to contact the protein-proximalN-acetylglucosamine, burying 200 A˚2
of total surface area, with Asp 100 and Arg 100B of PG9 making four
hydrogen bonds (Fig. 3b, c) (Kabat numbering29 is used in description
of antibody sequences; thus Arg 100B is two residues after Asp 100).
Additional hydrogen bonds are made by the base of the CDR H3
(by Asn 100P and by the double-mannose-interacting His 100R) to
terminal mannose residues, with Ser 32 and Asp 50 of the light chain
contributing three additional hydrogen bonds (Fig. 3b). In sum, a total
of 11 hydrogen bonds and over 1,150 A˚2 of surface area are buried in
PG9 heavy chain
PG9 light chain
1FD6 scaffold
CAP45 V1/V2
V2 loop
V1 loop
Asn 156 glycan
CDR H2
CDR H1
CDR H3
Asn 160 glycan
CDR L3
CDR L1
CDR L2
Figure 1 | Overall structure of the V1/V2 domain of HIV-1 gp120 in
complex with PG9. V1/V2 from the CAP45 strain of HIV-1 is shown, in
magenta ribbons, in complex with Fab of antibody PG9. The PG9 heavy and
light chains are shown as yellow and blue ribbons, respectively, with CDRs in
different shades. Although the rest of HIV-1 gp120 has been replaced by the
1FD6 scaffold (shown in white ribbons), the positions of V1/V2, PG9 and the
scaffold are consistent with the proposal that the viral spike, and hence the viral
membrane, is positioned towards the top of the page. The extended CDRH3 of
PG9 is able to penetrate the glycan shield that covers theV1/V2 cap on the spike
and to reach conserved elements of polypeptide, while residues in heavy- and
light-chain-combining regions recognize N-linked glycans. The disordered
region of the V2 loop is represented by a dashed line. Perpendicular views of
V1/V2 are shown in Figs 2 and 6, and the structure of PG9 in complex with V1/
V2 from HIV-1 strain ZM109 is shown in Supplementary Fig. 7.
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Overall, the structure of PG9 is consistent with published muta-
tional data10,14 (Supplementary Table 14). Some residues such as
Phe 176 are critical because they form part of the hydrophobic core
on the concave face of the V1/V2 sheet. Others form direct contacts:
for example, the tyrosine sulphate at residue 100H of PG9 interacts
with residue 168 when it is an Arg (strain ZM109) or Lys (strain
CAP45), but would be repelled by a Glu (as in strain JR-FL); JR-FL
is resistant to neutralization by PG9, but becomes sensitive if Glu 168
position of V1/V2 varies in themonomeric gp120 context. In contrast,
prior cryoelectron microscopy results indicate that the position of
V1/V2 in the unliganded Env trimer spike is xed
Additionally, we chose to map the antibody paratope by assessing
neutralization with arginine mutants. We selected the PG16 paratope
for characterization, as its recognition seemed to be both more
quaternary-structure preferring (Fig. 4a) and more V3 dependent
than that of PG9. We parsed its combining site into 21 surface seg-
Asp 100L
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Tys 100H
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Asn 100F
Asp 167
Lys 169
Lys 171
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N C
N
C
V1 loop
V2 loopD
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C
PG9 CDR H3
d
Figure 3 | PG9–V1/V2 interactions. a –f, Glycan, electrostatic and sequence-
independent interactions of antibody PG9 facilitate recognition of V1/V2 from
the ZM109 strain of HIV-1 gp120.a, PG9 is shown as a greymolecular surface,
and strands B and C of V1/V2 are shown as green ribbons. Mannose and
N-acetylglucosamine residues are shown in stick representation, as are the side
chains of Asn160 and 173. Electron density (2Fo2 Fc) is contoured at 1s and
shown as a blue mesh.b, Ribbon representations of strands B and C of ZM109
V1/V2 (green), PG9 heavy chain (yellow) and PG9 light chain (blue). V1/V2
glycans and PG9 residues that hydrogen bond are shown as sticks. Nitrogen
atoms are coloured blue, oxygen atoms are coloured red, and dotted lines
represent hydrogen bonds.c, Schematic of the Man5GlcNAc 2 moiety attached
to Asn160. GlcNAcs are shown as blue squares, andmannoses as green circles.
Hydrogen bonds to PG9 are listed to the right of the symbols, as is the total
surface area buried at the interface between PG9 and each sugar. H-bonds,
hydrogen bonds.d
Disulphide bonds in V1/V2 are shown as yellow sticks.
representation of V1/V2 (green) and PG9 CDR H3 (yellow). Hydrogen bonds
are represented by dotted lines. Main-chain interactions are shown in
side chain interactions in
a vertical axis). Details of the PG9 interaction with V1/V2 from the CAP45
strain of HIV-1 are shown in Supplementary Fig. 8.
Figure III.3: PG9 in complex with V1/V2 scaffold. The crystal structure adapted from
(McLellan et al., 2011). Beta-sheet interactions at the interface are highlighted.
pr vide coverage of the HCDR3 portion of a recombined gene, sufficient for my experi-
mental goals. I estimated that 0.4% of the sequences would be greater than 28-length at 3
standard deviations from the mean HCDR3 length. This approach in theory, would deliver
400,000 recombined very-long HCDR3 reads.
Using the scheme found in figure III.6, I indexed antibody gene repertoires from 64
different ealthy onors with indexes based on primer design by Bryan Briney and Jessica
Finn in the Crowe laboratory. First, I obtained white blood cells from 64 HIV-naïve donors
through the American Red Cross. No further information was obtained about each donor
except for hepatitis B, C and HIV negative results. The mRNA was purified from the pe-
ripheral blood mononuclear cells (PBMC), and subjected to an RT-PCR and PCR. The
HiSeq run was done in the VANderbilt Technologies for Advanced GEnomics (VAN-
TAGE). The raw data was reconstructed with paired-end algorithms and run through PyIg
(unpublished). This program called on V, D, and J gene segments for the HCDR3 region
and stored them to a database custom built for large amounts of information. The statistics
for the HiSeq run are found in table III.2. The full methodology can be found in appendix
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A B
C D
Figure III.4: Maturation sequence markers and HCDR3 length. Insertion and deletion (in-
del) frequency and mutation frequency is associated with affinity maturation and shows a
negative correlation with HCDR3 length (A). The correlation becomes more pronounced in
peripheral blood classed-switched B-cells, IgM and IgG (B). The percentage of the reper-
toire with long HCDR3s (>24 amino acids, C) and very long HCDR3s (>28 amino acids,
D) shows a statistically significant change from naïve B-cells to class-switched B-cells (***
– p < 0.001, * – p < 0.1).
VI.3.
Next, I queried my database to get a distribution for the frequency of HCDR3 lengths.
Without removing any redundancies of amino acid sequences, I binned each length and
got a distribution, referred to as “all sequences” (figure III.7 A). I then removed all redun-
dancies within each donor and plotted them as a function of length, referred to as “donor
unique” (figure III.7 A, B). Finally, I made a distribution that pooled all the sequences
together and removed all HCDR3 redundancies, referred to as “total unique” (figure III.7
A-C). The redundancies found in all donors combined, subtracted by all unique sequences,
are by shared in at least one donor. For example, for length of HCDR3 equal to 1, I have
174 occurrences when I add up “donor unique”. That is, for donor 1, I have X amount
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Figure III.5: The methodology can be split into four subsections that are a combination of
computational (dashed-line) and experimental work (solid-line). HIV-naïve donor blood is
collected from 64 adult donors and the HCDR3 is sequenced on the HiSeq Illumina plat-
form (A). The raw sequences are reconstructed and analyzed against germline databases
using custom software. The sequences are parsed and stored in optimized databases to han-
dle the large quantity of antibody sequences (B). HCDR3 sequences are chosen by length
and tested for PG9 mimicry using the ROSETTA software suite. Iterative rounds of mini-
mization, docking, and design, followed by rigorous statistical analysis allows for a robust
prediction of potential candidates from the HIV-naïve donor repertoire that may neutral-
ize HIV (C). A tractable number of sequences are synthesized and tested experimentally
through biophysical characterization and neutralization studies against HIV-1 (D).
of unique sequences among that donor added to X amount of sequences for donor 2, etc.
However, when I pooled all the sequences of length 1 first, and then removed redundancies,
I arrived at 17 “unique sequences”. That means there are 137 amino acid sequences found
in one or more donors. An easier way to view it is to plot the percentage of sequences at a
given length that are shared among one or more donor (figure III.7 D).
The mean length of HCDR3 sequences in my dataset was 16.40 ± 4.03. This finding
was in agreement with our previous work using a much smaller dataset (Briney et al.,
2012). Although there is no standard definition of a ‘long HCDR3’, I arbitrarily chose
the cutoff to be two or three standard deviations from the mean for long or very long
HCDR3s, respectively (24AA, 28AA, figure III.7 C). My recombination software (PyIg)
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Figure III.6: RT-PCR in round 1 allows addition of an internal index to categorize donors.
The cDNA is then subjected to a nested round 2 PCR where the necessary HiSeq plate
adaptors and sequencing regions are added that are used by Illumina. The sequencing
makes two pair-end reads that are later reconstructed.
also can assign V, D, and J gene segments using the BLAST algorithm (Ye et al., 2013).
I observed similar trends in D and J gene family usage as a function of length. DH3 and
JH6 family increased as length of HCDR3 increased (figure III.7 F, G). This finding makes
intuitive sense as these are the longest gene segments in their respective families. For V-
gene families, I did not observe a difference in germline gene usage as a function of length
(figure III.7 E). This trend also was reported with our previous work in which I sequenced
the entire antibody segment, however, I can’t be absolutely confident in my assignments of
V-gene considering I only have on average 20 bp of the V-gene. I can also narrow down
individual genes for the D-gene segment and observed an increase in DH2-2, DH2-15, DH3-
3, DH3-10 and DH3-22 as HCDR3 length increased (figure III.7H).
III.3 Addition of Non-Canonical Amino Acids in ROSETTA
The ROSETTA software suite was initially developed for ab initio folding of small globular
proteins using fragment-based search methods and knowledge-based potentials to score
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Figure III.7: Length distribution for all productive sequences (black dashed line), unique
among within each donor (blue dashed) and unique among every donor (black solid) (A).
Zoomed in distribution of “total unique” and “donor unique” to see overlap. Sequences that
are unique between donors are shaded in grey (B). “Total unique” with standard deviations
shown at 20, 24, and 28 (C). Percentage of shared sequence as a function of HCDR3 length.
“Shared sequence” is defined as being found in two or more donors (D). V gene families, D
Gene families and J Gene family frequencies for all sequences, long, and very long HCDR3
sequences (E, F, G respectively). D-gene families can further be divided into individual
gene frequencies for all, long, and very long HCDR3 sequences (H).
models (Simons et al., 1997). Because of this, the code for ROSETTA made protein amino
acid residues the smallest object. All proteins would be made up of residue objects, and all
building blocks would be made up of parameters that describe a residue object. This made
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Metric Counts
Raw Reads 514,312,664
Joined Reads 460,931,435
Unique Reads 167,667,706
Recombinant Reads 159,609,585
Productive CDR3s 118,440,255
Unique CDR3s by AA 23,357,390
30 Length CDR3s 74,457
Unique 30 Length CDR3s 24,917
Table III.2: Sequencing results from the
HiSeq of 64 donors. Raw reads indicate
the amount of reads that passed VANTAGE
quality metrics. Joined reads are reads
that found a paired end partner and could
be joined together. Unique reads removed
duplicates. Productive HCDR3s are those
reads that do not contain a stop codon.
Unique CDR3s are those HCDR3s that are
not duplicated by amino acid sequence. 30
length HCDR3s are those sequences that
are 30 amino acids long by IMGT number-
ing. Unique HCDR3 sequences are those se-
quences that are not duplicated in any donor
by amino acids.
sense at the time of ROSETTA’s inception given its primary purpose, but as the scoring
function was being developed for a wide variety of molecular modeling tasks, the residue
based code became difficult to implement for non-residue type molecules, i.e. drug-type
ligands, glycans, and post-translational modifications.
The PG9 complex relied on complex and high-mannose type glycans that were bound
to asparagine residues at HIV Env protein position N160 and N156 (HIV strain HXBc2
numbering) (McLellan et al., 2011). Removal of these residues abrogated binding to HIV
envelope (Doores et al., 2010). Thus, it was necessary to include both of these glycans in
my predictions. It also was necessary to encode these glycans as non-canonical amino acid
residues rather than post-translational modification due to the residue object requirement
of ROSETTA score function. I based the protocol of adding the two non-canonical amino
acids after the work of Renfrew and colleagues who developed a generalized protocol for
implementing non-canonical amino acids into ROSETTA (Renfrew et al., 2012). The pro-
tocol used a series of steps that I followed loosely that involved extraction of the residue,
minimization of the residue using quantum mechanics simulations, and description of the
new amino acid types as a series of parameters that ROSETTA can recognize. I first had to
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benchmark the non-canonical amino acid types before I could use them in the protocol. To
do this, I ran minimization and design against the glycan and determined if my best scoring
models were the closest to the native structure found in the PDB. The best scoring model
according to total energy was aligned with the native structure. I saw minimal deviation
from the native structure indicating that for good scoring models, the glycan conformation
is preserved (figure III.8 A). A general trend between the glycan score and the total score as
a function of the glycan RMSD (the deviation from the native conformation) was observed,
indicating that the glycan deviation follows the ROSETTA scoring function (figure III.8 B).
I also observed that PG9 HCDR3 amino acids were ideal for antibody-antigen complex
during redesign of the PG9-antigen (figure III.8 C).
III.4 High-Throughput Threading of HCDR3 Sequences
I took 4,000 random HCDR3 sequences from an available dataset of 26,417 (table III.2).
These sequences were “threaded” over the PG9 HCDR3 backbone and energetically min-
imized. I did not include the antigen in this first set of modeling experiments as my first
goals were to establish a high-throughput prediction model of PG9-like antibodies and
not necessarily anti-HIV gp120 specific neutralizing antibodies. This approach was for
an experimental contingency in case my modeling experiments predicted that none of the
sequences could bind gp120 antigen.
The threading protocol removes amino acid sequence identity of the HCDR3 loop and
replaces, or “threads”, one of the 4,000 random HCDR3 sequences from my dataset. After
the amino acid identity has been replaced, the PG9 antibody is energetically minimized and
scored with the ROSETTA scoring function which is detailed in chapter I.
Considering each model took approximately 1.2 CPU hours to complete at the comput-
ing cluster (https://vanderbilt.accre.com) at the time of writing, all 26,417 models would
have taken 31,700 CPU hours to complete. Considering ROSETTA takes approximately
1,000-10,000 models to determine energy landscape (Simons et al., 1999a; Bradley et al.,
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Figure III.8: Glycan addition and benchmarking template. Energetically minimized loop
of the PG9 HCDR3 overlaid on the native PG9-antigen complex (PDB-3U4E) (McLellan
et al., 2011). Native PG9-antigen is shown in darker colors while the redesigned, ener-
getically minimized and re-docked structures are shown in lighter colors. Light chain is
shown in blue, heavy chain grey, and antigen in magenta. The two glycans are shown in
stick representation. The native glycan positions are shown in transparent stick confor-
mation (A). The score of the glycan and the score of the model are shown as a function
of the glycan RMSD. On the y-axis are ROSETTA scores, and on the x-axis is the glycan
RMSD from native structure found in the PDB. The top panel is the total energy of the
complex compared with the glycan RMSD while the bottom compares the glycan score
to the glycan RMSD. A general trend is shown between the glycan deviation from native
conformation and an increase in score (B). Sequence logo of redesigned HCDR3 loop of
PG9 with glycans present. The x-axis shows PG9 native sequence (C).
2005a, 2003; Das et al., 2007; Raman et al., 2009), the time needed for completion was
approaching CPU times from 3.17 x 107 - 3.17 x 108 hours. I could utilize approximately
600 processors running in parallel, cutting down CPU times to 52,834 hours or ~six years.
These numbers were unrealistic at the time of writing, so I decided to optimize heuristics
methods that could be accomplished with a far fewer number of models. I chose 4,000
random sequences with 50 models as a strict cutoff to maximize data output within the
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capabilities of my computational resources.
To evaluate the threading protocol, I scored my models using the ROSETTA scoring
function and plotted it against the deviation from PG9’s native structure (figure III.9 A). As
a control, PG9 and PG16 also were put into the threading protocol to evaluate the scoring
function’s ability to make distinctions between poor scoring and favorable scoring models.
Considering I know that PG9 and PG16 sequences form PG9’s backbone conformation, I
expected a very low deviation from PG9’s crystal structure conformation. I also expected
ROSETTA’s scoring function to score these sequences as favorable relative to many of the
random HCDR3s that were evaluated in the protocol. Indeed, I observed that PG9 and
PG16 consistently ranked as the most favorable in terms of score and conformation and
confirmed the accuracy precision of my threading protocol (figure III.9 A).
In contrast, the randomly selected 4,000 HIV-naïve HCDR3 sequences tended to group
into three separate categories: 1) Those sequences which maintain the HCDR3 structure
of PG9 but scored poorly (figure III.9 B), 2) sequences that scored well but collapsed or
deviated away from PG9’s native conformation (figure III.9 D), and finally 3) sequences
that scored well and retained PG9’s native conformation (figure III.9 C). These three groups
gave a diverse sequence-energy landscape to be carried on into my heuristics in order to
evaluate the remaining 22,000 HCDR3 sequences.
III.5 Heuristics to Rapidly Score HCDR3 Sequences
Using the selected 4,000 HIV-naïve HCDR3 sequences, I randomly chose half of the se-
quences to be in the benchmark set or the training set. For the training set, 2,000 sequences
were evaluated with the ROSETTA scoring function. For each amino acid position 96-125
(PDB numbering), I filled a position structure specific scoring matrix (P3SM). For each po-
sition, and each amino acid identity, I gave an initial score of 0.0 to baseline yielding a 20 x
30 matrix, and averaged each amino acid identity score at each position (figure III.10 A,B).
The matrix can be visualized as a heat map with favorable scores in blue and unfavorable
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Figure III.9: The threading protocol for PG9 was evaluated for structural mimicry using the
ROSETTA scoring function. The models scores were evaluated and plotted against the root
mean squared deviation (RMSD) from the native PG9 HCDR3 structure. Lower scoring
models are closer to native structure (y-axis) while models closer to PG9 HCDR3 structure
have a lower RMSD (x-axis). Repeated measures of PG9 and PG16 were grouped close
to native structure and close to PG9 structure (blue and red points) while HIV-naïve donor
antibody sequences are shown are labeled HD (black points) (A). For figures B-D, HCDR3
structures were aligned to native PG9 (shown in transparency). The HCDR3s are colored
by their ROSETTA score with blue being a favorable scoring residue and red being an un-
favorable score. Three outcomes, sequences that retain PG9’s structure but produce an
unfavorable score (B, dashed red circle in figure A), sequences which produced a favorable
score but collapsed away from PG9 native structure (D, dashed orange circle in figure A),
and sequences that scored favorably and adopted PG9 conformation (C, blue dashed circle
in figure A).
73
scores in red (figure III.10 B).
The P3SM became my heuristic to rapidly score other sequences that were not run
through the computationally expensive threading protocol. I could validate my heuristic
by evaluating how well the P3SM predicted ROSETTA energies by applying it to the other
2,000 sequences in the benchmark set. The P3SM may not give absolute ROSETTA ener-
gies but should provide a relative ranking compared to other HCDR3 sequences. I observed
a 0.863 r2-value for a correlation between actual ROSETTA energies and P3SM predicted
energies. For the top 10% energies evaluated by the ROSETTA energy function, my corre-
lation fell to 0.300 (figure III.10C).
To determine the relative noise of the P3SM, I ranked the scores and determined the
position of PG9. It was found in 104th position out of all 26,417 sequences (0.3%). The
difference in the PG9 P3SM score and the top scoring sequence was 3.82 ROSETTA energy
units (REU). Thus, the final noise tolerance of my matrix was -34.84 ± 3.82 (-31.02 to
38.66) that encompassed approximately 1,000 sequences (figure III.10 D). I then defined
my P3SM heuristic to be able to accurately pick out the top 1000 out of 26,417 sequences
(3.79%).
III.6 Docking and Minimization of HCDR3 Variants
With 1,000 candidate sequences from the original sequence pool of 26,417, I ran the thread-
ing protocol again in the presence of the antigen and complex glycans that were added from
earlier sections (see addition of non-canonical amino acids). The threading protocol was
modified slightly to include all atom constraints, and an additional docking step and 100
models generated for each sequence (100,000 models). The full protocol is detailed in the
Appendix section VI.3 with a protocol capture in section VI.5. In addition to PG9 devia-
tions and total scores, I also evaluated binding energies, which are the change in free energy
(∆∆G). I defined the ∆∆G as follows:
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Figure III.10: Heuristics predict HCDR3 Sequences that mimic PG9 structure. 2,000 ran-
dom models were evaluated at each amino acid position. A cartoon representation of the
HCDR3 loop is shown with each position colored with a blue-red gradient according to
favorable to unfavorable amino acid identities, respectively (A). Each position was initially
assigned a score of 0.0 and enumerated through averaging each amino acid identity with
the score to fill a position structure specific scoring matrix (P3SM) from 2,000 HCDR3
sequences. The matrix was then used to rapidly score the other 2,000 models to predict a
ROSETTA score (B). A simple linear regression was applied to the actual ROSETTA energy
score of a sequence and it’s predicted score to give a coefficient of determination (r2) of
0.863. When only the top 10% by actual ROSETTA score were considered the coefficient
of determination dropped to 0.330 (C). Using the P3SM, PG9 scored 104th. Calculating
the difference in score between the top scoring sequence and PG9 left a noise tolerance of
3.82 ROSETTA energy units (REU). Calculating ± 3.82 REU of PG9 left 1,000 HCDR3
sequences that fell within the noise tolerance range of the P3SM (D).
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∆∆G= ∆GBound−∆GUnbound
Where,
∆GBound = RosettaScoreComplex
and
∆GUnbound = RosettaScoreSeparated
I decomposed the binding energies, total energies, and deviations into several metrics to
evaluate the models. Total energy, binding energy, and deviation (Cα - RMSD) for just the
HCDR3 portion of the model, the binding energy contribution by both of the glycans (N156
∆∆G and N160∆∆G, HIV strain HxBC2 numbering), and the total binding energy for the
entire model. Initially each of these metrics was evaluated individually to see where they
ranked or in pairs by plotting them against each other (figure III.11, left panel). Favorable
sequences were near PG9 in the plot. I also plotted HCDR3 metrics as heat maps and score
models qualitatively (figure III.11, right panel). Both of these methods were inefficient,
as each metric produces a different rank ordering of the HCDR3 sequences. Therefore, I
sought to combine these six metrics into one score to easily compare where each sequence
ranked in comparison to PG9. To combine the metrics, I assigned a Z-score to each metric
to find out where that model ranked. The Z-score was weighted for each scoring metric and
averaged to produce a weighted Z-score that was used to efficiently rank sequences with
one score using the following equation:
Weighted-Z=
∑Ni wi×Zi
N
where wi is the weight of each Z-score statistic i, Zi is the z score for the statistic i, and N
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Figure III.11: Scatter plots and heat maps for P3SM threading analysis. Each metric was
plotted on a separate axis and sequences which were found to score well were found in the
lower left of the graph. For example, HCDR3 binding energy is plotted against HCDR3
score. PG9 and PG16 were found to have favorable binding energy and score (left panel).
A heat map was generated for each metric for residues in the HCDR3. For example, con-
tribution to binding energy for each amino acid identity was plotted as a heat map. The
red-blue scale is for neutral to favorable reactions (right panel).
is the total number of statistics. The addition of the weights allowed optimization during
ad hoc analysis to ensure PG9 and PG16 were the most favorable weighted Z-score. The
final weights used in the protocol were:
1. Total ∆∆G — 3.0
2. HCDR3 ∆∆G — 1.0
3. HCDR3 Total Score — 1.0
4. HCDR3 CαRMSD — 0.5
5. N156∆∆G — 0.5
6. N160∆∆G — 0.5
I chose the top 80 HCDR3 HIV-naïve donor antibody sequences to carry on to experimental
steps, as this number was my upper limit to synthesize.
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III.7 Clustering of HIV-Naïve Sequences
Rather than synthesize all 80 HIV-naïve donor antibody sequences that were predicted to be
closest in structure to PG9, I instead considered that several of the sequences were related
siblings to each other. Indeed, upon clustering at a threshold 85% amino acid similarity (4
mutations), the sequences clustered into nine different groups, while five sequences formed
independent groups (figure III.12).
I next aligned the nucleotide and amino acid sequences to find sequence similarities
among antibodies in each of my PG9 clustering groups. Surprisingly, only the beginning
and end of the sequences corresponding to the base of the HCDR3 displayed a high degree
of similarity (figure III.12 A-B). The similarity arises from the in-frame JH-6 gene for
most long HCDR3 sequences, with the exception of cluster I and IG2, which used JH-4
and had evidence for significant J gene exonuclease activity, respectively (table III.3). I
also detected some nucleotide conservation for positions 27-36 corresponding to amino
acid 9-12, which resulted in a semi-conserved SSGY motif (figure III.12 A-B). Rather than
synthesize and express each of the 80 variants, I chose to synthesize one member from each
cluster and one of the sequences that did not cluster. These sequences were selected based
on their ROSETTA weighted Z-score metric within each cluster (table III.4).
III.8 Design of Top PG9-Mimicry Candidates
I realized that the models for these wild-type sequences sometimes contained clashes or
caused other strain in the HCDR3 loop that was reflected as a difference in normalized
Z-scores (table III.4) or as an energetic gap between the predicted energies of PG9 and the
top 80 variants selected (figure III.13 A). Because of this observation, I decided to run a
dock-design protocol that would relieve clashes and strains for unfavorable amino acids.
I also imposed a filter that gave bonuses for amino acids that were native to the starting
sequence. In this way, I was able achieve a higher level of PG9 mimicry by lowering the
energetic gap while retaining as many wild-type amino acids as possible (figure III.13).
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Figure III.12: PG9-mimicry candidates cluster into groups. The consensus nucleotide se-
quence were aligned for each cluster B-J. There was little sequence similarity in the junc-
tions except for the VH and JH gene. Sequence logo representations are shown above
the sequence to detect conservation. Five independent group sequences are also shown
(A). The same as (A) translated. Conserved elements are shown in the JH region due to
conserved use of the JH6 gene segment (B). The cladogram for each HCDR3 amino acid
sequence shows how the top 80 sequences clustered into 9 groups with some groups having
multiple sequences that differ by 1-4 amino acid mutations but were derived from the same
lineage (C).
I chose a variant from each cluster whose sequence recovery (the percentage of designed
sequences that were wild-type) and carefully analyzed each predicted mutation suggested
by ROSETTA. I ranked the mutations based on a fitness score. I defined the fitness score as
the change in total score for the mutation from the wild-type added to the change in binding
energy for the mutation compared to wild-type. If the fitness was found to be significant,
the mutation was confirmed by visual inspection in PyMoL (i.e., if ROSETTA predicts more
hydrogen bonds, are there more hydrogen bonds).
Briefly, I will explain the rationale for choosing the mutations for cluster B. Variant
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Cluster Members VH VD VJ V-D Length D-J Length D 5’-Exo D 3’-Exo J-Exo
B 29 V3-07*01 D3-09*01 J6*02 21 15 3 10 2
C 25 V4-34*01 D3-03*01 J6*02 10 24 0 6 2
D 2 V1-46*01 D3-03*01 J6*02 9 25 4 6 3
E 4 V1-02*02 D3-03*01 J6*03 4 23 0 4 0
F 5 V4-34*01 D3-16*02 J6*03 9 15 4 2 0
G 2 V1-02*02 D3-22*01 J6*02 16 16 7 3 10
H 2 V4-04*02 D3-22*01 J6*02 6 23 1 0 8
I 9 V4-34*12 D2-02*01 J4*02 54 9 4 12 2
J 3 V3-07*01 D3-03*01 J6*02 14 14 0 6 1
IG1 1 V3-07*01 D3-03*01 J6*03 8 29 2 4 9
IG2 1 V2-70*01 D3-22*01 J6*02 10 48 3 7 25
IG3 1 V1-02*02 D3-22*01 J6*02 11 21 6 0 5
IG4 1 V1-03*01 D3-03*02 J6*02 17 9 0 8 0
IG5 1 V4-34*01 D3-03*01 J6*02 12 29 2 6 7
PG16 1 V3-33*05 D3-03*01 J6*03 34 9 1 18 2
PG9 1 V3-33*05 D3-03*01 J6*03 34 0 1 2 9
Table III.3: Each of the nine clusters and independent sequences (IG1-5) and their rep-
resentative V, D, and J genes are shown. V-D and D-J lengths are the nucleotide lengths
of those junctions. D 5’-, D 3’-, and J-Exo were the amount of nucleotides excised in
the junctions to make a productive recombination. Point mutations in the junction are not
shown.
VU42252 was chosen as the representative candidate for design since it provided the best
sequence recovery to the wild-type sequence as well as beneficial fitness (figure III.14
A). Each mutation is plotted as a function of its fitness and grouped together by position
(figure III.14 B). If there was a large decrease in energy from the wild-type sequence, it
corresponded to an increase in fitness for a given mutation. Those mutations that had a
favorable change in fitness with a magnitude of greater than 1.5 ROSETTA energy units
were manually inspected with PyMoL (figure III.14 C,D). Two such mutations are shown
for position 106 (figure III.14 C, PDB numbering) and position 120 (figure III.14 D, PDB
numbering). For position 106, the wild-type serine was not preferred since it leaves a
large exposed gap between the antigen face and the antibody interface. Upon mutation
to an asparagine, the gap was filled in. Additionally the asparagine makes new hydrogen
bond contacts with the antigen. This finding was predicted to benefit the binding energy
and stabilization of the complex. Position 120 has a wild-type tyrosine that repels against
the large steric bulk of the glycan. A mutated asparagine at this position allows an inter-
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HCDR3 hydrogen bonds to stabilize the loop while also making additional hydrogen bonds
to the glycan. It is important to note that visual inspection using PyMol of these mutations
were reflected in the ROSETTA scoring function.
For cluster B, I chose six different positions to be mutated alone or in combination that
produced five different candidate variants. This proposed a panel of six different variants
to validate for cluster B, one wild-type sequence, and five mutational variants that ranged
from 3-10 mutations. The remaining clusters were analyzed similarly and in total, 10 wild-
type sequences were chosen for experimental characterization, and 74 different sequences
that were mutational variants of the representative cluster sequence were chosen.
Cluster Weighted Z-Score
Cluster B -1.24
Cluster C 0.28
Cluster D 0.11
Cluster E 0.15
Cluster F -0.34
Cluster F -0.20
Cluster G 0.31
Cluster H 0.11
Cluster I -2.54
Cluster J 1.48
PG9 -4.80
PG16 -1.87
IG 4 -1.46
Table III.4: Weighted scores of PG9-mimic clusters. The top scoring sequence for each
cluster are shown with weighted the Z-score.
III.9 Synthesis and Screening of PG9-Mimics
For the 84 variants, I chose a synthesis strategy that would allow us to swap in HCDR3
sequences with unique cloning sites rather than resynthesize the framework and HCDR1-
2 sequences redundantly. It was to this end that I introduced two unique cloning sites at
the 5′ end and the 3′ end of the HCDR3 sequence. Using these cloning sites, small gene
fragments could be synthesized rapidly and cost-effectively. I did not expect that all of
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Figure III.13: Energetic barriers for complete PG9-mimicry. The total HCDR3 energy and
binding energy are plotted for the top 80 sequences selected by normalized Z-score as well
as PG9 and PG16. There was a significant energetic gap between these sequences and
complete PG9 mimicry (A). After redesign, the sequences approached the energy of PG9
and PG16 (shown as connecting triangles to circles). The blue-red scale is the sequence
recovery percentage, indicating how much of the wild-type sequence was retained.
the 84 variants would express or bind HIV gp120 and decided to screen each candidate
for binding and expression on a small scale. I made 30 mL test cultures for recombinant
antibody expression to screen the supernatant for the presence of IgG antibody and its abil-
ity to bind gp120 protein. According to the literature cited by McLellan et al., only certain
gp120 monomers bind to PG9 using enzyme-linked immunosorbent assays (ELISA), while
PG16 binds gp120 monomers very weakly (McLellan et al., 2011). Therefore, I combined
fifteen different gp120 protein variants into an antigen cocktail to maximize the chances of
binding to each of my 84 PG9-mimics. This cross screening for antibody expression and
antigen binding was designed to pre-emptively select which of my 84 candidates should be
carried on to upscaled expression.
Figure III.15 plots my screening metrics for expression and binding. I binned each
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Figure III.14: Mutation analysis of clus-
ter B. A sequence logo representation of
the cluster B variant with the best se-
quence recovery is shown. The wild-
type sequence of the cluster B candi-
date named VU42252 is plotted on the
x-axis. The preferred mutations for each
position in the HCDR3 are shown on
the y-axis with the height of each let-
ter corresponding to ROSETTA’s prefer-
ence for that mutation (A). Each muta-
tion that was predicted to benefit fitness
is plotted by position. The more pre-
ferred mutations correspond to a more
negative number. A cutoff threshold of
1.5 ROSETTA energy units is shown as
a dashed line to indicate mutations that
were considered for experimental char-
acterization after manual inspection (B).
Manual inspection of the mutation at po-
sition 106 from the wild-type serine (left
panel) to asparagine (right panel). The
antigen is shown in beige or gray, for
the wild-type or mutation, respectively.
The surrounding residues are colored in
yellow. The HCDR3 loop is colored
blue. The asparagine hydrogen bonds
to the antigen, which favors binding en-
ergy and stabilization of the HCDR3
loop (C). Manual inspection of position
120 is plotted with the HCDR3 loop in
light blue, the heavy chain in green, and
the light chain in cyan. The glycans are
shown in stick representation. The de-
signed asparagine compared to the wild-
type tyrosine makes inter-HCDR3 stabi-
lizing hydrogen bonds as well as addi-
tional bonds with the glycan (C).
83
candidate to either be further characterized, or not. I based this decision on an expression
cutoff of at least 300 µg/L and a binding of at least 1 OD in ELISA at maximal concen-
tration. For some antibodies that did not express well but showed some binding activity, I
chose to carry on to further experimentation. The results are summarized in Table III.5 with
35 variants to be expressed at a larger scale. For these, I choose either a 300 mL expression
(10-fold expansion of volume) or a 1L (33-fold expansion of volume) expression based on
initial expression levels. These antibodies were purified and carried on to biophysical char-
acterization and neutralization studies. With the exception of cluster I, there was at least
one candidate from every cluster that would be further characterized (table III.5).
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Figure III.15: Expression and binding of 84 variants. Supernatants were tested for binding
for all 84 variants and plotted on the y-axis. The x-axis is the level of expression for
each variant. Plus symbols denote wild-type sequence, squares are mutants. I color by
cluster (NC is the non-clustered or independent group). Only variants that bound tightly
and expressed well were considered for upscaled expression and further characterization.
III.10 Biophysical Characterization of PG9-Mimics
I chose to use 8 gp120 monomers based on the ability of PG9 to bind them using my
ELISA experimental conditions. These monomers contained 5 clade B variants (BaL.01,
SC422661.8, 6535.3, RHPA4259.7, and TRJO4551.58), 2 clade C variants (CAP45.2.00.G3
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and ZM109F.PB) and 1 laboratory adapted SHIV chimera (HXBc2P3.2). I found that PG9
bound these 8 candidate monomers based on previous literature (McLellan et al., 2011)
and my own pilot studies (chapter IV). I coated each plate in a 384-well format with gp120
monomer and tested binding to the purified 35 variants I analyzed based on my expres-
sion/binding sieve analysis in the previous section. Due to replication of these experi-
ments, and consequently the amount of protein used, 4 variants were lost, leaving a total of
31 variants analyzed. I calculated effective concentration at half-maximal binding (EC50)
in ELISA of each variant against 8 gp120 monomers. I started my dilution at a very high
concentration in order to detect weakly binding antibodies. I set my cutoff for binding at
EC50 less than 100 µg/mL.
Not surprisingly, most variants did not bind with the same breadth and potency of PG9.
In fact, 16 of the variants characterized did not reach my threshold of binding for any of
the monomers tested (figures III.16, III.17). However, I found at least one gp120 monomer
that bound fifteen of my variants with an EC50 less than 100 µg/mL. I find the easiest
monomers to bind were BaL.01, ZM109F.PB, and CAP45.2.00.G3. My broadest antibody
was VU43171_6MUT from cluster C, which bound 7 out of 8 gp120 monomers (figures
III.16, III.17). My most avid antibody was VU28693_5MUT from cluster E, which bound
ZM109 and BaL.01 at a concentration of 1 µg/mL. For comparison, PG9 binds ZM109 or
BaL.01 with an EC50 of 0.03 µg/mL or 0.06 µg/mL, respectively. I also found a completely
wild-type antibody, that is, an antibody with no design modifications from ROSETTA, which
bound with an EC50 to BaL.01 or ZM109 at 3.7 µg/mL or 3.6 µg/mL, respectively.
III.11 Neutralization of HIV by HIV-Naïve Donor Antibodies by PG9-Mimics
From the literature, I know that changes in the HCDR3 loop sequence can dramatically alter
specificity (Pancera et al., 2010; Pejchal et al., 2010; Pancera et al., 2013). For instance,
making an antibody variant PG9 HCDR3 and a PG16 backbone was able to neutralize
additional viruses, while one with PG16 HCDR3 and PG9 backbone also was able to pick
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ID Cluster Name BaL.01 CAP45.2.00.G3 ZM109F.PB SC422661.8 6535.3 HXBc2P3.2 RHPA4259.7 TRJO4551.58
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Figure III.17: Heat-map of ELISA binding to gp120 monomers. Each cell represents the
effective concentration at half-maximal binding for each variant bound to 8 representative
viruses. The red-white-blue scale is a gradient from the maximum EC50 , to the minimal,
95 µg/mL to 0.03 µg/mL, respectively. I show the ID, a unique identifier, the cluster each
antibody falls in, and the name of the antibody that indicates how many mutations from the
wild-type sequence were present. The antibodies are sorted by their strength of binding to
BaL.01.
up additional breadth (Pejchal et al., 2010). The exact molecular mechanisms that allow
PG9 to bind most gp120 monomers and PG16 weakly bind gp120 monomers are currently
unknown(McLellan et al., 2011). Both PG9 and PG16 also do not bind gp120 monomers
there are able to neutralize indicating their preference for a trimer specific conformation. It
was because of this observation that I decided to test 31 out of my 35 HCDR3 variants for
neutralization against pseudoviruses that present native trimer (Montefiori, 2005). I sent
our antibody variants to a collaborator, Dr. David Montefiori, who designed and performed
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multiple neutralization assays to test recombinant HIV variants (DeCamp et al., 2014).
It would stand to reason that the relatively large EC50 observed in the binding studies
would result in equally large IC50 values from the neutralization assays. It was because
of this observation that I decided to start the assay concentrations of 100 µg/mL for the
neutralization screen. This decision made my neutralization screen protein-limited and at
the time of this writing, I could only test activity to two viruses, RHPA and RHPA.N160A.
From figure III.17, it is evident that these viruses are difficult to neutralize and we are
currently pursuing studies of much more neutralization susceptible viral strains from the
literature and figure III.17. Regardless, VU30400_7MUT from group G neutralized RHPA
at 49.3 µg/mL, while PG9 neutralized at 6.22 µg/mL. Both mAbs lost the ability to neu-
tralize RHPA.N160A, a knockout mutation for this class of antibody that removes the large
glycan at position 160, indicating its functional mimicry of PG9 (Doores et al., 2010).
III.12 Analysis of Mutations with ROSETTA
Lastly, I wanted to analyze the binding antibodies for sequence conservation to see if there
were any trends. Indeed, figure III.18 shows antibodies that bound BaL.01 with an EC50
less than 55 µg/mL. The neck of the HCDR3 loop showed great sequence conservation
for residues 95-97 with a sequence of amino acids VRE or VRD conserved sequence, and
residues 118-125 with a YYYYMDV motif, the wild-type sequence of an unmutated JH6
gene. These trends were observed for long HCDR3 class of antibodies in recent clustering
studies (North et al., 2011). I was more interested in conserved sequence elements that are
predicted to be at the antigen interface. For those residues, there was great sequence diver-
gence and only a few conserved elements were observed. I observed an aromatic residue
at position 104, an asparagine, glycine, and tyrosine and for positions 106-108. These se-
quences fall in a critical hairpin loop that is necessary to make the crucial turn in order to
align the beta-sheets necessary for making contact with the antigen. Indeed, ROSETTA pre-
ferred very few residues at this position due to the non-canonical torsions that were adopted.
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Figure III.18: Mutational analysis of HIV-naïve binding. HCDR3 sequences are shown for
variants that had EC50 values less than 55µg/mL and ranked 1-13 according to binding.
PG9 bound at the lowest concentration and served as a reference. Conservation is shown
as an identity plot above the sequence alignment. Sequences are colored white-black ac-
cording to their consensus conservation. The asterisks below the sequence alignment show
contact residues according to the native crystal structure. Representative structures of con-
served elements including an aromatic at position 104, an asparagine at position 106, and
a tyrosine at position 108 are shown with the antigen in black, the HCDR3 in blue, and the
interacting residues shown in yellow stick conformation. The aromatic residue buries a hy-
drophobic residue against the loop creating pi−pi stacking against the nitrogen backbone.
N106 was preferred at the position where torsion was necessary to adopt the loop beta-turn.
A tyrosine at position 108 hydrogen bonds with a glutamate on the antigen face stabilizing
the structure.
Other than those sequence elements, I saw great sequence diversity, particularly in the con-
tact residues predicted from the crystal structure and homology models (figure III.18).
III.13 Conclusions and Future Directions
A protective vaccine against HIV-1 will likely elicit broadly neutralizing serum antibody
response (Mascola et al., 1999; Burton et al., 2012; Hessell et al., 2009b, 2010, 2009a;
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Hessell and Haigwood, 2012). There are a limited number of neutralizing targets for these
bNAbs, which include the CD4-binding site, the V3-loop, the V1/V2-loop, the membrane
proximal region (MPER), and the outer N332 glycans (Walker et al., 2010). Here, I aimed
to target the V1/V2 loop due to the ubiquity of patients infected with HIV to target this
region with neutralizing antibodies (Walker et al., 2010; Gray et al., 2009; Lynch et al.,
2011; Georgiev et al., 2013). As discussed in the introduction, the RV144 trial, the only
HIV vaccine trial to date to show modest efficacy, showed that the principal correlate of
protection was the elicitation of V1/V2 binding mAbs and selective pressure on the V2
region of HIV Env (Rolland et al., 2012; Haynes et al., 2012a).
Recently, a genetic pathway for development of V1/V2 binding antibodies with long
HCDR3s has been elucidated for potent bNabs (Doria-Rose et al., 2014). A patient from
the CAPRISA cohort was studied longitudinally since initial HIV infection, and the re-
searchers found a modestly potent neutralizing antibody at week 58 post-infection by an
antibody with an HCDR3 length of 35 amino acids. In parallel the researchers had also
been taking PBMC samples at various time points throughout infection to find the genetic
pathway for the development of these neutralizing antibodies. Using pyrosequencing, they
found an unmutated antibody at week 30-38 without VH or VL gene mutations. Longitudi-
nal sequencing analysis showed this antibody mutates away from the unmutated common
ancestor (UCA) and picking up potency, with a total of 14 mutations in the HCDR3 re-
gions (40% mutation) at 58 weeks, but relatively is relatively germline in the other regions
(16%). The studies showed 54% mutations from the UCA in the HCDR3 with a neutral-
ization breadth up to 47%. This study showed the tremendous range of sequence diversity
that can converge onto one epitope while maximizing breadth and potency. This study is
exceptional in its design but does leave some unanswered questions. Firstly, the investi-
gators only derive their antibodies from VH3-30 gene encoded sequences. This approach
leaves out a tremendous amount of potential recombinations that could become neutraliz-
ers. This study also focused on one UCA phylogeny and patient. Although the UCA was
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said to be available at the original time of recombination, there is no evidence that this
antibody is present in completely HIV-naïve individuals as it was detected at 30-38 weeks
post-infection. This finding is not a true HIV-naïve study as it attempts to characterize the
developmental pathways of V1/V2 binding antibodies after infection.
I interrogated the long HCDR3 repertoire prior to infection rather than post-infection. I
used 64 different donors, maximizing my sequence pool and diversity. I also used a deeper
sequencing method to get the depth necessary to characterize such a broad repertoire. My
elegant combination of computational design with bioinformatically-driven heuristics al-
lowed me to interrogate the tremendous sequence diversity of the HIV-naïve antibody donor
repertoire. I aimed to answer two simple questions: do HIV-naïve donors possess long
HCDR3 sequences that potentially bind and neutralize HIV? If not, will a minimal number
of mutations allow them to bind V1/V2 epitopes and neutralize HIV?
The approach to answering these questions involved a four-part strategy that married
computational and experimental methods in order to investigate the HIV-naïve donor reper-
toire. First, I used deep sequencing to accumulate a vast pool of HCDR3 sequences. I then
used bioinformatics analysis with new algorithms to determine 30 amino acid length length
HCDR3 sequences. Using ROSETTA, I used these sequences to establish a heuristic that
would let us rapidly evaluate 30 amino acid length HCDR3 sequences for their ability to
form a PG9-type loop. This allowed us to trim down my vast sequence pool to a manage-
able number of HCDR3 sequences to study experimentally. ROSETTADESIGN allowed me
to simulate the process of somatic mutation by applying minimal designs to my sequences
in order to enhance potency and breadth.
I experimentally characterized 84 variants, a combination of 10 clusters returned from
the computational predictions, and 74 combinations of mutations predicted to enhance
binding. Of those, I trimmed the number down to 31 due to a lack of expression or binding
on initial screening. Of the 31 antibodies, I performed ELISA experiments on 8 repre-
sentative gp120 monomers finding that a total of thirteen mAb including two wild-type
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sequences had an EC50 less than 50 µg/mL, well within my tolerance to be considered a
binding antibody. For my neutralization work, one antibody variant neutralized a Tier-2
virus with a only 7-fold lower potency than PG9. I expect that many more of my variants
will neutralize under optimal experimental conditions. Neutralizing a Tier-2 virus with an
antibody from an HIV-naïve donor is ambitious for my studies of HIV-naïve binders and I
expect that a Tier-1 virus, may be potentially easier to neutralize.
My work has several implications for vaccine design as it demonstrates that the reper-
toire of multiple HIV-naïve donors contains antibodies with long HCD3s that have the
ability to bind gp120. This finding demonstrates how close an HIV-naïve donor is to ac-
tually mimicking a mAb that is known to be a broad and potent V1/V2 binding antibody.
It was long thought that a repeated vaccination schedule that would gradually induce the
necessary somatic mutations would be needed to recapitulate the broad and potent antibod-
ies that bind the CD4-binding site. Here I show that an average HIV-naïve donor is closer
to producing a broadly neutralizing mAb than initially hypothesized (Mikell et al., 2011).
This potential paradigm shift in vaccine design would aim to prime for these B-cells with
long HCDR3s and then boost for specificity, offering protection from HIV-1 challenge.
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CHAPTER IV
Redesign of A Long HCDR3 Antibody
IV.1 Introduction
Recent studies described the isolation of a number of human monoclonal antibodies (mAbs)
with broad and potent neutralizing activity, many of which exhibit unusual features (Bon-
signori et al., 2011; McLellan et al., 2011; Walker et al., 2009, 2011). As discussed in the
chapter I, broadly neutralizing antibodies to HIV generally contain high levels of somatic
mutations or exceptionally long HCDR3 lengths. The V2/V3 neutralizing class of anti-HIV
antibodies which includes PG9, PG16, CH01, CH04, PGT141 and PGT145 all have a long
heavy chain complementarity determining region 3 (HCDR3) and possess unique struc-
tural elements that interact with complex protein and glycan features reaching past a large
bulk of complex and high mannose glycans to interact with a short segment termed strand-
C5. These antibodies share similar neutralization sensitivity including glycan knockouts
and strand-C point mutations that interact with interface residues (Doria-Rose et al., 2012;
Doores et al., 2010). For PG9 and its clonally related sibling PG16, crystal structures have
been solved in complex with V1/V2 gp120 showing that these antibodies both engage the
epitope with their HCDR3 loop in a similar ways with the exception of glycan interactions
(Pancera et al., 2013). While PG16 prefers hybrid type glycans at position N173 (HIV
variant HXBc2 numbering), PG9 has little dependence.
IV.1.1 Experimental Rationale
As an extension of my work in chapter III that considers antibodies with exceptionally
long HCDR3s, I chose to pursue a redesign study of the broadly neutralizing antibody
PG9. This allowed me to ask relatively simple questions that may have broad and far-
reaching implications for antibody and vaccine design. Is the native sequence of PG9
optimal for binding and neutralization potency? PG9 and PG16 converge on structure and
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binding modes but they are encoded by different sequences. Therefore, I hypothesized
that the HCDR3 loop of PG9 could be redesigned to achieve improved affinity of binding,
increased potency, and breadth of neutralization for diverse HIV strains.
There has already been precedent for chimeric antibodies of PG9/PG16 where a motif
from PG16 responsible for the recognition of complex type glycans was transposed onto
PG9 in order to increase potency and breadth. This approach allowed PG9, which initially
had no preference for complex type glycans at position 173 (HIV variant HxBC2), to bind
those glycan types with stronger affinity, while retaining PG9s ability to bind high mannose
type antibodies. This chimeric antibody extended the breadth of PG9 with a small subset
of mutations on the light chain CDR3 loop termed PG9-RSH (Pancera et al., 2013).
In addition, NIH45-46, a broadly neutralizing mAb that shows structural mimicry for
CD4 and closely resembles VRC01, was mutated by one amino acid in the HCDR2 loop
(Scheid et al., 2011; Diskin et al., 2011). The mutation was not designed computationally;
rather, the investigators aligned the bound structure of NIH45-46 with CD4 and observed
that CD4 had a hydrophobic burial of a phenylalanine residue at position 54 (figure IV.1 A).
This interaction was recapitulated in another antibody, VRC03, with a tryptophan residue
at position 54. The wild-type amino acid G54 did not fully recapitulate the CD4 interaction
as it left a large gap between the gp120 outer domain and the HCDR2 (figure IV.1 A). The
investigators predicted that a mutation to either a hydrophobic residue, such as the pheny-
lalanine of CD4, or the tryptophan used by VRC03 would increase potency by increasing
the mimicry of CD4. Indeed, a mutation to tryptophan at position 54 (NIH45-46G54W) in-
creased neutralization potency for a majority of the viral strains tested and up to 2,000-fold
for one of the strains (figure IV.1 B,C).
Using the high-throughput sequencing data obtained in chapter III, I predicted I could
map the energy landscape of the HCDR3 structure using the ROSETTA scoring function.
That is, we sought to look at amino acid sequences at all positions of the HCDR3 and
determine their overall level of fitness for each position. Does PG9 contain the optimal
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Figure IV.1: Rational design of NIH45-46 to increase neutralization potency. The gp120
bridging sheet is shown as a surface representation with CD4 shown in yellow and NIH45-
46 shown in purple (A). Spider plots showing the neutralization profile for NIH45-46 and
point mutant NIH45-46G54W are shown. The length of the line corresponds inversely with
the IC50 value. Each circle represents a ten-fold change in IC50 (B,C). Figure adapted from
(Diskin et al., 2011)
sequence for the HCDR3 loop? If I didn’t see a complete recovery of PG9 sequence, I
could then predict that other sequence combinations or point mutations exists that enhance
fitness of the HCDR3 and may increase breadth and potency to HIV. Again, these mutations
would then be carried over to the laboratory to be tested experimentally with binding and
neutralization assays.
IV.2 Mapping the Energy Landscape of PG9
I retrieved the atomic resolution structure of the complex of mAb PG9 with the CAP45.2.00.G3
variant V1/V2 scaffold from the Protein Data Bank (PDB ID:3U4E) (McLellan et al.,
2011). A large number of naturally-occurring 30-amino-acid (30 AA) length HCDR3 anti-
body sequences was identified in antibody gene repertoires from high-throughput sequenc-
ing of antibody amplicons from RNA of B-cells of HIV-negative donors. Retrieval of this
dataset is discussed at great length in chapter III. A heat map of amino acid occurrences is
displayed in figure IV.2 A for 30-length HCDR3s. Diversity among the repertoires is seen
for all positions 98-118. The sequence conservation at the 5′ and 3′ ends of the HCDR3
sequences, 96-98 and 118-125, respectively, are due to the ARD motif that make up the
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5′ end of a canonical neck of a long HCDR3 loop or the JH6 template sequence, which
was seen in a majority of long HCDR3 sequences (North et al., 2011; Briney et al., 2012).
Between these two stretches of sequence conservation, I observed large sequence diversity.
Glycine, tyrosine and serine are generally tolerated at all positions, while proline, lysine
and methionine are found less frequently between positions 99-117 (figure IV.2A). This
phenomenon is well established in loop unstructured regions connecting beta-sheets in an-
tibodies (Minuchehr and Goliaei, 2005; De et al., 2005). This propensity for a structure to
tolerate a diverse set of amino acid sequences was the focus of the current study. The idea
is that there is tremendous sequence space to be explored in 30-length HCDR3s that may
further enhance breadth and specificity.
My methods are described fully in the appendix VI.3, but use the same general protocol
as described in Chapter III. I used the software suite ROSETTA to determine the ability of
diverse 30-AA HCDR3 sequences to tolerate the structure of the hammerhead configuration
of the HCDR3 of PG9 by threading 4,000 naturally-occurring unique sequences over the
PG9 HCDR3 structure. Once the sequences are threaded, I scored them by evaluating the
ROSETTA scoring function for each position. The contribution to the total score of each
position (the sum of all scoring terms of ROSETTA), which can be thought of as thermal
stability, and the contribution to the binding energy (the total score in complex subtracted
from the total score in a separated interface) of each position were evaluated. These scores
are best viewed as heat maps (figure IV.2 B,C). These two metrics, total score and binding
energy, can be summed to determine what I define as the mutational “fitness”. In this way,
I trimmed the tremendous sequence space as viewed in the heat map in figure IV.2 A, to
a focused sequence space containing mutations that advantageously affect either thermal
stability or binding energy. These metrics are shown in the heat maps of figure IV.2 A-B,
offer an advantage structure-based metrics in exploring design. As expected, PG9 itself
scored as the most fit sequence for a majority of amino acid positions for the HCDR3 (dots
plotted in figure IV.2).
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Figure IV.2: Amino acid usage and energy landscape of PG9. Mutation identity is plotted
on the x-axis with each of the positions in the 30-length HCDR3 on the y-axis. The usage of
each amino acid is shown in a log2 blue-red scale counted from 26,422 HCDR3 sequences
(A). 4,000 randomly selected sequences were chosen and their individual score from the
ROSETTA energy function is shown on a blue-white scale (B). The contribution of the same
4,000 randomly selected sequences contribution to binding energy is shown on a blue-white
scale (C). For A-C, the PG9 native sequence is shown as a dot.
IV.3 Redesign of PG9
Rather than pick the amino acids that had the best fitness for each position, I allowed
a complete redesign of the PG9 HCDR3 loop using ROSETTADESIGN. My reasons for
choosing this method rather than a simple matrix lookup generated in the previous section
were two fold:
1. Complete redesign can account for cooperative mutations. Consider position 99 that
has a wild-type alanine for PG9. My heat maps for the energy landscape predicted
that there are many more favorable mutations I could make including an aspartic
acid, asparagine or tyrosine. However, I are unaware if the new mutations have the
potential to be cooperative. That is, do the aspartic acid, asparagine, or tyrosine
require neighboring mutations to be fully stable? The complete redesign allowed
me to account for cooperative mutations while recapitulating the energy landscape
predicted in section IV.2.
2. Using a combination of filters and movers based on my specific design goals, I pre-
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vented ROSETTA from designing amino acids too far away from the original PG9
sequence, position, and structure. I can also tell the ROSETTA scoring function to
optimize for binding energy, thermal stability, or a combination thereof. This infor-
mation would be lost on a matrix lookup (Fleishman et al., 2011a; Kaufmann et al.,
2010; Kuhlman and Baker, 2000).
Again, the full design protocol is detailed in the in the Appendix (Chapter VI.3) and
follows the same basic structure as the redesign of sequences detailed in Chapter III. I
designed 1,000 decoys allowing small docking perturbations and minimal backbone move-
ment. I filtered the design to optimize for binding energy. That is, only obtain sequences if
they were better than binding energy of PG9wt.
The easiest way to view the sequences returned from the PG9 redesign is with a se-
quence logo representation (figure IV.3 A). The x-axis is the PG9wt sequence while the
height of the letters at each position, measured in bit, measure ROSETTA’s preference for
that amino acid given the nature of the design challenge. As expected from the observa-
tions from the energy landscape (figure 4.2), the original PG9 sequence was returned for a
majority of the positions, considering the evolutionary sequence bias of the PG9 structure
(nature optimizes sequences for the PG9 structure). Regardless, any time an amino acid
was returned in 10% or more of the models, I further inspected the design fitness of the
mutation.
I measured the design fitness as a sum of the difference in total energy from wild-type
sequence and the difference in binding energy from the wild-type sequence (∆∆G + total
score). For some of the positions, multiple amino acids were suggested by ROSETTA rather
than the wild-type amino acid sequence (figure IV.3 A,B). For most positions, the design
fitness was negligible, falling above the noise threshold (figure IV.3 B, dashed-line). How-
ever design at antibody amino acid positions 104, 109, 115, 120, and 123 (PDB number-
ing) suggested alternative amino acids that were predicted to benefit HCDR3 fitness for the
antibody-V1/V2 interaction (figure IV.3 B).
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I wanted to make sure that each of these mutations made intuitive sense upon examina-
tion of the structure. I viewed each mutation in context and compared it to the wild-type
amino acid. My aim was to determine if this mutation was an artifact and to confirm that
it was non-cooperative with other mutations, that is, the mutation enhances fitness alone
and not in cooperation with many other mutations made to the sequence. This is because I
wanted to retain as much of the PG9wt sequence as possible. These visual inspections are
shown in figure IV.3 B in the table, with a full justification given. If a mutation was found to
be non-cooperative, and still enhanced fitness, it was considered for experimental charac-
terization (green squares), N109Y and D115N met these criteria. I also considered N109L
and a cooperative mutation A99S and Y120N as they showed strong stabilization through
inter-HCDR3 loop hydrogen bonding. I also made one combinatorial mutation that in-
cluded the double cooperative mutant A99S-Y120N and two single mutations D115N and
N109L. This variant is simply referred to as PG9_4MUT (figure IV.3C). I did not pursue
further evaluation of designs that appeared to compromise the structural integrity of the
HCDR3 loop by visual inspection.
IV.4 Experimental Characterization of PG9 Variants
For the five mutational variants of PG9, I used a similar cloning strategy as described in
Chapter III that takes advantage of unique cloning sites between the HCDR3 5′ and 3′
ends. Each of the variants expressed well, and protein concentration was not a limiting
factor. I began by testing all the variants against a 15 antigen mix of gp120 Env proteins to
qualitatively measure binding. In this preliminary study, the double mutant, A98S-Y120N
produced a significantly lower signal than that of PG9, and this variant was not considered
further.
PG9wt does bind to some gp120 monomers (although PG9wt also can neutralize HIV
variants for which it does not bind to monomer). I used a panel of representative gp120
monomers from HIV clades B and C to perform screening for binding of PG9 variants to
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wt tyrosine makes hydrogen bond with wt G107 backbone. The mutant 107F takes on the exact same side-
chain configuration as the wt tyrosine but doesn't make the hydrogen contact to stablize the loop.
Mutant F109 makes a inter-HCDR3 hydrophobic stack contacted with a designed phenyalanine at position 
104. It loses a hydrogen bond contact from a wt asparagine side-chain.
The leucine packs well if there is a mutated 111F, but the 111F is not preferred by Rosetta. However, it also  
packs against wt proline at position 102. Also packs against a lysine at position 40 on the antigen face.
This mutatation packs against everything the 109L does and it has a polar group facing the solvent as well. 
The Dunbrack score is also highly favored.
Favored Rosetta Dunbrack. The hydrogen bonds are all retained by the mutant asparagine. Additional 
hydrogen bond made by the sp2 oxygen over to a glutamate at position 36 on the antigen. Rosetta prefers the 
polar NH2 group of the asparagine facing the solvent. 
The additional inter-HCDR3 loop hydrogen bonds that the mutant asparagine requires that positon 99 also be 
a mutant serine making this mutation cooperative. The wt tyrosine makes another inter-loop hydrogen bond 
with the backbone atoms to a wt proline 102.
The solvation is really poor but it makes an extra hydrogen bond with a wild-type tryptophan at position 126. It 
also makes another hydrogen bond with a mutant serine at position 96. 
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Figure IV.3: Redesign of PG9 HCDR3. For 1,000 designed models, the sequences returned
are best viewed as a sequence logo. The x-axis is the PG9wt sequence while the y-axis
represents the preference, measured in bit, of the amino acid identities, identified by the
height of the letter (A). For sequences that were returned greater than 10% of the time, I
manually inspected their fitness as a measure of binding energy and thermal stability (y-
axis). Some positions had more than one amino acid favored and are grouped by color.
ROSETTA noise is plotted as a dashed line at -1 REU. The more negative a mutation is, the
more it is beneficial to the PG9 complex. Each mutation is visually inspected and justified
(table). They are either a single point mutations that benefits, a cooperative mutation that
benefits, no change in fitness, and detriment to fitness, as green, yellow, grey, and red,
respectively (B). The final mutations that are chosen to be carried out experimentally are
three point mutations and two combinations thereof (C).
Env (Li et al., 2006, 2005). The results were in good agreement with previous studies of
the binding of PG9wt to gp120 monomers (McLellan et al., 2011). For these PG9 variants,
I calculated half-maximal effective concentration (EC50 ) values. For each gp120 monomer
tested, the PG9 variants N109L and N109Y exhibited 2.3-14.2 fold stronger binding than
did PG9wt (figure IV.4), while PG9 variant D115N exhibited comparable binding energies
to PG9wt. PG9_4MUT exhibited 2-100 fold reduced binding. This finding is most likely
due to the A98S-Y120N mutation that I had previously determined as deleterious.
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I also determined the EC50 for binding of these PG9 variants to a recombinant form of
native gp140 trimer that is recognized by PG9, termed BG505-SOSIP.66419-21. In these
assays, both PG9 variants N109L and N109Y exhibited 3.5- or 5.9-fold stronger binding
respectively than PG9wt. In addition to the stronger binding affinity, the variant N109Y
bound to trimer with a complete sinusoidal curve and a strong maximum signal mimicking
the binding profile of the glycan-specific mAb 2G12, which is optimal for binding to the
trimer (Sanders et al., 2013) (figure IV.4A). The extreme change in maximal signal is in-
triguing, and may suggest changes in valency of P9 to the trimer although this has not been
confirmed (Julien et al., 2013).
I next tested the panel of redesigned PG9 variants and PG9wt for neutralizing activity
against a panel of viruses displaying PG9-susceptible or -resistant HIV Env molecules,
using a TZM-bl neutralization assay (Montefiori, 2009). The PG9 variant N109Y exhibited
increased neutralization potency for all viruses tested, including viral variants for which
PG9wt did not have activity (i.e., had neutralization concentration >33 µg/mL) (figure
IV.4B). Remarkably, PG9 variant N109Y neutralized at 3.72 µg/mL an HIV strain with
the N160A mutation that removes the glycan at that position that is required for binding of
PG9wt6. The PG9 variant N109L also exhibited an increase in potency against HIV strains
compared to PG9wt, although not at the same level as the PG9 variant N109Y. In all assays
tested, N109Y and N109L consistently had enhanced breadth and potency.
The magnitude of the improvement to neutralization was modest in some cases, but
the improvement was consistent over a wide variety of HIV strains and showed significant
p-values (p < 0.05) for 10 out of the 15 virues for PG9_N109Y and 4 out of the 15 viruses
for N109L (table IV.1). Using a meta-analysis for all p-values tested gave a p-value of
5.44 x 10−15 and 7.36 x 10−4 indicating a strong statistical significance observed for the
increase in potency of neutralization for PG9_N109Y and PG9_N109L respectively. I also
found a decrease in potency to be statistically significant for 8 out of the 15 viruses tested
for PG9_D115N and a combined p-value of 2.64 x 10−8.
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HIV Strain
PG9               
wt
PG9          
N109L
PG9                
N109Y
PG9             
D115N
PG9        
4MUT
BaL.01 0.54 0.04 0.05 > >
CAAN5342.A2 1.20 0.47 0.44 1.06 2.33
CAP45.2.00.G3 0.03 0.01 0.01 0.13 9.45
HXBc2P3.2 2.41 0.25 0.49 0.74 7.78
RHPA4259.7 0.66 0.13 0.16 1.32 15.70
SC422661.8 2.48 0.25 0.31 1.89 24.87
TRJO4551.58 0.17 0.05 0.07 0.39 >
ZM109F.PB 0.02 0.01 0.00 0.04 2.27
6535.3 0.26 0.10 0.09 0.49 7.74
BG505 SOSIP.664 1.48 0.42 0.25 3.63 2.86
7165 > > > > >
AC10.0.29 > > > > >
QH0692.42 > > > > >
PVO.4 > > > > >
REJO4541.67 > > > > >
THRO4156.18 > > > > >
TRO.11 > > > > >
YU2 > > > > >
WITO4160 0.03 0.01 0.01 0.05 0.07
X1632_S2_B10 0.47 0.24 0.13 4.20 19.20
X2278_C2_B6 0.07 0.01 0.02 0.35 2.70
Ce703010217 0.02 0.01 0.01 0.03 0.04
BG505.N332 0.04 0.02 0.02 0.11 0.28
CNE55 1.13 1.80 0.65 8.60 25.20
SC422661.8 0.11 0.04 0.05 1.40 11.10
Du422.1 1.90 0.15 0.44 2.80 5.00
TH023.6 1.80 0.30 0.20 13.70 >
R2184.c04 0.28 0.49 0.11 17.20 >
TRO.11 > 11.03 3.10 > >
SC22.3C2 > > 12.90 > >
Ce1086_B2 > > 18.60 > >
398_F1_F5_20 > > 10.80 > >
TH023.6 /N160A.5 > > 3.72 > >
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Figure IV.4: Representative binding curves are shown with the optical density at 450 nm
shown on the y-axis plotted against the log10 concentration in µg/mL on the x-axis (A).
All EC50 values were calculated from the curves like the ones shown in (A) as well as the
neutralization IC50 against a 15 virus panel (B)
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HIV Strain
PG9_N109Y 
vs.            
PG9wt
PG9_N109L 
vs.            
PG9wt
PG9_D115N 
vs.            
PG9wt
WITO4160 0.0003 0.2238 0.0027
X1632_S2_B10 0.0800 0.2999 0.0432
X2278_C2_B6 0.0049 0.0156 0.0605
Ce703010217 0.0655 0.0671 0.0148
BG505.N332 0.1371 0.2350 0.0284
CNE55 0.2997 0.3538 0.0021
SC422661.8 0.0049 0.0087 0.0011
Du422.1 0.0048 0.0192 0.1132
TH023.6 0.0462 0.0913 0.0161
R2184.c04 0.0088 0.3112 0.0015
TRO.11 0.0047 0.0102 ND
SC22.3C2 0.8890 0.2221 0.4173
Ce1086_B2 0.0430 ND ND
398_F1_F5_20 0.0002 ND ND
TH023.6 /N160A.5 0.0001 ND ND
Fishers Combined 
Probability 5.44E-15 7.36E-04 2.64E-08
< .05
< .01
< .001
p-values for Neutralization t-tests
Table IV.1: Statistical tests for neutralization breadth of PG9 variants. The IC50 values
between each neutralization assay for PG9_N109Y, PG9_N109L, and PG9_D115N were
compared with a student’s non-parametric t-test against the IC50 value for PG9. They are
shown as p-values for each viral variant. A total p-value for each antibody is shown as a
Fisher’s combined probability.
IV.5 Models to Corroborate Experimental Outcome
I sought to develop a predictive model to determine the molecular basis for the increased
potency and breadth of these PG9 variants using the ROSETTA scoring function. I gener-
ated three different mutants D115N, N109L and N109Y, which were compared to that of
PG9wt using the ROSETTA scoring function (figure IV.5 A). I analyzed the top 25 models
for each of the scoring metrics shown. my scoring metrics were binding contribution for
the HCDR3, binding for the full complex, total score for the bound and unbound struc-
ture (∆∆G). For each metric calculated, I observed statistically significant improvements in
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HCDR3 stabilization for N109L or N109Y (p < 0.01 or p < 0.001, respectively), but none
of my other metrics.
Upon examination of the predicted structures of the top scoring models, I found the an-
tibody position 109 was located on an antiparallel beta-sheet at the apical tip of the HCDR3
forming a hydrophobic pocket near the interface of the antigen and apical tip (figure IV.5
B). The pocket is formed by antibody residues Y104, Y110 and P102 of the antibody heavy
chain (PDB numbering). In addition, D167 on the antigen face makes contact with this po-
sition. Examination of the structure revealed that the bulk of the hydrophobic amino acid at
this position of the pocket contributes to stabilization of the preferred structure of HCDR3.
The small hydrophobic bulk of the asparagine fills the pocket, but as the bulk increased to
a leucine and then a tyrosine, the predictive model suggested a further stabilization of the
HCDR3 loop. In addition, the polar group on the end of the designed tyrosine at position
109 points into solvent space, recapitulating the effect of the polar head of the original
asparagine PG9wt.
It is important to note that since I calculate the stabilization as the total energy of the
HCDR3 loop, it can be dissected into the individual scoring terms given by ROSETTA.
These are both described in the chapters I and the appendix VI. I have broken the total score
down for the HCDR3 loop in figure IV.6. There is little deviation for most of the scoring
terms, however, both the attractive force term, the solvation term in the ROSETTA scoring
function are improved for the N109L and N109Y mutations. In addition the N109Y shows
a favored pi-pi term. These interactions are accounted for in the model as the N109 position
is between a large hydrophobic bulk. In addition, position N109Y also achieves a more
favorable pi-pi stacking interaction with residue Y110 compared to PG9wt as the aromatic
ring of the designed tyrosine can stack with position 110.
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Figure IV.5: The top 25 models for each binding metric were analyzed. The x-axis indi-
cates each of the variants and the y-axis is the ROSETTA energy units. The metrics are
decomposed by binding energy (A) and thermal stabilization (B). Just the HCDR3 is con-
sidered (left) or the entire complex (right). Surface representation of position 109. Green
is the antigen labeled V1/V2, blue is the HCDR3 loop, dark green is the N160 glycan.
Each mutation of interest is shown as a sphere representation that is adjusted to fit the
ROSETTA atom radius. Spheres are colored by atom type with oxygen in red, nitrogen
blue, and carbon in grey. Hydrogens are removed for clarity.
IV.6 Discussion
These results have important implications for antibody and vaccine design. The studies
reveal the power of ROSETTA computational modeling to design antibodies with improved
function using structural predictions. Remarkably, the improvements in neutralizing po-
tency and breadth observed here for PG9 variants were achieved not by altering interface
residues, but rather by increased stability of HCDR3 loops discovered using a holistic
model to determine stability of an antigen-antibody complex. This finding is consistent
with recent mutagenesis experiments showing that non-contact residues are essential for
antigen recognition by many broadly neutralizing antibodies to HIV (Klein et al., 2013).
Non-contact residues in antibody frameworks contribute to high affinity binding by facil-
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Figure IV.6: Decomposed scoring terms for PG9 variants. The contribution of individual
scoring terms to the total energy score for the HCDR3 loop for each mutation. The pre-
dictive model used 1000 simulations for each variant. Each scoring term for ROSETTAis
shown in the y-axis panel. The y-axis value is the score for that energy term.
itating formation and stability of a pre-configured, low energy binding site (Willis et al.,
2013; Manivel et al., 2000; Marlow et al., 2010; Wedemayer et al., 1997; Schmidt et al.,
2013). Optimally configured binding sites form ordered paratopes that pay a smaller en-
tropic penalty upon forming antibody-antigen complexes (Marlow et al., 2010).
This work shows the efficiency of combining ROSETTADESIGN computational exper-
108
iments with expert knowledge and wet laboratory validation experiments. For a HCDR3
loop of 30-AAlength, 600 single point mutants are possible, and the number of variants
with more than one mutation is enormous. From this large potential set of mutated anti-
bodies, ROSETTADESIGN identified a focused panel of candidate PG9 variants, from which
a small subset was considered favorable, and two of five experimentally tested variants ex-
hibited enhanced potency and breadth of neutralization. The computational experiments
provided tremendous enrichment for variants with improved binding, but as expected was
not completely accurate. For example, although the model suggested that D115N would
have the greatest increase in fitness (figure 4.3) this variant was not improved in activ-
ity. The negative result is important, as ROSETTA often predicts design failures, and their
exploration is fundamental in improving the ROSETTA algorithm and scoring function
for the most accurate representations of experimental observation. This computational-
experimental feedback has been instrumental to my work and will be the target of my
future directions.
With the combination of high-throughput sequencing, rapid threading, and experimen-
tal feedback, I complete a robust bioinformatics pipeline that can rapidly test antibodies
for improvement based solely on their in silico predictions. The results here suggest that
there probably is a diversity of antibodies with long and structured HCDR3s that fit the
PG9 topology in nature with HIV neutralizing activity that have yet-to-be discovered. I
hypothesize this conclusion from three parts of evidence:
1. Examination of the energy landscape of PG9 suggests that there are mutations that
are predicted to be better suited for the PG9 topology.
2. PG9 and PG16 diverge in sequence but converge on a structural topology and have
approximately identical specificities and potencies (McLellan et al., 2011; Pejchal
et al., 2010; Pancera et al., 2010).
3. I have discovered point mutations in PG9 that enhance breadth and specificity.
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These yet to be discovered antibodies may possess higher HIV inhibitory activity and
breadth than the antibodies that are currently in hand. Additional antibody exploration
efforts may be worthwhile to identify antibodies of interest with which to design epitope
mimetic vaccines, as has been successfully recently implemented (Correia et al., 2014;
Jardine et al., 2013).
IV.7 Conclusions and Future Directions
Two observations may be critical to explore in this current work. The maximum signal
difference in the binding assay for the BG505-SOSIP trimer between my variants and the
PG9wt is worth further exploration. Julien and colleagues observed that PG9 recognizes
the trimer asymmetrically (Julien et al., 2013). There are three epitopes displayed on the
apical tip of the gp120 trimer, yet PG9 only has a 1:3 valency of binding to HIV Env. The
molecular mechanism for this trimeric preference is unavailable due to the high resolu-
tion of the structure reported in the study, but the model suggests that PG9 may interact
with the adjacent N160 glycan. Could the mutation cause a change in valency in binding?
This change would explain to the maximal signal change in my binding assay. Future ex-
periments could replicate the study performed by Julien et al. either with high-resolution
gel-filtration or isothermal titration calorimetry.
Another observation is the glycan independence of the binding of the N109Y variant.
It was originally thought that the binding of any V1/V2 binding antibody would depend on
glycans at position N160 and N156/N1706 considering they not only block the recessed
C-strand epitope, but make considerable binding contributions for both PG16 and PG9
(McLellan et al., 2011; Pancera et al., 2013). It was demonstrated that these glycans are
needed for recognition and specificity, as mutational experiments completely abrogated
neutralization. I was able to replicate that finding, however, my variants still neutralized
HIV glycan knockout viruses, albeit, at much lower potency (3.52 µg/mL). It is worth
replicating this “glycan independence” with many more viral species that have been muta-
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genized to knockout glycans. I have already begun to pursue this aim.
Finally, I can attempt to repeat the application of this entire technology to mutagenesis
of PG9’s sibling, PG16. I already have the mutational candidates, and the antibody cDNAs
are being synthesized at the time of this writing. It is important to keep in mind that PG16
specific to the trimeric-Env, so variants can only be tested with neutralization experiments
or if I synthesize stable trimer (Sanders et al., 2013).
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CHAPTER V
Conclusions and Future Directions
V.1 Chapter II - Multi-state design and polyspecificity
I expand on the limitations of ROSETTADESIGN by looking at the imperfect agreement
between what we expect ROSETTADESIGN to recovery and what was actually observed.
I bin these into three categories, mature sequence bias, evolutionary sequence bias, and
incomplete ensemble bias. Section II.7 accounts for mature sequence bias, which may
be the most abstract concept. When a residue is “important” for most of the antibody-
antigen complexes, it should be recovered often. However if it only is important in a few
complexes, then any given residue can meet the design challenges for the complexes in
which it is not important.
Section II.8 refers to evolutionary sequence bias. Here we may see imperfect agreement
with the design and actual antibody sequence simply because the antibody has not achieved
maximal potency. ROSETTADESIGN may have selected better amino acid sequences for
the epitope. Given enough time to for complete antibody evolution, the sequence may have
matched. This is founded on the principle that ROSETTADESIGN gives the best sequence
for any design challenge.
Section II.9.1 gives the limits of computation including the finite ensemble size that
states there are not enough PDBs to compensate for “structural space” that ROSETTADESIGN sam-
ples. This section also details some of the more classic limitations including the limits of
the ROSETTA scoring function and limitations of the sampling algorithms. In the future this
may be ameliorated with more structures being deposited to the PDB, and improvements
to the scoring function including explicit solvent modeling.
The power of chapter II is in the future directions. While we use multi-state design
to interrogate the flexibility of the germline repertoire, the end goal was always to design
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Figure V.1: Multi-state design of broadly neutralizing influenza antibodies. Initially, the
antibody CR6261 only binds and neutralizes only Influenza A subtypes. Using multi-state
design I plan to make minimal mutations at the interface that allow binding to Influenza
type B while retaining binding to Influenza type A. This principle allows me to design in
cross-specificity.
cross-binding antibodies. Many pathogens which evade traditional vaccination do so by
evolving multiple serotypes or antigenic variants that encompass a tremendous sequence
space. HIV, Influenza and dengue virus (DENV) are such examples of antibodies that
use antigenic variation as a means to evade a broadly protective immunogenic response.
It is to these pathogens that a broad cross-reactive response will be critical (Corti and
Lanzavecchia, 2013; Lanzavecchia and Sallusto, 2009; Corti et al., 2011; Simonelli et al.,
2013). Multi-state design will be invaluable in the design of these antibodies. Consider V.1,
here we take a known cross-reactive group 1 antibody against influenza known as CR6261
(Throsby et al., 2008) which does not bind to Influenza type B.
I even took this idea into the lab looking at special cases for influenza antibody. I
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considered the antibody CR6261 as it was bound to the stem portion of influenza (Corti
et al., 2011). At the stem region, their is less conformational diversity. I hypothesized
that this epitope loses neutralization affinity due to point mutations at the interface rather
than large conformational shifts that are evident in the head region. This would be easier
for ROSETTADESIGN to recover. First, I wanted to create a proof-of-concept by seeing if
we can enhance specificity to already known binders. I chose H1/South Carolina/1918 and
H5/Vietnam/2004 pandemic strains as both had a crystal structure bound to CR6261. Using
multi-state design, I asked ROSETTADESIGN to enhance binding to both variants. Figure
V.2 shows the design process. The sequence logo in (A) shows the amino acids preferred at
the interface. For (B), we analyzed the fitness of each mutation as either having beneficial
or deleterious effects. If it enhanced fitness for both H1 and H5, we made the mutations
in the laboratory. They indeed did enhance binding to both variants compared to wild-type
CR6261 (figure V.2 C.).
Of course this proof-of-concept can extend well beyond influenza. My plan was to
use this to get a serotype specific antibody to bind (and therefore, potentially neutralize)
cross-serotype, cross-group, and cross influenza sub-type. However, many labs are trying
to design cross-reactive antibodies. One advantage of multi-state design is that if you fine-
tune specificity you do not have to lose specificity to your original epitope. For example,
in a paper by Simonelli et al. (Simonelli et al., 2013), they used computational modeling
along with NMR restraints to place give a molecular definition of an anti-DENV against
all four DENV serotypes. They then used their knowledge of rationale design to fine tune
specificity to each serotype individually. However, upon making one mutation specific to
a given serotype often abrogated binding to the others. Therefore it is possible to enhance
breadth at the cost of specificity. This type of problem is ideal for multi-state design as it
can fine tune specificity without predicted loss of binding to your original epitope.
In related work, structural viral homologs could also be used in multi-state design.
For example, an antibody found in chronically exposed repository infected patients bound
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Figure V.2: Preliminary for MSD proof-of-concept. A sequence logo for all positions
considered for redesign at the interface. Higher letters indicate ROSETTA’s proclivity for a
certain amino acid sequence (A). Fitness analysis of each position is a sum of stability and
binding energy. Lower energies indicate better fitness. Ideally, both H1 and H5 would have
decreased fitness energy. Stars indicate mutations that were made experimentally (B). The
binding affinities from the suggested mutations from ROSETTA. The double mutant gives
the best binding affinity (C).
and neutralized four different paramyxoviruses, human respiratory syncytial virus (HRSV),
human metapneumovirus (HMPV), bovine RSV (BRSV) and pneumonia virus of mice
(PVM) (Corti et al., 2013). This antibody was found by screening a common structural
homolog (prefusion protein F) against anti-HRSV screened from over 200 donors to nar-
row down their search. I hypothesize that this type of structural information can be used
in multi-state design to make de novo designed cross-neutralizers much the way nature
selected cross-neutralizers from these patients.
Finally, there is much use for this algorithm’s fitness function. While I describe anti-
body design in the context of designing for a certain antigen, it may be beneficial to design
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against. I can modify the scoring function in such a way where we select mutations that will
design for one antigen, and design against others. This allows any fine tuning of specificity
changes that are needed against antibodies while not compromising the structural integrity
of the immunoglobulin fold. I can imagine this will be an invaluable tool for designing
against antigens that are found to be related to autoimmunity.
V.2 Chapter III - Broadly neutralizing antibodies from HIV-naïve donor repertoires
In chapter III, I used antibody design to interrogate the HIV-naïve repertoire to answer a
simple question for the paradigms of HIV vaccinology. How close is the naïve donor reper-
toire to eliciting neutralizing antibodies? I used the principles guided by both reverse and
forward vaccinology (Burton et al., 2012). Reverse vaccinology principles require that the
broadly neutralizing antibodies are first characterized from chronically infected patients.
I used the the V1/V2 binding antibody PG9 that was discovered in a chronically infected
African donor (McLellan et al., 2011; Walker et al., 2009). This is where I introduced a
new paradigm into vaccinology. Rather than used structure based immunogen design from
the PG9 epitope which has been characterized, I instead investigated the healthy donor
repertoire. In my early work here, I had helped discover long HCDR3s in healthy donors,
and it was with this information I wanted to pursue this question.
I conclude that although there are some antibodies from the HIV-naïve donor repertoire
that are able to mimic PG9 hammerhead like configuration, there are very few from our
population pool. Even those that we did find needed some amounts of mutation that honed
specificity to make these antibodies truely binding and neutralizing.
There is an absolute limitation to this study, and that is the amount of long-HCDR3
sequences we started with. Out of one-half-billion sequences, we only were able to obtain
26,000 unique 30-length sequences that were viable in our study. That is an incredibly
low amount. Along with Andy Fire, Jessica Finn and myself, we have devised new clever
experiments that can potentially enrich for long HCDR3s. We have noticed that in this
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Figure V.3: HCDR3 of JH6 gene families. A distribution curve for HCDR3 sequences is
shown for all VDJ familes (black). When only JH6 genes are considered, the mean length
shifts from 15.56 to 18.06. If only JH6 and VH3 gene families are considered the mean
shifts down to 17.92.
study and previous studies, that most antibodies with long HCDR3s contain a JH6 gene
segment (Briney et al., 2012). In addition, PG-type antibodies often use VH3-30 genes.
This makes the initial PCR rounds for gene-specific targeting a simple task. Rather than
use ambiguous primer-sets for all gene families, I plan to use just specific primers to JH6
and VH3-30 for amplification of B-cell mRNA transcripts. I can actually predict that this
will enhance the mean HCDR3 length from 15.56 to 18.06 (figure V.3). In addition, new
advances in high resolution gel electrophoresis allow single base pair resolution and pu-
rification. That would allow only very-long HCDR3 sequences to be purified and enriched
from the canonical length background. Using this, I could truly use this population pool in
my newly created bioinformatics pipeline to test the HIV-naïve donor sequences.
One problem that is mentioned is the potential framework bias. Although it has been
demonstrated that the HCDR3 loop is responsible for a majority of the contact and by ex-
tension the mechanism of neutralization (Pejchal et al., 2010; Pancera et al., 2010), it can’t
be ruled out that the framework provides some contribution to binding in the LHCDR3 and
HCDR2 region (McLellan et al., 2011). However, in recent studies, mutations all the way
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back to germline have shown that these mutations aren’t absolutely necessary necessary
to necessitate binding and by extension neutralization (Klein et al., 2013). In chapter II,
we find at least fifty percent of the the germline framework may be necessary for binding,
even those residues that lie extremely distal to the interface. This leads me to believe in
an inherent framework bias in our study. I used PG9 framework as the complete sequence
to the rest of the heavy chain and the light chain was unknown (the current technology is
limited at the time of writing). But other studies show us that surrounding mutations of the
HCDR3 loop allow it to form its native conformation (Wong et al., 2011). I want to know
the effects of other germline frameworks on HIV-naïve HCDR3 loops.
I proposed a display technology solution to this problem. If I can isolate 30-length (or
longer) HCDR3 sequences from the B cell repertoire, I can engineer cloning sites into them
as I have done for the PG9 framework. However, each cloning site will be slightly upstream
of the HCDR3 site. In this manner we can use any germline framework to test each HIV-
naïve conformation. In this way, we can test inherit framework bias from each germline
framework on the healthy HCDR3 sequence. For the amount of HCDR3 sequences I get
(roughly estimate 100,000 using the technique described above), I can test this on each VH
gene family, giving 5.2 million different combinations of antibodies I can test and remove
framework bias. In addition, I can combine germline light chain repertoires to increase
our combinations. I feel like this would be like an incredibly useful experiment to find
antibodies from HIV-naïve donors with the absolute minimum amount of mutations. In
this way I can get an absolute threshold to describe what a vaccine will need to elicit using
a very inexpensive technology.
V.3 Chapter IV - Broadly neutralizing antibody redesign
I indicate some of the issues with redesign and highlighted them in the publication that ac-
companies chapter IV. For instance, ROSETTADESIGN, indicated that D115N would be the
most beneficial mutation. When I characterized this mutation experimentally, I found this
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mutation to actually hinder binding. This is due to some of the limitations of ROSETTA that
have been discussed at length, especially in chapter II where I discuss the limits of the
ROSETTA scoring function. This is being addressed by a large number of ROSETTA col-
laborators in the Commons with more accurate representation of hydrogen bondings and
explicit solvent models.
The excitement of future endeavors with the redesign of antibodies is the most exciting
and probably one of the most straight forward future directions I have. For one, this type
of design which we applied to PG9 can be applied to any antibody, whether it be broadly
neutralizing or modestly potent. ROSETTA allows us to tailor the scoring function to de-
sign for stability or binding energy, which we have found to be a necessary component to
increasing potency and breadth of contemporary antibodies.
One step I have taken with future directions, is applying the same methodology to
PG9s sister antibody PG16. In figure V.4, an initial pilot study using the same redesign
methodology has been performed. As is evident, some of the PG16 variants are able to
bind BaL gp120 monomers with greater affinity. There is a huge caveat at the current time
of this study. These PG16 HCDR3 loops were put on the PG9 backbone with the exception
of PG16wt. The PG9 framework may be responsible for the antibody binding BaL gp120
monomer. I have begun taking these constructs and putting them on PG16 backgrounds
to see if there is difference in PG9/PG16 backbone. If there is, that gives plausibility to
framework bias as discussed above.
The future for antibody redesign is staggering, especially in context of evolutionary
sequence bias as introduced above. Researchers isolate antibodies in the middle of their
evolutionary cycle where they may not be optimized for potency and breadth, only the
ability to bind and not necessarily to a threshold. With the redesign principles that we
have gained insight into with PG9 redesign, it opens up an exciting new avenues for any
antibodies, and aids in understanding the principles that need to be considered for the grand
challenge in antibody design, the de novo design of a nM binder.
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Figure V.4: An initial pilot study with PG16 HCDR3 variants on a PG9 backbone. All
the variants have a PG9 backbone except for PG16wt which may explain the strength in
binding. Various negative and positive controls are shown for other viral species.
V.4 Other Applications of Antibody Design
My very first specific aim was to establish a correlation between in silico binding energy
and experimental binding energy. This was the start of a very tedious process of making
diverse HIV antigen to test two broadly neutralizing antibodies VRC01, and b12 (Wu et al.,
2009; Li et al., 2011). As I began reading the literature, most notably a study done by Kwon
and colleagues (Kwon et al., 2012), I noticed that the VRC01 bound gp120 was different
from the b12 bound structure where the b12 bound structure is in the pre-CD4 bound state
and VRC01 is in the CD4-bound state. I hypothesized that, VRC01 would be entropically
limited because it would always need to change the conformation of gp120 in order to bind.
However when it does so, it exposes an extremely conserved epitope.
To first test this hypothesis, I wanted a baseline of gp120 binding using ELISAs and
EC50 as a metric. Figure V.5 panel A and B show these curves for many variants of gp120
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for b12 and VRC01, respectively. I then started to use ITC to get a better metrics of how
each antibody was binding (figure V.5 C), and I found that VRC01 made many hydrogen
bonding contacts, but gave up huge entropic penalties. Much work is needed on this front
as an accurate ITC for each variant is absolutely necessary to confirm this hypothesis, but
the initial work of creating constructs and protein has been done. It is also important to
note that the reported literature values may be different from mine which again underlines
the importance of in house experiments.
With the EC50 values, I can plot an in silico binding energy vs. the experimental bind-
ing energy (figure V.5) and find that there is no correlation for VRC01 but good correla-
tion for b12. This result is intriguing as the conformational shift is not accounted for in
ROSETTA and there are probably many other states that gp120 samples. A mechanism of
resistance has been worked out with brute force (Li et al., 2011), but I would like to confirm
in silico.
These results are very preliminary and would best be guided by ITC experiments for
the rest of the variants, but much of the work has been done.
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Figure V.5: CD4 binding mAbs mechanisms of escape. Binding ELISAS against clade
B and C gp120 monomers for CD4 binding antibody b12 (A) and VRC01 (B). Isothermal
titration calorimetry of VRC01 antibody against b12 highlighting enthalpic domination (C).
Experimental vs. literature binding values show a weak correlation (D). Computational
predicted binding energy for homology modeling of VRC01 and gp120 variants and b12
and gp120 variants correlates well for only b12.
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CHAPTER VI
Appendix
VI.1 Appendix I - ROSETTA Glossary
All-atom - in the case of sampling, synonymous with fine movements and often including
side chain information; also referred to as high-resolution
Benchmark - another word for a test of a method, scoring function, algorithm, etc. by
comparing results from the method to accepted methods/models
Binary file - a file in machine-readable language that can be executed in silico
BioPython - a set of tools for biological computing written and compatible with Python
Build - to compile the source code so it may be used as a program
Centroid - in ROSETTA centroid mode, side chains are represented as unified spheres cen-
tered at the residues center of mass
Cluster center - the geometric center of a cluster, or group, of models
Clustering - grouping models with similar structure together
Comparative model - a protein model where the primary sequence from one protein (tar-
get) is placed, or threaded, onto the three dimensional coordinates of a protein of known
structure (template)
Cyclic coordinate descent (CCD) - based on robotics, CCD loop closure is used to build
loops in ROSETTA by fragment assembly and close loops by decreasing the gap between
two termini in three-dimensional space
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De novo - from the sequence; also called ab initio, with no experimental guidance
Directory - synonymous with a folder, usually contains one or more files or other folders
Distance matrix - a matrix containing the pairwise distances for every point in a set of
points
Dunbrack rotamer library - a set of likely side chain conformations for the twenty canon-
ical amino acids based on protein structures in the Protein Data Bank (PDB)
Executable - binary file used to execute the program
Force field/Scoring function/Energy function/Potential - often used interchangeably; a
means of assessing the energy of the generated models
Fragment - in ROSETTA folding and loop building, a set of three-dimensional coordinates
corresponding to a given amino acid sequence fragment
Database - also called the fragment library, contains all the interchangeable data needed
for ROSETTA
Gap - in sequence alignment, a gap is inserted when the sequences are of low homology;
usually appear as a dash (-); the gaps form a sequence alignment correspond to areas where
loops are built during comparative modeling
GDT/GDT_TS - global distance test (total score); a measure of similarity between two
protein structures having the same amino acid sequence; the largest set of residues Cα-
atoms in the model structure falling within a defined distance cutoff of their position in the
experimental structure
Gradient-based minimization - also known as minimization by steepest descent; in this
case, a means of energy minimization in which one takes steps proportional to the negative
of the gradient of the function (energy) at the current point
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High-resolution - in the case of sampling, synonymous with fine movements and often
including side chain information
Homology model - a more specific type of comparative model where the protein sequence
of interest (target) is a homolog of the protein of known structure (template)
Interface delta - the interface delta score is defined as the contribution to the total score
for which the presence of the ligand is responsible
Kinematic loop closure (KIC) - robotics-inspired loop closure algorithm which analyti-
cally determines all mechanically accessible conformations for torsion angles of a peptide
chain using polynomial resultants
Knowledge-based - in the case of ROSETTA, based on information obtained from struc-
tures found in the PDB
Libraries - in computing, a collection of code and data (classes and functions) used by a
piece of software and is often used in software development
Ligand - the part of the structure that binds to a protein to serve some biological purpose
Low-resolution - a somewhat subjective term, in the case of sampling, synonymous with
coarse movements of the protein and/or ligand backbone and side chains; the individual
atoms of low-resolution structures or models cannot be resolved, or observed
Metropolis criterion - often combined with the Monte Carlo sampling algorithm; allows
for generation of an ensemble that represents a probability distribution
Model - in the case of this protocol, a structure generated by ROSETTA; sometimes called
a decoy
Monte Carlo sampling - a randomized and repetitive computational sampling method
Mover - a generic class that takes as input a pose and performs some modification on that
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pose; for example, a mover might take in a pose and rotate every residue
Namespace - in computer science, an abstract container holding a logical grouping of
unique identifiers or symbols; in ROSETTA, examples of namespaces are loops, relax, etc.
Native-like - close to the experimentally determined structure; a model that is native-like
usually has an RMSD to the experimentally determined structure of < 2Å
Options file - often called a flags file; a file containing ROSETTA options that can be
passed to a ROSETTA executable after the @ symbol; can be easier to use than passing
ROSETTA options over the command line
Pack/repack - in ROSETTA, side chains are packed/repacked by switching out rotamers
and scoring them using the ROSETTA scoring function
Pose - in ROSETTA protocol, a three-dimensional conformation of the ligand, protein, or
ligand/protein complex at any given time-point
Python - interpreted, object-oriented, high-level programming language http://www.python.
org/
Relax - in ROSETTA, an iterative protocol of side chain repacking and gradient-based min-
imization; often referred to as full-atom (or all-atom) refinement
Robetta ROSETTAstructure prediction server (http://robetta.bakerlab.org/) freely available
to not-for-profit users
RosettaCommons - a group of more than twenty labs that develop the ROSETTA software
suite
REU - arbitrary energy units specific to the ROSETTA scoring function
RosettaScripts - also called “the scripter” or ROSETTAXML; an XML-like language that
allows for specifying modeling tasks in ROSETTA
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Rotamer - rotational conformer of an amino acid or ligand side chain
SCons - a tool for constructing software from its source code http://www.scons.org/
Script - in computer programming, a script is a sequence of instructions that is interpreted
or carried out by another program rather than by the computer processor (as a compiled
program is)
Source code - human-readable files that are the implementation of the program; are written
in C++ in ROSETTA
Target - in comparative, or homology, modeling, the protein for which we are generating
a model; the target sequence is the primary sequence of the protein for which we want to
make a model
Template - in comparative modeling, the protein of known structure on which the target is
threaded
Threading - placing the primary sequence of one protein (target) on the three-dimensional
coordinates of a protein of known structure (template) based on a sequence alignment loop
building
XML - Extensible Markup Language; in this case, used to write protocols to pass to
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VI.2 Appendix II - ROSETTA Scoring Terms
Scoring Term Explanation of Scoring Term
Attraction The Van de Walles scoring term to indicate how much attraction
residues have on each other
Dunbrack A statistical probability score indicating how often a side-chain
configuration has been seen in the protein data bank (PDB)
Repulsion The Van De Walles scoring term to indicate how much repulsion
residues have on each other
Solvation How well are hydrophobics packed away from solvent and hy-
drophillic groups are facing solvent
Ramachandran A statistical probability of how well φ -ψ angles fit into the Ra-
machandran plot as a function of secondary-structure
Total A summation of all individual scoring terms to get a total score
∆∆G The change in total energy score when residues are moved out of
complex
φ -ψ Prob A statistical probability score of how well a side-chain configura-
tion has been seen given a φ -ψ angle in the PDB
Cation-pi A score encompassing how the configuration of positive cation at
the end of a charged residues interact with pi orbitals
pi-pi A score encompassing how two pi orbitals interact
HCDR3 Stabilization The total score of residues only found in the HCDR3
Full Complex Stabilization The total score of all residues representing a free energy of the
model
HCDR3 Binding The contribution to ∆∆G by residues found in the HCDR3
Full Complex Binding The ∆∆G for the entire complex
Table VI.1
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VI.3 Appendix III - Materials and Methods
VI.3.1 Chapter II - Materials and Methods
VI.3.1.1 Selection of Antigen-Antibody Complexes
Diverse antigen-antibody complexes were collected from the Protein Data Bank (PDB;
www.pdb.org) in which antibodies in different complexes were derived from the same pre-
dicted heavy chain variable gene segment. Candidate complexes were queried from the
protein databank using the IMGT-3D structural query editor for immune system receptors
(Kaas et al., 2004). PDB structures were used as design candidates if they met the follow-
ing criteria: 1) the antibody was encoded by a VH1-69, VH3-23, or VH5-51 gene segment,
2) the structure contained a human immunoglobulin, and 3) the ligand type was a protein
complex. The search yielded 10, 8, or 3 antibody-antigen complexes encoded by the heavy
chain variable gene segments VH1-69, VH3-23, or VH5-51, respectively. Nature of the
antigen and antibody isotype were not considered in the selection as the 21 complexes rep-
resent an exhaustive search of the PDB for these gene-segments. The gene segments were
aligned using the ClustalW2 multiple sequence alignment algorithm (Larkin et al., 2007).
Each input structure was energetically minimized using the ROSETTAscoring function but
constrained to PDB input backbone coordinates (Das et al., 2007).
VI.3.1.2 Multi-state Design of Antigen-Antibody Complexes
Three design experiments were performed, one for each of the three germline segments
(VH1-69, VH3-23, or VH5-51) using the multi-state design mode of the ROSETTA algo-
rithm and scoring functions. I adapted a generalized multi-state design protocol that was
described in detail previously that perform design on multiple antibody-antigen complexes
at once (Leaver-Fay et al., 2011a). Briefly, each computational design experiment com-
puted an optimal sequence predicted to define a low-energy structure. In the multi-state de-
sign experiments, an energetic consensus sequence for all of the states was predicted, rather
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than treating each state as a separate entity. The energy for a given sequence was computed
and designated the “design fitness” for all states. The corresponding amino acids were
derived from the alignment (e.g., heavy chain amino acid 5 on complex A corresponded
to heavy chain amino acid 5 on complex B). The details of the multi-state algorithm is
described elsewhere (Leaver-Fay et al., 2011a).
VI.3.1.3 Single-State Design of Antigen-Antibody Complexes
Single-state design was performed using the ROSETTA multi-state application. The algo-
rithm was altered so that only one complex was considered for each of the 10, 8, or 3 design
experiments with VH1-69, VH3-23, or VH5-51 complexes, respectively.
VI.3.1.4 Design Analysis of Multiple- or Single-State Design
For each design experiment, 100 independent design trajectories were calculated. Sequence
logos then were generated using the Berkley web-logo server (http://weblogo.berkeley.
edu/) (Crooks et al., 2004). Information for each sequence logo can be extrapolated as
follows extending the work of Schneider et al. (Schneider and Stephens, 1990). For each
variable position, the probability of seeing each of the 20 naturally encoded amino acids pi
was computed and compared with the background probability pb = 1/20 = 5%. To quan-
tify the deviation of the observed probability from the background probability I compute
the self-information for each of the 20 amino acids as Ii = pi x log2(20 x pi) in ‘bit’. If
the amino acid occurs as often as expected from the background probability, Ii is zero. Ii
becomes larger if the amino acid is over-represented and approaches 4.32 if pi = 100%. A
total bit-score for the sequence design was obtained by summing all individual bit-scores
for each amino acid. The bit-scores for the target sequence then were analyzed, and statis-
tics were computed using Prism software version 5.0 (GraphPad Software). For compar-
isons between germline sequence and mature sequence within the same design experiment,
a Wilcoxon matched pairs test (non-normal, paired t-test) was used to compute the p-value
at 99% confidence level. For comparison between design experiments, a student’s paired
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t-test was used to compute the p-value at 99% confidence level.
VI.3.1.5 Amino Acid Environment
The neighbor vector algorithm quantitatively determines the surface-exposure of a given
residue and is described by Durham and colleagues elsewhere (Durham et al., 2009).
Briefly, each Cβ is computed to a vector and each vector is given a score based on the
number and orientation of each Cβ in the proximity. The weight of each neighbor falls of as
a function of distance. For interface scores, the change in neighbor vector was used, where
the neighbor vector score of the amino acids in the unbound antibody is subtracted from
the neighbor vector scores of the complex. Interface residues would have a large change in
neighbors and proportional to the change in neighbor vector score.
VI.3.1.6 Phi-psi Angle Calculations
All VH framework residues were grouped by complex. For each residue, phi-psi angles and
secondary structure classification were determined using DSSP (Kabsch and Sander, 1983).
For each residue position across all complexes considered in design, the standard deviation
of the phi-psi angles was calculated if they were included in the beta-sheet framework. A
student’s t-test was performed between the standard deviations between residue positions
that recovered to germline (bit-score > 1), or did not recover to germline (bit-score < 1).
For a reference, a deviation for all framework beta-sheet positions was also calculated for
all residues even if they were not included in the design protocol.
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VI.3.2 Chapter III - Materials and Methods
VI.3.2.1 RNA Extraction
Peripheral blood mononuclear cells were isolated from 64 HIV-uninfected individuals (HIV-
naïve) by processing leukoreduction filters as previously described (Weitkamp and Crowe,
2001). Briefly, RC2D leukoreduction filters were obtained from the American Red Cross
and were backwashed with 35 mL of sterile PBS with 10mM EDTA. The resulting PBMC
suspension was overlaid onto 15 mL of HistoPaque 1077 and centrifuged at 600 RCF for
25 minutes. The buffy coat was removed and washed twice with fresh PBS with 10mM
EDTA. Total RNA was isolated from 10 million PBMCs using the RNeasy kit according to
the manufacturer’s standard operating procedure.
VI.3.2.2 cDNA Synthesis, PCR Amplification and Purification
cDNA was synthesized from 100 ng of total RNA and 10 pmol of each RT-PCR Illumina-
adapter primers in duplicate 50 µL RT-PCR reactions using the OneStep RT-PCR system.
The RT-PCR reactions were performed in a BioRad DNA Engine PTC-0200 thermal cycler
running the following protocol: 50◦C for 30:00, 95◦C for 15:00, 35 cycles of (94◦C for
0:45, 58◦C for 0:45, 72◦C for 2:00), 72◦C for 10:00. cDNA synthesis was confirmed on a
1% E-Gel EX. After which duplicate reactions were pooled. 2 µL of each cDNA sample
and 20 pmol of each indexed Illumina-adapter primer were used to template 100 µL PCR
amplification reactions in duplicate using the AmpliTaq Gold polymerase system. Thermal
cycling was performed using the following protocol: 95◦C for 10:00, 10 cycles of (95◦C
for 0:30, 58◦C for 0:45, 72◦C for 2:00), 72◦C for 10:00. Amplicons were purified from
the PCR reaction mix using the Agencourt AMPure XP system following the standard
protocol, and duplicate reactions were pooled during the final elution. The removal of
primers and correct amplicon size was confirmed on a 1% E-Gel EX. Each amplicon sample
was quantified using a Qubit fluorometer and the Quant-iT® dsDNA HS Assay Kit and
8 indexed amplicon samples were pooled for each of the 8 lanes on the Illumina HiSeq
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flowcell.
VI.3.2.3 Illumina HiSeq Protocol
The amplicon libraries underwent quality control by running on the Agilent Bioanalyzer
High Sensitivity DNA assay to confirm the final library size and on the Agilent Mx3005P
qPCR machine using the KAPA Illumina library quantification kit to determine concen-
tration. For each library a 2 nM stock was created and denatured with NaOH. 12 pM of
denatured libraries were loaded on the Illumina cBot for cluster generation on a paired-
end flow cell. The flow cell was then loaded onto the Illumina HiSeq 2000 utilizing v3
chemistry and HTA 1.8. The raw sequencing reads in BCL format were processed through
CASAVA-1.8.2 for FASTQ conversion and demultiplexing. The RTA chastity filter was
used and only the pass filter reads were retained for further analysis.
VI.3.2.4 Paired-End Read Assembly and Junction Analysis
FASTQ paired end reads were input into PANDAseq assembler software to produce a single
sequence that was indexed by donor and position (Bartram et al., 2011). Each sequence
was uploaded to a custom database using the MongoDB framework that carried donor,
position, sequence, and Phred quality score. The resulting sequences were concatenated
and converted to FASTA format using BioPython SeqIO module (Cock et al., 2009). Heavy
chain CDR3 (HCDR3) junctions were analyzed using custom software. The software was
modified to run in parallel on a high throughput computing cluster and to condense output
to a minimum number of fields. The software was also modified to output the junction
results in JSON format. The sequences were analyzed with BioPython to remove sequence
ambiguity in each donor. The JSON files were then uploaded to the custom database using
MongoDB framework. The two databases were linked by their donor id and position.
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VI.3.2.5 30 Length HCDR3 Selection and Position Specific Structure Scoring Matrix
(P3SM) Generation
The custom database was queried for 30-length HCDR3 amino acid sequences generating
> 26,000 unique sequences. 4,000 random sequences were selected for the pilot analy-
sis in order to generate a custom position specific structure score matrix (P3SM) for PG9
HCDR3 structure. PG9 in complex with scaffolded template CAP45 (PDB ID: 3U4E) was
used as a starting structure. The structure was stripped of waters and heavy chain and
light chain constant regions. For the first round pilot, I also removed the CAP45 com-
plex. Next, I used ROSETTASCRIPTS application available with the software suite from
the ROSETTACOMMONS (www.rosettacommongs.org) to thread and minimize the random
HCDR3 sequences from HIV-naïve donors (Fleishman et al., 2011a). 50 decoys of each
sequence were allowed to energetically minimize after threading yielding 200,000 models.
2,000 sequences (100,000 models) were used to fill the 30 by 20 P3SM using ROSETTA per
amino-acid energies of the HCDR3 loop. The remaining 2,000 sequences were used to
benchmark the P3SM protocol.
VI.3.2.6 Selecting Sequences from the P3SM Heuristic for Validation
After benchmark validation, the random 4,000 sequences were used in a final construction
of a P3SM. Rapid prediction of score for each of the 26,000 HIV-naïve HCDR3 sequences
were calculated using the P3SM. PG9’s sequence scored 112nd out of 26,000 giving a noise
tolerance of -3.82 REU (The top scoring sequence subtracted from the PG9 Score). Using
± 3.82 as my noise tolerance from PG9’s score, 1,000 candidate sequences were selected
to be further evaluated in complex.
VI.3.2.7 Sequence Tolerance Evaluated by Rosetta Design in Complex
The top 1,000 candidate sequences evaluated by the P3SM were carried on to a separate
ROSETTA protocol. This protocol evaluated sequence tolerance in complex with CAP45
antigen and surrounding glycans. N-linked glycan 156 and 160 (HXBC2 numbering) were
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both included in the complex input to ROSETTA as a non-canonical amino acid using the
method described in Renfrew et al. (Renfrew et al., 2012). After determining proper
binding orientation with PG9, the entire complex was threaded with HIV-naïve sequences.
High-resolution docking perturbations were allowed but highly constrained to initial orien-
tation using standard ROSETTA constraints files. I generated 100 models for each naïve se-
quence and calculated a binding energy for each complex as:
∆∆G= ∆GBound−∆GUnbound
were,
∆GBound = RosettaScoreComplex
and
∆GUnbound = RosettaScoreSeparated
In addition, the protocol was run a second time with sulfated tyrosines at positions 100G
and 100H (Kabat numbering) if a tyrosine appeared at those positions in the HIV-naïve se-
quences. Complex energies and interface binding metrics were parsed into a MySQL
database for further analysis using included scripts from BioPython.
VI.3.2.8 Bootstrapping with Complex Energies
The energy of each model evaluated in complex was reapplied to the P3SM and again ran
through each HIV-naïve donor sequence to predict a Rosetta energy using the same method-
ology as described. The bootstrapped models were included in the rest of the protocol.
VI.3.2.9 HIV-Naïve Complex Energy Evaluation
To filter naïvesequences into a realistic number to synthesize I evaluated multiple metrics.
To weight each sequence, Z-Scores were assigned for the following score term metrics.
HCDR3 total energy, HCDR3 Cα-RMSD, HCDR3 ∆∆G (the contribution to binding en-
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ergy from just the HCDR3), total ∆∆G, ASN156 ∆∆G, and ASN158 ∆∆G. The Z-score is
a measure of how many standard deviations a scoring metric fell from the mean. In terms
of energy, all negative Z-Scores are preferred. When a Z-score was assigned for each HIV-
naïvecomplex sequence, an average weighted Z-score was calculated using the following
equation:
Weighted-Z=
∑Ni wi×Zi
N
Weights (wi) for each score term in the equation: total ∆∆G -3.0, HCDR3 Cα-RMSD -
0.5, HCDR3-∆∆G -1.0, HCDR3 Score - 1.0, ASN156 ∆∆G - 0.5, and ASN158 ∆∆G - 0.5.
This comprehensive metric can be used to rank-order each complex. In addition I used
PG9 as a positive control and determined how many standard deviations away each of the
HIV-naïve complex scoring terms were from PG9’s score using the following equation:
Compare Score=
X¯ScoringTerm− X¯PG9ScoringTerm
σPG9ScoringTerm
The compare score can then be weighted using the previous equation using the same
weights to give one comprehensive metric to rank-order each HIV-naïve sequence. The
top 50 sequences were selected based on the average of the weighted compare score and
weighted Z-score. 32 additional models were included from the bootstrapped protocol in
the final results yielding 82 candidate HIV-naïve sequences for experimental characteriza-
tion.
VI.3.2.10 Clustering Analysis
The sequences were clustered with ClustalW2 built in clustering algorithm after a multi-
ple sequence alignment. The ClustalW plugin was used from the Genious Software suite
(http://www.geneious.com/). The dendrogram was manually inspected and clusters were
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assigned yielding 10 candidate sequence groups for experimental characterization.
VI.3.2.11 Design Analysis for Sequence Tolerance
Using the ROSETTADESIGN algorithm, the HIV-naïve sequences tested for recovery using
a small energetic bonus for favoring the native sequence (Kuhlman and Baker, 2000). I
applied a filter to minimize score and binding energy while favoring the native sequence.
100 models were generated using this protocol. After analysis, the sequence recovery
was added to the Z-score metrics and the compare score using a weight of -2.0 (negative
weight for favoring positive deviations) and reevaluated. Within each cluster, the HIV-
naïve sequence with the highest recovery and lowest Z-Score was further evaluated. For
each mutated position, if a mutation was seen in greater that 10% of the models and gave
an energetic bonus of greater than 1.5 ROSETTA Energy Units (REUs), it was manually
inspected using PyMOL and compared with the native sequence along with the native PG9
sequence from the native crystal complex (PDB ID: 3U4E).
VI.3.2.12 Antibody Expression
To prepare HIV-naïve PG9 variants and PG9 variant point mutations, I used recombinant
expression in mammalian cells as previously described (Xu et al., 2010). Briefly, the MAb
PG9 heavy- and light-chain genes were cloned into the pEE6.4 and pEE12.4 vectors, re-
spectively. A BsiWI and XhoI cloning site were generated at AA position 95 and 110
(Kabat numbering), respectively. Using the unique cloning sites, the HIV-naïve HCDR3 se-
quences were synthesized and cloned into the PG9 backbone. The DNA was co-transfected
at a 1:1 heavy-light chain ratio into HEK 293F using polyethylenimine transfection reagent
at a ratio 2:1 of PEI to DNA. 30 mL of culture was used for each variant and supernatant
was collected on day 3.
CAP45 gp120 was cloned into pCNA3.4 using HindIII and EcoRI restriction sites. A CD5
signal peptide and 8X HIS tag was cloned onto the 5′ and 3′ end respectively. The DNA
was transfected into HEK293F using polyethylenimine at a ratio of 2:1. On day 7, the
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supernatant was collected and purified with a 5 mL Talon cobalt HIS affinity column ac-
cording to the manufactures specifications. The protein was concentrated using centrifugal
units with a 100 kD cutoff.
VI.3.2.13 PG9/HIV Naïve Variant Antiboy Characterization
ELISA plates were coated with 2 µg/mL of goat-anti-human (H+L) unlabeled antibody in
PBS Buffer at 4◦ overnight. The wells were washed with 0.05% Tween and PBS Buffer
all of the following steps. Using 2% powdered milk and 1% goat serum, the wells were
blocked for 2 hours at room temperature. 200 µL of supernatant collected from expression
were applied to each well and allowed to complex with the capture antibody for 1 hour at
37◦. Starting at 25 µg/mL, 100 µL CAP45 gp120 was serially diluted at 1:3 in duplicate
and allowed to bind for 1 hour at 37◦. 100 µL of mAb b12 was used diluted at 1 µg/mL in
blocking buffer and allowed to incubate for 1 hour at 37◦. 100 µL of 1:5,000 of goat-anti-
human labeled with horseradish peroxidase secondary was added to each well and allowed
to incubate for 1 hour at 37◦. 100 µL of 3,3′,5,5′-tetramethylbenzidine was added to each
well. The reaction was stopped with 1N HCL and read at 450 nM absorbance. The EC50
of each HIV-naïve variant was compared with PG9 positive control.
VI.3.2.14 Statistics and Graph Generation
All statistics were calculated in the R-programming language (http://www.r-project.org) or
GraphPad package. All graphs were generated in GraphPad package or the ggplot2 library
(http://ggplot2.org) in the R-programming language.
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VI.3.3 Chapter IV - Materials and Methods
VI.3.3.1 Position Specific Scoring Matrix to Determine the Tolerance of Diverse Se-
quences to the Hammerhead Structure of PG9
We obtained large numbers of human PBMCs from 64 otherwise healthy HIV-negative sub-
jects by recovering cells from leuko-reduction filters obtained from the Nashville, TN Red
Cross. Bryan Briney extracted total RNA from white blood cells retained in the filters, then
performed RT-PCR amplification of expressed antibody heavy chain genes using primers
designed to amplify all human heavy chain antibody sequences (Briney et al., 2012). I
determined the sequences of the HCDR3 region of the amplicons using HiSeq next gener-
ation sequencing (Illumina) according to the manufacture’s instructions. Amplifying and
sequencing 64 donors separately yielded a total of 5.14 x 108 HCDR3 sequences. A subset
of 4,000 randomly selected 30-amino acid length HCDR3 sequences was used to deter-
mine what amino acids were tolerated by antibodies in the hammerhead configuration of
the PG9wt HCDR3 by threading each sequence over the backbone coordinates of PG9wt
using ROSETTA. The backbone was energetically minimized with iterative rounds of small
docking perturbations. Scores of each amino acid were input into a custom position spe-
cific scoring matrix (PSSM). The matrix then was used to rapidly compute the remaining
30 length amino acids predicted score given by ROSETTA.
VI.3.3.2 Redesign of PG9 HCDR3
Using the ROSETTADESIGN algorithm, iterative rounds of design, docking, and minimiza-
tion were applied to each position in the HCDR3 with a small energetic bonus applied to
recovery of the native sequence (Kuhlman and Baker, 2000). 100 models were generated
using this protocol (see protocol capture). For each mutated position, if a mutation was
seen in greater that 10% of the models and gave an energetic bonus of greater than 1.0
ROSETTA energy Units, it was manually inspected using PyMOL and compared with the
native sequence along with the native PG9 sequence from the native crystal complex (PDB
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ID-3U4E) (McLellan et al., 2011).
VI.3.3.3 Antibody and gp120 Expression
To prepare HIV-naïve PG9 variants and PG9 variant point mutations, I used recombinant
expression in mammalian cells as previously described (Xu et al., 2010). Briefly, the mAb
PG9 heavy- and light-chain genes were cloned into the pEE6.4 and pEE12.4 vectors, re-
spectively (Lonza). BsiWI and XhoI cloning sites were generated at AA position 95 and
130, respectively. HIV-naïve HCDR3 sequences were synthesized, and cloned into the
PG9 backbone (GeneArt) using the unique cloning sites. The DNA was co-transfected at
a 1:1 heavy-light ratio into FreeStyle 293-F cells (Life Technologies) using 25 kDa lin-
ear polyethylenimine (PEI, Polysciences Inc.) transfection reagent at a ratio 2:1 of PEI to
DNA. 30 mL of culture was used for each variant and supernatant was collected on day 5
and purified on a protein G column (GE).
Each gp120 was cloned into pCDNA3.4 (Life Technologies) using HindIII and EcoRI re-
striction sites. A CD5-signal peptide and 8x His tag was cloned onto the 5’ and 3’ end,
respectively. The DNA was transfected into FreeStyle 293-F cells using PEI at a ratio of
2:1 (Life Sciences). On day 5, the supernatant was clarified and the protein purified on a
5 mL HisTALON cobalt column (Clontech) according to the manufacturers specifications.
The protein was concentrated using Amicon Ultra centrifugal filters with a 100 kD cut-
off (Millipore, Billerica, MA) and further purified on a Superdex column (GE) using size
exclusion. BG505 SOSIP.664 trimer was received as a gift from John Moore.
VI.3.3.4 PG9 Variant Characterization
ELISA plates were coated with 3 µg/mL of gp120 and incubated overnight at 4◦C. The
wells were washed with phosphate buffered saline with 0.05% Tween (PBS-T) in all of the
following steps. The uncoated sites on the wells were blocked with 2% skim milk and 1%
goat serum in PBS-T for 2 hours at room temperature. All antibodies were diluted serially
in two-fold starting from 25 µg/mL for 24 dilutions. Horseradish peroxidase-conjugated
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goat-anti-human IgG was added to each well and allowed to incubate for 1 hour at 37◦C and
color developed with 3,3,5′,5′-tetramethylbenzidine (Thermo). The reaction was stopped
with 1N HCl and read at 450 nM. The EC50 of each PG9 variant was compared with PG9
positive control.
For BG505 SOSIP.664 Trimer, ELISAs were performed according the protocol as pre-
viously described (Sanders et al., 2013). Maxisorp 96-well plates (Nunc) were coated
overnight with mAb D7324 (Aalto Bioreagents) at 5 mg/mL in 0.1 M NaHCO3, pH 8.6
(100 µL/well). After the washing and blocking steps, purified, D7324-tagged BG505 Env
proteins were added at 800 ng/mL in PBS and 2% milk for 2 h at ambient temperature
and the unbound Env proteins were washed away. PG9 and PG9-variants were diluted to
25 µg/mL in PBS with 10% sheep serum/2% milk and diluted serially 2-fold and allowed
to incubate for 2 h at room temperature followed by 3 washes with PBS-T. Horseradish
peroxidase-conjugated goat-anti-human IgG was added for 1 h at a 1:3,000 dilution (fi-
nal concentration 0.33 mg/mL) in 10% sheep serum/2% milk, followed by 5 washes with
PBS-T. Color development and optical density measurement was done as above.
VI.3.3.5 Neutralization Assays
Neutralization was measured as a function of reductions in luciferase (Luc) reporter gene
expression after a single round of infection in TZM-bl cells as described (Montefiori, 2009;
Simek et al., 2009). This assay has been formally optimized and validated and was per-
formed in compliance with Good Clinical Laboratory Practices (Sarzotti-Kelsoe et al.,
2013). TZM-bl cells were obtained from the NIH AIDS Research and Reference Reagent
Program, as contributed by John Kappes and Xiaoyun Wu. Briefly, virus at a dose of
50,000-150,000 relative luminescence units (RLU) equivalents was incubated with serial
3-fold dilutions of test sample in duplicate in a total volume of 150 µL for 1 hr at 37◦C
in 96-well flat-bottom culture plates. Freshly trypsinized cells (10,000 cells in 100 µL of
growth medium containing 75 µg/mL DEAE dextran) were added to each well. One set of
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control wells received cells + virus (virus control) and another set received cells only (back-
ground control). After a 48 hour incubation, 100 µL of cells was transferred to a 96-well
black solid plates (Costar) for measurements of luminescence using the Britelite Lumines-
cence Reporter Gene Assay System (PerkinElmer Life Sciences). Neutralization titers are
the dilution at which RLU were reduced by 50% compared to virus control wells after
subtraction of background RLUs. Assay stocks of molecularly cloned Env-pseudotyped
viruses were prepared by transfection in 293T cells and were titrated in TZM-bl cells as
described (Li et al., 2005). Additional details of the assay and all supporting protocols may
be found at http://www.hiv.lanl.gov/content/nab-reference-strains/html/home.htm.
All of the Env-pseudotyped viruses used for these assays exhibited a Tier 2 neutralization
phenotype except for TH023.6 and TH023.6/N160A.5, which exhibited a tier 1A pheno-
type. The Envs for these pseudoviruses were derived from genetic subtypes A (398_F1_-
F5_20), B (WITO4160.33, X2278_C2_B6, SC422661.8, TRO.11, SC22.3C2.LucR.T2A.ecto),
C (Ce703010217, Du422.1, Ce1086_B2), G (X1632_S2_B6) and CRF01_AE (CNE55,
R2184.c04).
VI.3.3.6 Statistics and Graph Generation
All statistics were calculated in the R-programming language (http://www.r-project.org)
or Prism package (GraphPad) through the Ipython interface www.ipython.org. All graphs
were generated in Prism package or the ggplot2 library (http://ggplot2.org) in the R-programming
language.
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VI.4 Appendix IV - Experimental Standard Operating Procedures
VI.4.1 Antibody Synthesis From Crystal Structures
I will detail the process of gene synthesis for the Crowe Lab Lonza vector system using a
workable example.
VI.4.1.1 Full Heavy Chain Variable
Using PG9 Heavy Chain as a working example.
Get sequence from crystal structure
Using the PDB ID: 3U36 I get the heavy chain sequence in FASTA format:
>PG9_crystal_structure_3U36
QRLVESGGGVVQPGSSLRLSCAASGFDFSRQGMHWVRQAPGQGLEWVAFI
KYDGSEKYHADSVWGRLSISRDNSKDTLYLQMNSLRVEDTATYFCVREAG
GPDYRNGYNYYDFYDGYYNYHYMDVWGKGTTVTVSSASTKGPSVFPLAPS
SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKGLEVLFQ
Truncate to variable regions
The variable region starts with EVQ or EQL and usually ends with TVSS. This is
a bit subjective, but for this purpose, it does not really matter since I will prepend a
sequence:
>PG9_variable_domain
QRLVESGGGVVQPGSSLRLSCAASGFDFSRQGMHWVRQAPGQGLEWVAFIK
YDGSEKYHADSVWGRLSISRDNSKDTLYLQMNSLRVEDTATYFCVREAGGP
DYRNGYNYYDFYDGYYNYHYMDVWGKGTTVTVSS
Reverse translate
Use a reverse translator to get nucleotide sequences.
>PG9_variable_nucleotide
CAGCGCCTGGTGGAAAGCGGCGGCGGCGTGGTGCAGCCGGGCAGCAGCCT
GCGCCTGAGCTGCGCGGCGAGCGGCTTTGATTTTAGCCGCCAGGGCATGC
ATTGGGTGCGCCAGGCGCCGGGCCAGGGCCTGGAATGGGTGGCGTTTATT
AAATATGATGGCAGCGAAAAATATCATGCGGATAGCGTGTGGGGCCGCCT
GAGCATTAGCCGCGATAACAGCAAAGATACCCTGTATCTGCAGATGAACA
GCCTGCGCGTGGAAGATACCGCGACCTATTTTTGCGTGCGCGAAGCGGGC
GGCCCGGATTATCGCAACGGCTATAACTATTATGATTTTTATGATGGCTA
TTATAACTATCATTATATGGATGTGTGGGGCAAAGGCACCACCGTGACCG
TGAGCAGC
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Prepend 5′ region
I will prepend a 5’ smaI site (CCCGGG) and a portion of the leader sequence to keep
it in frame (TCTGGCT). The leader sequence will be kept in frame and cleaved.
>PG9_with_smaI
(CCCGGG)TCTTGGGCTCAGCGCCTGGTGGAAAGCGGCGGCGGCGTGGTG
CAGCCGGGCAGCAGCCTGCGCCTGAGCTGCGCGGCGAGCGGCTTTGATTT
TAGCCGCCAGGGCATGCATTGGGTGCGCCAGGCGCCGGGCCAGGGCCTGG
AATGGGTGGCGTTTATTAAATATGATGGCAGCGAAAAATATCATGCGGAT
AGCGTGTGGGGCCGCCTGAGCATTAGCCGCGATAACAGCAAAGATACCCT
GTATCTGCAGATGAACAGCCTGCGCGTGGAAGATACCGCGACCTATTTTT
GCGTGCGCGAAGCGGGCGGCCCGGATTATCGCAACGGCTATAACTATTAT
GATTTTTATGATGGCTATTATAACTATCATTATATGGATGTGTGGGGCAA
AGGCACCACCGTGACCGTGAGCAGC
Append 3′ region
I then add on an ApaI restriction site (GGGCCC) along with additional nucleotides
(GCCGGTACCAA) to keep it in frame.
>PG9_with_smaI/ApaI
(CCCGGG)TCTTGGGCTCAGCGCCTGGTGGAAAGCGGCGGCGGCGTGGTGCA
GCCGGGCAGCAGCCTGCGCCTGAGCTGCGCGGCGAGCGGCTTTGATTTTAGC
CGCCAGGGCATGCATTGGGTGCGCCAGGCGCCGGGCCAGGGCCTGGAATGGG
TGGCGTTTATTAAATATGATGGCAGCGAAAAATATCATGCGGATAGCGTGTG
GGGCCGCCTGAGCATTAGCCGCGATAACAGCAAAGATACCCTGTATCTGCAG
ATGAACAGCCTGCGCGTGGAAGATACCGCGACCTATTTTTGCGTGCGCGAAG
CGGGCGGCCCGGATTATCGCAACGGCTATAACTATTATGATTTTTATGATGG
CTATTATAACTATCATTATATGGATGTGTGGGGCAAAGGCACCACCGTGACC
GTGAGCAGCGCCGGTACCAA(GGGCCC)
Order Product
This will be the final product ordered. It is very important that you optimize for
mammalian systems. You also do not introduce the following sites: HindIII, EcoRI,
SmaI, ApaI. In addition, do not remove the SmaI or ApaI sites that I just added.
VI.4.1.2 Full Lambda Chain Variable
Using PG9 Lambda Chain as a working example.
Get sequence from crystal structure
Using the PDB ID: 3U36 I get the light chain sequence in FASTA format:
>PG9_crystal_structure_3U36_light_chain
QSALTQPASVSGSPGQSITISCQGTSNDVGGYESVSWYQQHPGKAPKVVIY
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DVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEGDYYCKSLTSTRRRVFG
TGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWK
ADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGS
TVEKTVAPTECS
Truncate to variable regions
The variable region starts with QSAL and usually ends with GQP. This is a bit sub-
jective, but for this purpose, it does not really matter since I will prepend a sequence:
>PG9_light_chain_variable
QSALTQPASVSGSPGQSITISCQGTSNDVGGYESVSWYQQHPGKAPKVVIY
DVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEGDYYCKSLTSTRRRVFG
TGTKLTVLGQP
Reverse translate
Use a reverse translator to get nucleotide sequences. They will be optimized so it
does not matter.
>PG9_LC_variable_nucleotide
CAGAGCGCGCTGACCCAGCCGGCGAGCGTGAGCGGCAGCCCGGGCCAGAG
CATTACCATTAGCTGCCAGGGCACCAGCAACGATGTGGGCGGCTATGAAA
GCGTGAGCTGGTATCAGCAGCATCCGGGCAAAGCGCCGAAAGTGGTGATT
TATGATGTGAGCAAACGCCCGAGCGGCGTGAGCAACCGCTTTAGCGGCAG
CAAAAGCGGCAACACCGCGAGCCTGACCATTAGCGGCCTGCAGGCGGAAG
ATGAAGGCGATTATTATTGCAAAAGCCTGACCAGCACCCGCCGCCGCGTG
TTTGGCACCGGCACCAAACTGACCGTGCTGGGCCAGCCG
Prepend 5′ region
I will prepend a 5′ SalI site (GTCGAC) and a nucleotide (T) to keep it in frame.
>PG9_with_SalI
(GTCGAC)TCAGAGCGCGCTGACCCAGCCGGCGAGCGTGAGCGGCAGCCCGG
GCCAGAGCATTACCATTAGCTGCCAGGGCACCAGCAACGATGTGGGCGGCTA
TGAAAGCGTGAGCTGGTATCAGCAGCATCCGGGCAAAGCGCCGAAAGTGGTG
ATTTATGATGTGAGCAAACGCCCGAGCGGCGTGAGCAACCGCTTTAGCGGCA
GCAAAAGCGGCAACACCGCGAGCCTGACCATTAGCGGCCTGCAGGCGGAAGA
TGAAGGCGATTATTATTGCAAAAGCCTGACCAGCACCCGCCGCCGCGTGTTT
GGCACCGGCACCAAACTGACCGTGCTGGGCCAGCCG
Append 3′ region
I then add on an NotI restriction site (GCGGCCGC) with no additional nucleotides.
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>PG9_with_SalI/NotI
(GTCGAC)TCAGAGCGCGCTGACCCAGCCGGCGAGCGTGAGCGGCAGCCCGG
GCCAGAGCATTACCATTAGCTGCCAGGGCACCAGCAACGATGTGGGCGGCTA
TGAAAGCGTGAGCTGGTATCAGCAGCATCCGGGCAAAGCGCCGAAAGTGGTG
ATTTATGATGTGAGCAAACGCCCGAGCGGCGTGAGCAACCGCTTTAGCGGCA
GCAAAAGCGGCAACACCGCGAGCCTGACCATTAGCGGCCTGCAGGCGGAAGA
TGAAGGCGATTATTATTGCAAAAGCCTGACCAGCACCCGCCGCCGCGTGTTT
GGCACCGGCACCAAACTGACCGTGCTGGGCCAGCCG(GCGGCCGC)
Order Product
This will be the final product ordered. It is very important that you optimize for
mammalian systems. You also do not want to avoid the following sites. HindIII,
EcoRI, SalI and NotI. In addition, do not remove the SalI or NotI sites that I just
added.
VI.4.1.3 Designing a swappable vector
This was how I made a PG9 vector with a swappable HCDR3 sequence. This particular
protocol will work for any HCDR3 sequence that uses JH6, but can be extended to any
family based on the constant FR4 sequences that are needed.
Get HCDR3 and FR4 Sequence
First thing I need is the HCDR3 sequence. Considering that I’m only adding restric-
tion sites (RE) to the HCDR3 region, I will only consider that in the example. Make
sure this sequence contains CVR (the beginning of the HCDR3) and TVSS (the end
of FR4). Those two regions will contain the restriction sites when we are done. Then
we can back translate.
TTTTGcgtacgCGAAGCGGGCGGCCCGGATTATCGCAAC
--F--C--V--R--E--A--G--G--P--D--Y--R--N
GGCTATAACTATTATGATTTTTATGATGGCTATTATAAC
--G--Y--N--Y--Y--D--F--Y--D--G--Y--Y--N
TATCATTATATGGATGTGTGGGGCAAAGGCACCACCGTG
--Y--H--Y--M--D--V--W--G--K--G--T--T--V
ACCGTctcgagC
--T--V--S--S
The restriction sites are shown in lower case in the HCDR3 region. BsIWI (cgtacg)
and XhoI (ctcgag). It is just a matter of swapping that sequence into the Lonza vector.
Order Construct
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cccgggTCTTGGGCTCAGCGCCTGGTGGAAAGCGGCGGCGG
CGTGGTGCAGCCGGGCAGCAGCCTGCGCCTGAGCTGCGCGG
CGAGCGGCTTTGATTTTAGCCGCCAGGGCATGCATTGGGTG
CGCCAGGCGCCGGGCCAGGGCCTGGAATGGGTGGCGTTTAT
TAAATATGATGGCAGCGAAAAATATCATGCGGATAGCGTGT
GGGGCCGCCTGAGCATTAGCCGCGATAACAGCAAAGATACC
CTGTATCTGCAGATGAACAGCCTGCGCGTGGAAGATACCGC
GACCTATTTTTGcgtacgCGATAGCGGCGGCTATGATTTTT
GGAGCGGCTATGAAGTGGGCCTGGAAAACCGCGAAAACTAT
TATTATTATGGCATGGATGTGTGGGGCAAAGGCACCACCGT
GACCGTctcgagCGCCGGTACCAAgggccc
This construct can be ordered now with the two restriction sites flanking the HCDR3
sequence. When you order the construct, keep the restriction sites BsiWI, XhoI,
ApaI, HindIII, EcoRI, and SmaI. You can clone this full vector with SmaI and ApaI.
VI.4.1.4 Synthesizing HCDR3 Only
If the swappable construct with BsiWI and ApaI sites was made, you can simply order
the HCDR3 sequence using the technique below. Here is a random 30-length sequence
(2383:160514).
Get HCDR3 Sequence of Interest
We will use the IMGT definition of HCDR3.
>2383:160514
CAREGGDYDFWSGYYRGYSGYGEEHYYYMDVW
Cut Off Leading Sequences
This is usually a CVR or CAR. We don’t need these sequences since the vector has
them.
>2383:160514_truncated
EGGDYDFWSGYYRGYSGYGEEHYYYMDVW
Reverse Translate
>2383:160514_nucleotide
GAAGGCGGCGATTATGATTTTTGGAGCGGCTATTATCGCGGCTAT
AGCGGCTATGGCGAAGAACATTATTATTATATGGATGTGTGG
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Add 5′ Sequence
Adding the BsiWI sequence (CGTACG) along with a nucleotide (C) to keep it in
frame.
>2383:160514_nucleotide
CGTACGCGAAGGCGGCGATTATGATTTTTGGAGCGGCTATTATCG
CGGCTATAGCGGCTATGGCGAAGAACATTATTATTATATGGATGT
GTGGGGCAAA
Add 3′ Sequence
Have to add a lot of the constant region (GGCAAAGGCACCACCGTGACCGT)
since it takes a several nucleotides to get to the 5’ XhoI site (CTCGAG).
>2383:160514_BsiWI_XhoI
CGTACGCGAAGGCGGCGATTATGATTTTTGGAGCGGCTATTATCG
CGGCTATAGCGGCTATGGCGAAGAACATTATTATTATATGGATGT
GTGGGGCAAAGGCACCACCGTGACCGTCTCGAG
Order Sequence
When you order the construct, keep the restriction sites BsiWI, XhoI, ApaI, HindIII,
EcoRI, and SmaI. You can clone this into the HCDR3 swap vector with BsiWI and
XhoI.
VI.4.1.5 Restriction Map - All Constructs
For reference figure VI.1.
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Figure VI.2
VI.4.2 HIV Neutralization Assay
Pre-Neutralization Assay - -Make growth media (GM) also called TZMbl media. (DMEM
high glucose 1X + 110 mg/mL NaPy + 1X Pen-Strep + 10% heat inactivated FBS) -If you
are testing serum, make sure to heat inactivate.
Neutralization Assay Using the plate setup found in figure VI.2.
1. Put 150 µL of GM into column 1
2. Put 100 µL of GM in the rest of the wells
3. Start with 7.5 µg/mL of antibody in the Dil 1 wells (Row H, columns 3-12). This
well be serially diluted 3 fold and give a final dilution of 0.2 µg/mL.
4. Fill columns 3-12, row H up to 150 µL with GM.
5. Use 50 µL of these rows to do a serial 3-fold dilution. Discard the 50 µL out of the
remaining row to ensure only 100 µL s left.
6. Make a viral stock of 10 mL of GM to 4,000 TCID50. Viruses must be titered (see
other protocols).
7. Add 50 µL of 4,000 TCID50 stock to columns 2-12. Make sure you don’t do column
1.
8. Cover and incubate at 37◦C for 2 hours.
While the virus and antibodies are incubating. Prepare the cells to be added at the end of
the incubation.
1. TZMbl cells should be confluent. Decant cell culture and wash with sterile PBS.
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2. Add 5 mL of tryspin (to T150 flask) and incubate for 1 minute.
3. Aspirate trypsin and incubate cells at 37◦C for five minutes.
4. Add 10 mL of growth media and count cells.
5. Dilute cells in 500 mL falcon tube to 100,000/mL with GM.
6. If it has been two hours, take the virus and antibody plates and add 100 µLof cells to
every well.
7. Cover and incubate at 37◦C for 48-72 hours.
8. From every well aspirate 100 µL of GM.
9. Add 100 µL of Bright Glow Luciferase reagent and mix 10 times in every row.
Incubate for 2 minutes.
10. Record the luminescence on a luminometer.
11. If background is low enough, IC50 can be recorded from automatic PRISM non-linear
regression analysis after log2 transformation of concentrations.
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VI.5 Appendix V - Computational Standard Operating Procedures
Here I will detail the computational procedures including running ROSETTA and analyzing
data with scripts that are often available in the Meiler Lab Scripts repository or available
on request. Also a lot of the procedures are detailed in IPython Notebooks and will also be
available on request. Using ROSETTA version 80616601370
VI.5.1 Chapter I - Multi-State Design
Here I will detail how I ran ROSETTADESIGN for multi-state design and how I analyzed
the results. I will use the simplified example of IGHV5-51 which only contains three sets
of molecular structures. There is a great protocol capture for complex procedures attached
to the publication by Andrew Leaver-Fay showing how to design for and design against in
multiple states (Leaver-Fay et al., 2011a).
VI.5.1.1 Running ROSETTA Multi-State Design
To run multi-state design, I have to prepare several files.
• Entity File - A file containing the amount of residue positions to design as well as
instructions for the packer to behave on all proteins. For example, we could want the
packer only to use certain rotamers around the interface. This could be handled with
the entity file.
• Correlation File - Tells how residues correlate to each other. For example, residue 1
on protein A should be designed with residue 2 on protein B etc.
• Secondary Residue File - This is a residue file as defined in the documentation, but
will only instruct the packer to operate on each protein individually. Every state must
have it’s own secondary residue file.
• Fitness File - A master file containing all other files as well as instructions for the
fitness function.
Clean PDB - First, I can download all three protein PDBs with the clean_pdb.py script.
Clean PDB supports the following syntax:
c l e a n _ p d b . py <PDB_ID> <CHAINS>
We only want the asymmetric unit in the crystal structure, so it helps to manually inspect the
PDBs. We need one heavy chain, one light chain, and one antigen. I just go to www.pdb.org
to find these chain codes.
c l e a n _ p d b . py 2B1A HLP
c l e a n _ p d b . py 2XWT ABC
c l e a n _ p d b . py 3HMX HLB
Although not absolutely necessary, it makes it easier to label the chain IDs the same. All
heavy chains have H, light L, and antigen A. There is a change PDB id script which allows
us to quickly rename chain IDs. The script takes the following syntax.
s e t _ p d b _ c h a i n _ i d . py o l d _ c h a i n new_chain i n p u t o u t p u t
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I have looked through all the PDBs and figured out which names to change.
s e t _ p d b _ c h a i n _ i d . py P A 2B1A_HLP . pdb 2B1A_HLA . pdb
s e t _ p d b _ c h a i n _ i d . py A H 2XWT_ABC. pdb 2XWT_HBC. pdb
s e t _ p d b _ c h a i n _ i d . py B L 2XWT_HBC. pdb 2XWT_HLC. pdb
s e t _ p d b _ c h a i n _ i d . py C A 2XWT_HLC. pdb 2XWT_HLA. pdb
s e t _ p d b _ c h a i n _ i d . py B A 3HMX_HLB. pdb 3HMX_HLA. pdb
To ensure the starting structures use the correct numbering scheme, we should renumber
each chain starting with 1.
renumber_pdb . py 2B1A_HLA . pdb 2 B1A_clean . pdb
renumber_pdb . py 2XWT_HLA. pdb 2XWT_clean . pdb
renumber_pdb . py 3HMX_HLA. pdb 3HMX_clean . pdb
Now we can remove all temporary files. Only *_clean.pdb files should remain in the work-
ing directory. The next thing to do would be to find all positions with at least one difference.
This requires manual inspection of the alignment. For the VH gene, there are 29 amino acid
positions that will differ from germline in at least one position. These positions will be con-
sidered. Given that data, we can construct the entity residue file.
#The e n t i t y . r e s f i l e
#The number o f p o s i t i o n s t o d e s i g n
29
# Allow a l l amino a c i d s
# e x c e p t c y s t i n e and use r o t a m e r l i b r a r i e s 1 ,2
# and a r o m a t i c 2 .
ALLAAxc EX 1 EX 2 EX ARO 2
# b e g i n n i n g o f r e s i d u e f i l e
s t a r t
The correlation file maps how each residue in each file should map to the others. There will
be three correlation files, one for each state. Since each amino acid lines up, i.e. design
position 5 in 2B1A with position 5 in 3HMX, all the correlation files will be the same. Here
is an example of one correlation file.
# a l l . c o r r
#The f i r s t column i s t h e e n t i t y ,
# t h e second i s t h e r e s i d u e number f o r t h a t s t a t e ,
# t h e l a s t i s t h e c h a i n .
1 5 H
2 14 H
3 16 H
4 23 H
5 24 H
6 29 H
7 30 H
8 31 H
9 32 H
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10 34 H
11 40 H
12 46 H
13 48 H
14 51 H
15 52 H
16 54 H
17 58 H
18 65 H
19 70 H
20 72 H
21 74 H
22 76 H
23 77 H
24 80 H
25 84 H
26 88 H
27 93 H
28 97 H
29 98 H
A secondary residue file is also needed in case any extra packing tasks are needed to be
supplied to each state. For example, we could tell one PDB state to design around the in-
terface in single state design mode while everything in the correlation file designs together.
I do not require extra design tasks for this protocol so all secondary residue files will be the
same. For example,
# t e l l s t h e p a c k e r t o use a l l n a t u r a l s i d e
# c h a i n c o n f i g u r a t i o n s f o r e v e r y t h i n g
# t h a t i s n o t b e i n g d e s i g n e d .
NATRO
# t h e i n p u t s i d e c h a i n i s a l l o w e d
u s e _ i n p u t _ s c
# s t a r t t h e r e s i d u e f i l e
s t a r t
We next to create a states file that has the PDB, correlation file and secondary resfile names
in it. Name them 2B1A.states, 2XWT.states, and 3HMX.states. They should look like the
following when opened.
#2B1A . s t a t e s
i n p u t _ f i l e s / 2 B1A_clean . pdb i n p u t _ f i l e s / a l l . c o r r i n p u t _ f i l e s /
a l l . 2 r e s
#2XWT. s t a t e s
i n p u t _ f i l e s / 2 XWT_clean . pdb i n p u t _ f i l e s / a l l . c o r r i n p u t _ f i l e s /
a l l . 2 r e s
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#3HMX. s t a t e s
i n p u t _ f i l e s / 3HMX. pdb i n p u t _ f i l e s / a l l . c o r r i n p u t _ f i l e s / a l l . 2
r e s
Lastly, a fitness file needs to be constructed to tell multi-state how to design. I call this file
fitness.daf and it points to the locations of the states files.
# i n i t i a l i z e t h e s t a t e s and what t h e s t a t e s f i l e name i s
STATE_VECTOR A i n p u t _ f i l e s / 2B1A . s t a t e s
STATE_VECTOR B i n p u t _ f i l e s / 2XWT. s t a t e s
STATE_VECTOR C i n p u t _ f i l e s / 3HMX. s t a t e s
# t e l l d e s i g n t o min imize en e r g y f o r each s t a t e
SCALAR_EXPRESSION best_A = vmin ( A )
SCALAR_EXPRESSION bes t_B = vmin ( B )
SCALAR_EXPRESSION bes t_C = vmin ( C )
# F i t n e s s − d e s i g n t o min imize a l l e n e r g i e s s i m u l t a n e o u s l y
FITNESS bes t_A + bes t_B + bes t_C
Running Rosetta Multi-State Design
The ROSETTAexecutable is called mpi_msd.mpi.<operatingsystem>. It must be compiled
in MPI mode as each state is assigned to a processor. The command line takes the following
options.
• entity_resfile - The resfile that we created in the input portion
• fitness_file - The fitness file we created in the input portion
• ms::pop_size - How many sequences to keep in memory at once (100 is a good
number)
• ms::generation - How many sequence generations should MSD go through see (Leaver-
Fay et al., 2011a) to find see how the genetic algorithm selects sequences.
• ms::numresults - How many results to output. Will output top N sequences.
• ms:fraction_by_recombination - How often should a cross-over even take place be-
tween sequences in the population. Read (Leaver-Fay et al., 2011a) for details on the
genetic algorithm.
• database - The location of the database.
I construct an options file with all those options (options.txt) that looks like this.
− e n t i t y _ r e s f i l e e n t i t y . r e s f i l e
− f i t n e s s _ f i l e f i t n e s s . d a f
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−ms
−p o p _ s i z e 100
−g e n e r a t i o n s 435
−n u m r e s u l t s 100
−f r a c t i o n _ b y _ r e c o m b i n a t i o n . 0 4
−d a t a b a s e my / r o s e t t a / d a t a b a s e / l o c a t i o n /
Finally we can run ROSETTA using the following command after starting MPD.
mpd && mpiexec −n 4 / my / r o s e t t a / l o c a t i o n / mpi_msd . mpi .
m y o p e r a t i n g s y s t e m \
@ i n p u t _ f i l e s / o p t i o n s . t x t
Warning!
ROSETTA may complain about some of the comments (anything starting with #) not
being recognized, if so, just remove it from the file
The output will be 300 files, 100 for each of the states. We only need to analyze 100 files
considering that the designed entities will be the same for all three files. For example,
position 5 will be the same for 2B1A, 2XWT, and 3HMX.
VI.5.1.2 Analysis of MSD Output
I wrote a design analysis script called design_analysis.py which encompasses many design
analysis tools. I will only go into the functionality that is necessary to use, but you can read
the options file for more use.
d e s i g n _ a n a l y s i s . py −−h e l p
>> Design A n a l y s i s
___________________________________________________________
Th i s s c r i p t i s i n t e n t e d t o encompass t h e e n t i r e
f u n c t i o n a l i t y
o f d e s i g n a n a l y s i s . E v e r y t h i n g you c o u l d want t o do wi th
d e s i g n
i s c a l l e d upon i n t h i s s c r i p t . The most b a s i c f u n c t i o n a l i t y
i s
t o p a s s a l i s t o f pdbs o r g e t a p o s i t i o n m a t r i x o f
o c c u r e n c e s
c o u n t o f j u s t one l i n e .
The f u n c t i o n a l i t y e x t e n d s from t h e r e by g i v i n g b i t s c o r e s ,
changes i n energy , g i v i n g p o s i t i o n s p e c i f i c s c o r i n g m a t r i c e s
o f your des ign , g i v i n g a c u s t o m i z a b l e s e q u e n c e logo . Th i s i s
a
c o m b i n a t i o n o f many s c r i p t s and c l a s s e s .
o p t i o n a l a rgumen t s :
−h , −−h e l p show t h i s h e l p message and e x i t
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N e c e s s a r y :
PDB f i l e s have t o be i n c l u d e d
* . pdb The PDB f i l e s t o be a n a l y z e d
Recommended O p t i o n s :
Wi l l g i v e you a more c o m p l e t e a n a l y s i s based on a r e s f i l e
,
and a n a t i v e pdb t o compare i t t o .
−−n a t i v e _ p d b N_PDB , −p N_PDB
The n a t i v e pdb f i l e t o compare a g a i n s t
−−c o r r c o r r . c o r r , −c c o r r . c o r r
Get t h e r e s u l t s d e f i n e d on ly i n t h e c o r r f i l e
−−r e s r e s f i l e . r e s f i l e , −r r e s f i l e . r e s f i l e
Get t h e r e s u l t s d e f i n e d on ly i n t h e r e s i d u e f i l e
Outpu t O p t i o n s : P l e a s e r e a d c a r e f u l l y :
These a rgumen t s change f i l e name , which f i l e i s p r i n t e d ,
which i s o u t p u t t o a d i c t i o n a r y , and g i v e v e r b o s e p r i n t i n g
−−ve rbose , −v
e v e r y t h i n g p r i n t e d t o a f i l e w i l l a l s o be shown
on t h e s c r e e n
−−p r e f i x PREFIX , −P PREFIX
The p r e f i x f o r what a l l t h e o u t p u t f i l e s w i l l be
−− s c o r e _ f i l e s O_FILES [ O_FILES . . . ] , −s
What do you want o u t p u t t o a f i l e ?
Can l i s t a s a s p a c e s e p e r a t e d ( eg −s n d nd ) :
a − f u l l a n a l y s i s d i c t
d − g i v e a n a l y s i s o f j u s t d e s i g n e d r e s i d u e s
n − j u s t t h e n a t i v e r e s i d u e s s c o r e s a r e shown
nd − j u s t t h e n a t i v e r e s i d u e s o f t h e r e s i d u e s d e s i g n e d
D e f a u l t s t o f u l l a n a l y s i s d i c t i o n a r y
−b Should t h e o u t p u t be i n b i t s c o r e ?
D e f a u l t s t o o c c u r e n c e s i n s t e a d o f b i t s c o r e
−S I f you s p e c i f y a n a t i v e f i l e and a d e s i g n f i l e ,
i t w i l l g i v e you an o u t p u t o f t h e s t a t s o f t h e
d e s i g n
R o s e t t a Energy A n a l y s i s :
O p t i o n s f o r o u t p u t i n g o p t i o n s a b o u t en e r gy s c o r e s ,
t h e d i c t i o n a r i e s a n a l y z e d depend on what you asked
f o r u s i n g t h e −s o u t p u t o p t i o n s f l a g
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−−r o s e t t a , − t Th i s o p t i o n w i l l o u t p u t a . c sv f i l e o f t h e
model , cha in , r e s i d u e , r e s i d u e number , and r o s e t t a s c o r e s .
B i t Sco re O p t i o n s :
o p t i o n s f o r b i t s c o r e m e t r i c f o r each d e s i g n e d r e s i d u e
−n do you want t h e b i t s c o r e s t o be
n o r m a l i z e d by t h e shannon e n t r o p y
Sequence Logos O p t i o n s :
These o p t i o n s h a n d l e t h e s e q u e n c e l o g o s t h a t can be o u t p u t
from t h e d e s i g n a n a l y s i s s c r i p t , and u s e s t h e a p i o f
weblogo
t o do so .
−−seq , − l
Turn on Sequence Logos f o r a l l t h e d i c t i o n a r i e s
you s u p p l y g i v e n i n an . eps f i l e
−−p a t h LOGO\ _PATH , −l p LOGO\ _PATH
What i s t h e p a t h t o weblogo s o f t w a r e ?
D e f a u l t s t o m e i l e r l a b e n v i r o m e n t
−−f o r m a t { eps , jpg , png , p n g _ p r i n t , pdf , jpeg , svg , l o g o d a t a }
What f o r m a t do you want t h e s e q u e n c e logo i n ?
−−u n i t s { b i t s , n a t s , k t , kJ / mol , k c a l / mol , p r o b a b i l i t y }
What do you want t h e u n i t s o f t h e s e q u e n c e
logo t o be i n ? D e f a u l t s t o b i t s .
−−s t a c k s S_STACKS
How many s e q u e n c e s p e r l i n e i n t h e logo , d e f a u l t = a f t e r
f o r t y l e t t e r s i t w i l l go t o a new l i n e .
−−s t a c k _ w i d t h S_STACK_WIDTH
How wide i s each s t a c k i n t h e logo . Value o f 25 i s
u s e f u l
f o r x−a x i s l a b e l s >3 c h a r a c t e r s and 30
f o r l a b e l s a s ’ sequence_numbers ’ .
−− t i t l e S_TITLE
The t i t l e o f your s e q u e n c e logo
−−x _ l a b e l S_X_AXIS
What do you want t h e x a x i s t i t l e d ?
−−y _ a x i s _ h e i g h t S_Y_HEIGHT
How high do you want t h e Y a x i s ,
c u r r e n t l y 4 . 3 2 which i s t h e maximum
a c h e i v a b l e s c o r e i n a u n b i a s e d d e s i g n
−−y _ l a b e l S_Y_LABEL
T i t l e o f Y−Axis
−−e r r o r _ b a r s S_Y_ERROR
158
Do you want e r r o r b a r s t u r n e d on , YES /NO?
−− f i n e _ p r i n t S_FINE
Fine P r i n t
−−c o l o r _ s c h e m e
{ auto , c h e m i s t r y , cha rge , c l a s s i c ,
h y d r o p h o b i c i t y , monochrome }
The c o l o r scheme of t h e s e q u e n c e logo .
D e f a u l t s t o C l a s s i c
−− l a b e l s { sequence , numbers , sequence_numbers }
The x−a x i s l a b e l s can e i t h e r t a k e on t h e
n a t i v e r e s i d u e s s e q u e n c e g i v e n wi th a n a t i v e
pdb f i l e o r t h e number ing o f t h e pdb r e s i d u e .
−−debug
Get t h e f u l l command l i n e o f what was p u t i n t o weblo
It’s obvious that this analysis can do a lot, but I will stick with the basics. First a new input
that is completely germline. We can do this with the packer. There is a script called make_-
res.py which will make a residue file from a FASTA file. I use this to take the germline
sequence and thread it over one of my inputs. Then that input can be used as our template.
>IGHV5-51*01
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEW
MGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMY
YCAR
Then we can use the make_res.py script.
make_res . py IGHV5−51. f a s t a > IGHV5−51. r e s
This residue file can then be used to mutate one of our templates back to germline.
/ p a t h / t o / r o s e t t a / b i n / f i x b b . d e f a u l t . < o p e r a t i n g _ s y s t e m > \
−s 2 B1A_clean . pdb
− r e s f i l e IGHV5−51. r e s −d a t a b a s e / p a t h / t o / d a t a b a s e \
−o 2 B1A_germline . pdb
Now we can use the analysis script from the analysis directory
. . / a n a l y s i s / d e s i g n _ a n a l y s i s −p . . / i n p u t _ f i l e s / 2 B1A_clean . pdb
\
−S −b −s nd −c . . / i n p u t _ f i l e s / a l l . c o r r
. . / o u t p u t _ f i l e s / msd_outpu t_ *A* . pdb
>>
# s c o r e vs matu re
T o t a l B i t Sco re o f Des ign ===> 28 .4534
T o t a l Shannon En t ropy of Des ign ===> 115 .9577
Normal ized B i t Score f o r d e s i g n ===> 0 .2454
and
159
. . / s c r i p t s / d e s i g n _ a n a l y s i s −p a n a l y s i s / 2 B1A_germline . pdb \
−S −b −s nd −c . . / i n p u t _ f i l e s / a l l . c o r r
. . / o u t p u t _ f i l e s / msd_outpu t_ *A* . pdb
>>
# s c o r e vs matu re
T o t a l B i t Sco re o f Des ign ===> 50 .2318
T o t a l Shannon En t ropy of Des ign ===> 115 .9577
Normal ized B i t Score f o r d e s i g n ===> 0 .4337
This gives a design score towards 0.35 for the germline sequence and 0.24 for the mature
sequence. Everything can be repeated this exact way. For single state design you can keep
the fitness file exactly the same, but remove the other states.
# i n i t i a l i z e t h e s t a t e s and what t h e s t a t e s f i l e name i s
STATE_VECTOR A 2 b1a . s t a t e s
STATE_VECTOR B 2xwt . s t a t e s
STATE_VECTOR C 3hmx . s t a t e s
# t e l l d e s i g n t o min imize en e r g y f o r each s t a t e
SCALAR_EXPRESSION best_A = vmin ( A )
SCALAR_EXPRESSION bes t_B = vmin ( B )
SCALAR_EXPRESSION bes t_C = vmin ( C )
# F i t n e s s − d e s i g n t o min imize a l l e n e r g i e s s i m u l t a n e o u s l y
FITNESS bes t_A
And run the exact same procedures.
VI.5.2 Chapter II - Database and Design
This section accompanies chapter II. I will go over uploading the sequences to a database,
selecting the correct sequences, threading, and finally design.
VI.5.2.1 Sequence Analysis
The methods section detailed how I actually sequence the amplicons from 64 healthy
donors, but processing them takes quite a bit of computational work. The VANTAGE
core at Vanderbilt returns the sequencing runs as two paired end reads in FASTQ format.
They must be “stiched” together to make one read. For example, I have provided 100,000
sequences from the forward and reverse reads to be stiched togher from donor 54. I use
a stitching algorithm called “pandaseq” to process theses (Bartram et al., 2011). These
commands are incredibly simple to run but do require that you first download and install
“pandaseq” (https://github.com/neufeld/pandaseq).
/ u s r / l o c a l / b i n / pandaseq −f i n p u t _ f i l e s / u n s t i c h e d /
u n s t i c h e d _ f o r w a r d . f a s t q −r i n p u t _ f i l e s / u n s t i c h e d _ r e v e r s e .
f a s t q −T 23 > s t i c h e d / s t i c h e d . f a s t a
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Pandaseq will automatically output to the fasta format which is convenient for the next
step. Please note, that although I have put 100,000 sequences to be stitched together, pan-
daseq will only find about a quarter of them. That is because I have not provided the entire
file. However, I have provided 100,000 sequences in the directory “input_files/stiched/s-
tiched.fasta” to be used in subsequent steps. To analyze the sequences I use PyIg, my own
sequence aligner against Ig mAbs that’s based on IgBLAST (Ye et al., 2013). I will proba-
bly publish this soon when it is more stable. For human IgG’s it works incredibly simple to
use. For the full source code email jwillis0720@gmail.com, as it’s currently unpublished
at the moment.
. / PyIg
usage : i g b l a s t [−h ] −q query . f a s t a [−d DB_PATH] [− i
INTERNAL_DATA]
[−a AUX_PATH] [−y { Ig , TCR, custom } ] [−or {
human , mouse } ]
[−nV NUM_V] [−nD NUM_D] [−nJ NUM_J] [−dgm
D_GENE_MATCHES]
[− s { imgt , k a b a t } ] [−x EXECUTABLE] [−o OUT] [−
t TMP]
[−e E_VALUE] [−w WORD_SIZE] [−pm
PENALTY_MISMATCH]
[−nP NUM_PROCS] [−op OUTPUT_OPTIONS] [−z ] [−c
] [− j ]
o p t i o n a l a rgumen t s :
−h , −−h e l p show t h i s h e l p message and e x i t
N e c e s s a r y :
These have t o be i n c l u d e d
−q query . f a s t a , −−que ry que ry . f a s t a
The f a s t a f i l e t o be i n p u t i n t o
i g B l a s t
D a t a b a s e P a t h s :
−d DB_PATH, −−db_pa th DB_PATH
The d a t a b a s e p a t h t o t h e g e r m l i n e
r e p e r t o i r e
− i INTERNAL_DATA, −− i n t e r n a l _ d a t a INTERNAL_DATA
The d a t a b a s e p a t h t o i n t e r n a l d a t a
r e p e r t o i r e
−a AUX_PATH, −−a u x _ p a t h AUX_PATH
The a u x i l a r i a y p a t h t h a t c o n t a i n s
t h e f rame o r i g i n s o f t h e g e r m l i n e
genes f o r each r e p e r t o i r e .
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Helps p roduce t r a n s l a t i o n and o t h e r
m e t r i c s
I g B l a s t S p r e c i f i c :
I g B l a s t S p e c i f i c O p t i o n s wi th a D e f a u l t
−y { Ig , TCR, custom } , −−t y p e { Ig , TCR, custom }
I s t h i s an IG or TCR r e c o m b i n a t i o n
−or {human , mouse } , −−organ i sm {human , mouse}
The organ i sm r e p e o r t i r e t o b l a s t
a g a i n s t
−nV NUM_V, −−num_v NUM_V
How many V−genes t o match ?
−nD NUM_D, −−num_d NUM_D
How many D−genes t o match ?
−nJ NUM_J, −−num_j NUM_J
How many J−genes t o match ?
−dgm D_GENE_MATCHES, −−d_gene_matches D_GENE_MATCHES
How many n u c l o d t i e d s i n t h e D−gene
must match t o c a l l i t a h i t
−s { imgt , k a b a t } , −−domain { imgt , k a b a t }
Which c l a s s i f i c a t i o n sys tem do you
want
G e n e r a l S e t t i n g s :
−x EXECUTABLE, −−e x e c u t a b l e EXECUTABLE
The l o c a t i o n o f t h e e x e c u t a b l e ,
d e f a u l t i s / u s r / b i n / i g b l a s t n
−o OUT, −−o u t OUT o u t p u t f i l e p r e f i x
− t TMP, −−tmp TMP t e m p o r a r y d i r e c t o r y t o s t o r e f i l e s
i n .
D e f a u l t s t o . / tmp
−e E_VALUE, −−e _ v a l u e E_VALUE
Real v a l u e f o r e x c p e c t a t i o n v a l u e
t h r e s h o l d i n b l a s t .
Pu t i n s c i e n t i f i c n o t a t i o n
−w WORD_SIZE , −−w o r d _ s i z e WORD_SIZE
Word s i z e f o r w o r d f i n d e r a l g o r i t h m
−pm PENALTY_MISMATCH, −−p e n a l t y _ m i s m a t c h PENALTY_MISMATCH
P e n a l t y f o r n u c l e o t i d e mismatch
−nP NUM_PROCS, −−num_procs NUM_PROCS
How many do you want t o s p l i t t h e
j o b a c r o s s , d e f a u l t i s t h e number
o f p r o c e s s o r s
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O u t p u t t i n g O p t i o n s :
−op OUTPUT_OPTIONS , −−o u t p u t _ o p t i o n s OUTPUT_OPTIONS
Open t h i s f i l e and comment o u t
o p t i o n s you don ’ t want i n your
f i n a l f i l e .
The f i r s t column i s t h e name of t h e
o p t i o n .
The second column i s used by t h e
p a r s e r and s h o u l d n o t be changed .
−z , −−z i p Zip up a l l o u t p u t f i l e s
−c , −−c o n c a t e n a t e Turn o f f a u t o m a t i c c o n c a t e n a t i o n and
d e l e t i o n o f t e m p o r a r y f i l e s .
F i l e s a r e s p l i t up a t t h e b e g i n n i n g
t o run a c r o s s m u l t i p l e p r o c e s s o r s
−j , −−j s o n Use t h e JSON o u t p u t o p t i o n t h a t w i l l
f o r m a t t h e t e x t d r i v e n i g b l a s t o u t p u t t o a j s o n
document .
D e f a u l t s t o CSV
I’ll keep it simple for the protocol capture, but want to show how robust PyIg can be.
Assume you are in the PyIg directory under PyIg/src/
py thon2 . 7 e x e c u t i o n . py −q i n p u t _ f i l e s / s t i c h e d / s t i c h e d . f a s t a
−d d a t a f i l e s / d a t a b a s e / − i i n t e r n a l _ d a t a / −a d a t a f i l e s /
o p t i o n a l _ f i l e / −y Ig −or human −nV 1 −nD 1 −nJ 1 −s imgt
−o p r o t o c o l _ c a p t u r e −nP 23 −z − j
Each option is listed in the help. Make sure you see which each one does. For instance
-nP needs to be carefully considered since it is the number or processors it will be run on.
The output to this command line is a protocol_capture.json.gz file that will be uploaded to
a Mongo database. One entry (with default output settings) looks like this.
{
" _ i d " : " donor_10_1000 " ,
" raw_seq " : "TGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGT
ATATTACTGTGCGAAAGAACTATATGATAGTAGTGGTTATTACTACTTCC
TGCCTTCTTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACG
GTCACCGTCTCCTCAGGTAAG" ,
" d _ r e g i o n " : "TATGATAGTAGTGGTTATTACTAC" ,
" c d r 3 _ a a " : "AKELYDSSGYYYFLPSYYYYGMDV" ,
" fw4_aa " : "WGQGTTVTVSSGK" ,
" f u l l _ s e q _ a a " : "AKELYDSSGYYYFLPSYYYYGMDVWGQGTTVTVSSGK" ,
" cd r3 " : "GCGAAAGAACTATATGATAGTAGTGGTTATTACTACTTCCTGCCTT
CTTACTACTACTACGGTATGGACGTCTG" ,
" top_d " : "IGHD3−22*01" ,
" v _ d _ j u n c t i o n " : "ACTA" ,
" t o p _ j " : " IGHJ6 *02" ,
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" c d r 3 _ a a _ l e n g t h " : 24 ,
" fw4 " : "TGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGGTAAG" ,
" d _ j _ j u n c t i o n " : "TTCCTGCCTTCT" ,
" d _ o r _ j _ j u n c t i o n " : " " ,
" top_v " : "IGHV1−69*06" ,
" f u l l _ s e q " : "GCGAAAGAACTATATGATAGTAGTGGTTATTACTACTTCCT
GCCTTCTTACTACTACTACGGTATGGACGTCTGTGGGGCCAAGGGACCACGGTCA
CCGTCTCCTCAGGTAAG" ,
" f u l l _ s e q _ a a " : "AKELYDSSGYYYFLPSYYYYGMDVWGQGTTVTVSSGK" ,
" d _ b i t _ s c o r e " : 4 8 . 3 ,
" d _ e v a l u e " : "3 e−10 .0" ,
" d _ a l i g n m e n t _ l e n g t h " : 24 ,
" d_que ry_seq " : "TATGATAGTAGTGGTTATTACTAC" ,
" d _ s u b j e c t _ s e q " : "TATGATAGTAGTGGTTATTACTAC" ,
" d _ p e r c e n t _ i d e n t i t y " : 100 ,
" d _ p e r c e n t _ p o s i t i v e s " : 100 ,
" d_mismatches " : 0 ,
" d _ p o s i t i v e s " : 24 ,
" d _ i d e n t i c a l " : 24 ,
" d _ s u b j e c t _ l e n g t h " : 31 ,
" d _ s c o r e " : 24 ,
}
To download and install mongo, consult the manual
(http://docs.mongodb.org/manual/installation/). This installation will also include all the
tools that making uploading files very easy. The output of PyIg should be “protocol_-
capture.json.gz”. We can then upload this json file to mongodb using the “mongoimport”
application.
Note:
I assume you have an instance of MongoDB running. Please consult the documentation to
run an instance of MongoDB. For example,
mongod −−db pa th mongo_db_data / &
gu nz ip a n a l y z e d _ f i l e s / p r o t o c o l _ c a p t u r e . j s o n . gz &&
mongoimport −d t e s t _ d a t a b a s e −c p r o t o c o l _ c a p t u r e −− f i l e
a n a l y z e d _ f i l e s / p r o t o c o l _ c a p t u r e . j s o n
Here I have made a database called test_database and a collection called protocol_capture.
First thing to do is remove redundancies within mongo. To do that, I can make a simple
index on the “Input Sequence” key and drop duplicates.
mongo t e s t _ d a t a b a s e
>db . p r o t o c o l _ c a p t u r e . e n s u r e I n d e x ( { ’ cdr3_aa ’ : 1 } , { un iqu e : t r u e ,
dropDups : t r u e } )
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The next thing I want to do is remove non-productive sequences. PyIg outputs a productive
field, using mongo, I can tell the database to drop any “document” that contains a stop
codon in the HCDR3.
>db . p r o t o c o l _ c a p t u r e . remove ( { " p r o d u c t i v e _ c d r 3 " : " F a l s e " } )
For ROSETTA, I want only the thirty length HCDR3s. I can use “mongoexport” for this
query along with an ‘awk’ statement to get out the 30 length fasta files.
mongoexpor t −d t e s t _ d a t a b a s e −c p r o t o c o l _ c a p t u r e −q ’{"
c d r 3 _ a a _ l e n g t h " : 3 0 } ’ −−csv − f i e l d s " _ i d " , " c d r 3 _ a a " | awk
−F " , " ’{ gsub ( " \ " " , " " , $1 ) ; gsub ( " \ " " , " " , $2 ) ; p r i n t ( " >" $1 " \
n " $2 ) } ’ > 30 _ l e n g t h . f a s t a
This fasta file will be used in the remainder of the protocol. I will not go over all the
different types of analysis I can do with this database for the purpose of this protocol.
VI.5.2.2 PSSM Heuristics
Using the fasta file “analysed_files/30_length.fasta” generated in the previous section, a
quick script written in python to get random 2,000 sequences is shown below.
# ! / u s r / b i n / env py thon
from Bio import SeqIO
import random
import s y s
h a n d l e = open ( s y s . a rgv [ 1 ] )
r e c o r d s = SeqIO . p a r s e ( hand le , " f a s t a " )
d i c t i o n a r y = {}
f o r seq in r e c o r d s :
d i c t i o n a r y [ seq . i d ] = s t r ( seq . seq )
r a n d o m _ d i c t = random . sample ( d i c t i o n a r y . i t e m s ( ) , 2 0 0 0 )
wi th open ( s y s . a rgv [ 2 ] , ’w’ ) a s f :
f o r seq in r a n d o m _ d i c t :
f . w r i t e ( ‘ ‘ >{0} \ n { 1 } \ n ’ ’ . f o r m a t ( seq [ 0 ] , seq [ 1 ] ) )
And use it to get 2000 random sequences:
. / ge t_2000_random . py . . / a n a l y z e d _ s e q u e n c e s / 3 0 _ l e n g t h . f a s t a
2000 _random . f a s t a
Using ROSETTADESIGN, I will generate 2,000 resfiles that tell the packer to mutate the
HCDR3 into each of the entries in the fasta file. To do this, there is a script available from
the Meiler lab called “fasta_to_resfile.py” which will generate the resfiles necessary.
f a s t a _ i n t o _ r e s . py 2000 _random . f a s t a 95 126 H 0
The rest of the protocol uses ROSETTASCRIPTS to do the design. For ROSETTASCRIPTS,
you need an xml file, options file, and command line. The xml file is a scripting file that
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tells ROSETTA specific set of instructions (here I will name it threading.xml). The first step
is relatively simple only doing a design and a full-atom minimization (called relax).
< d o c k _ d e s i g n >
<SCOREFXNS>
< /SCOREFXNS>
<FILTERS>
< / FILTERS>
<TASKOPERATIONS>
< I n i t i a l i z e F r o m C o m m a n d l i n e name= i f c l / >
< R e a d R e s f i l e name= r r f i l e n a m e=%%r e s f i l e s%% / >
< / TASKOPERATIONS>
<MOVERS>
<PackRotamersMover name= pr t a s k _ o p e r a t i o n s = i f c l , r r /
>
< F a s t R e l a x name= f r t a s k _ o p e r a t i o n s = i f c l / >
< /MOVERS>
<APPLY_TO_POSE>
< / APPLY_TO_POSE>
<PROTOCOLS>
<Add mover_name= pr / >
<Add mover_name= f r / >
< /PROTOCOLS>
< / d o c k _ d e s i g n >
The only caveat here is that we specify the resfile as a variable so the protocol does not
have to be hard-coded. The command line will specify each resfile to give to the job. First,
an option file must be produced as a simple text file.
−o u t
−pdb_gz
−p a r s e r
−p r o t o c o l i n p u t _ f i l e / t h r e a d i n g . xml
−s i n p u t _ f i l e s / i n p u t _ p g 9 _ n o _ a n t i g e n . pdb
−n s t r u c t 100
Lastly the command line which will include the resfile as an option (named run.csh).
# ! / b i n / csh
s e t r e s = $1
s e t o u t = ‘ basename $ r e s . r e s f i l e ‘
mpiexec −n 101 my / r o s e t t a / p a t h r o s e t t a _ s c r i p t s . m p i s t a t i c .
l i n u x g c c r e l e a s e @opt ions . t x t −o u t : p r e f i x $ou t −p a r s e r :
s c r i p t _ v a r s r e s f i l e s =${ r e s } > o u t . l o g
And to run the command I simply use an awk script to generate all the commands.
l s * r e s f i l e | awk ’{ sys tem ( " run . csh " $1 ) } ’
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Note: This should be run on a computer cluster as 100 processors are needed in the
above protocol
The next step is to run the output PDB files and generate a position-specific scoring matrix.
This is easily accomplished with the “create_pssm_from_threading.py” script that is also
found in the Meiler lab scripts repository. A simple command to generate a PSSM.
. / c r e a t e _ p s s m _ f r o m _ t h r e a d i n g . py −g −r r e s f i l e s PG9 . r e s f i l e −
n 2000 . p3sm * . pdbs
The output .p3sm can now be used to predict the top N sequences from the 30_length.fasta
generated earlier in the protocol.
. / c r e a t e _ p s s m _ f r o m _ t h r e a d i n g . py −r r e s f i l e s / PG9 . r e s f i l e −s −
p 2000 . p3sm a n a l y s i s _ f i l e s / 3 0 _ l e n g t h . f a s t a
This generates a file called “scored_fasta.output”. I use awk and some other gnu commands
to get the top 1000 scored fasta files.
s o r t −nk 3 s c o r e d _ f a s t a . o u t p u t | head −n 1000 | awk ’{ p r i n t
( " >" $1 " \ n " $2 ) } ’ > top1000 . f a s t a
Finally, I can make all the resfiles using the same command as before.
f a s t a _ i n t o _ r e s . py top1000 . f a s t a 95 125 H 0
For the full design protocol using these sequences and resfiles. See the next section on PG9
redesign (subsection VI.5.3).
VI.5.3 Chapter III - PG9 Design
This protocol capture will detail the how to use ROSETTADESIGN to predict mutations that
enhance specificity. This accompanies the manuscript Willis et al. Nature Med. (submit-
ted). It assumes that you have a ROSETTA license from www.rosettacommons.org.
VI.5.3.1 Preparing the input files
Using PG9/CAP45 complex, I have prepared a ROSETTA compatible file called PG9_in-
put.pdb. This has spcecial identifiers for the glycans that ROSETTA’s database can under-
stand. To create your own glycan input, an excellent protocol capture is provided in an
accompanying manuscript by Doug Renfrew (Renfrew et al., 2012).
The design protocol used runs through the following steps.
• Favor native residue - gives bonuses to sequences which match PG9wt
• Design/minimize/dock iteratively
• Constrain movements so glycans retain input position
• Relax the energy of the structure
• Re-dock
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• Score binding energy and structure energy
For this redesign we need several input files. The XML script, options file, residue file, and
constraint file. The most complex of which, the XML file, informs Rosettaof our protocol.
Use the following .xml file which is found under:
/input_files/threading_design.xml
XML-File
< dock_des ign >
<SCOREFXNS>
R e d e f i n e s c o r i n g f u n c t i o n t o t a k e i n c o n s t r a i n t s
< s c o r e w t s w e i g h t s = t a l a r i s 2 0 1 3 >
<Reweight s c o r e t y p e = a t o m _ p a i r _ c o n s t r a i n t we i gh t =0 .5 / >
</ s c o r e w t s >
< s c o r e d o c k w t s w e i g h t s = t a l a r i s 2 0 1 3 p a t c h = docking >
<Reweight s c o r e t y p e = a t o m _ p a i r _ c o n s t r a i n t we i gh t =0 .5 / >
</ s co re do c kw t s >
</SCOREFXNS>
<FILTERS>
DDG f i l t e r f o r d e s i g n − w i l l d e s i g n u n t i l t h i s
i s s a t i s f i e d
<Ddg name=ddg chain_num =2 ,3 r e p a c k =1
s c o r e f x n = t a l a r i s 2 0 1 3 t h r e s h o l d =−20/>
When dock ing or min imiz ing , won ’ t v i o l a t e atom−p a i r s
d e f i n e d
i n g l y c a n _ c o n s t r a i n t s
<ScoreType name= a t o m _ p a i r _ c o n s t r a i n t s c o r e f x n =
s c o r e d o c k w t s
s c o r e _ t y p e = a t o m _ p a i r _ c o n s t r a i n t t h r e s h o l d =100/ >
</FILTERS>
<TASKOPERATIONS>
< I n i t i a l i z e F r o m C o m m a n d l i n e name= i f c l / >
< R e a d R e s f i l e name= r r d f i l e n a m e =" i n p u t _ f i l e s /
n o r m a l _ d e s i g n . r e s f i l e " / >
</TASKOPERATIONS>
<MOVERS>
Gives bonuses f o r i n p u t r e s i d u e s
< F a v o r S e q u e n c e P r o f i l e name= f s p s c a l i n g =" prob "
we ig h t =1 .5 u s e _ c u r r e n t =1
m a t r i x ="IDENTITY" s c o r e f x n s = s c o r e w t s / >
P e n a l i z e s movements t o f a r away from
g l y c a n
< C o n s t r a i n t S e t M o v e r name= p a i r _ o n
c s t _ f i l e =" i n p u t _ f i l e s / g l y c a n _ c o n s t r a i n t s . c s t " / >
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Design s t e p t h a t t a k e s i n r e s i d u e f i l e
<PackRotamersMover name= p r _ d e s i g n s c o r e f x n = s c o r e w t s
t a s k _ o p e r a t i o n s = r r d , i f c l / >
Turns o f p e n a l i z a t i o n
< C o n s t r a i n t S e t M o v e r name= p a i r _ o f f c s t _ f i l e =none / >
Docks p r o t e i n a round i n t e r f a c e
<Docking name=dock s c o r e _ h i g h = s c o r e d o c k w t s f u l l a t o m =1
l o c a l _ r e f i n e =1 jumps =1 t a s k _ o p e r a t i o n s = i f c l / >
Docks u n t i l MonteCar lo c r i t e r i o n i s s a t i s f i e d
< Gene r i cMon teCar lo name=gmc_dock mover_name=dock
f i l t e r _ n a m e = a t o m _ p a i r _ c o n s t r a i n t d r i f t =0/ >
Minimize e n e r gy o f p r o t e i n
<MinMover name=min s c o r e f x n = s c o r e w t s c h i =1 bb=1 jump =1/ >
Design p r o t o c o l
< P a r s e d P r o t o c o l name= des ign_pp >
<Add mover= p a i r _ o n / >
<Add mover= p r _ d e s i g n / >
<Add mover=gmc_dock / >
<Add mover=min / >
<Add mover= p a i r _ o f f / >
</ P a r s e d P r o t o c o l >
Run d e s i g n u n t i l b i n d i n g e n e r gy t h r e s h o l d i s s a t i s f i e d
< Gene r i cMon teCar lo name=gmc_design
mover_name= d e s i g n _ p p f i l t e r _ n a m e =ddg d r i f t = F a l s e / >
Relax p r o t e i n
< F a s t R e l a x name= f r s c o r e f x n = s c o r e w t s
t a s k _ o p e r a t i o n s = i f c l / >
Get DDG
<ddG name= per_ddg chain_name ="H, L"
s c o r e f x n = t a l a r i s 2 0 1 3 p e r _ r e s i d u e _ d d g =1/ >
</MOVERS>
<APPLY_TO_POSE>
</APPLY_TO_POSE>
<PROTOCOLS>
Ordered l i s t o f s t e p s f o r t h e p r o t o c o l
each d e f i n e d i n t h e mover o r f i l t e r d e f i n i t i o n s
<Add mover_name= f s p / >
<Add mover_name=gmc_design / >
<Add mover_name= p a i r _ o n / >
<Add mover_name= f r / >
<Add mover_name= p a i r _ o f f / >
<Add mover_name= per_ddg / >
<Add f i l t e r _ n a m e =ddg / >
</PROTOCOLS>
</ dock_des ign >
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The behavior of the these instructions is described fully in (Fleishman et al., 2011a). They
are divided up into a set of movers, filters and task of operations. All of the movers
and filters along with their options are explained at the Rosetta Commons users guide
(https://www.rosettacommons.org/docs/latest/RosettaScripts.html).
Options-File
The options file are passed to the application. Defines output and input options as well as
other options which can’t be defined in the XML file.
−s i n p u t _ f i l e s / p g 9 _ i n p u t . pdb # i n p u t PDB
−n s t r u c t 200 # t h e number o f o u t p u t models t o g e n e r a t e
−dock ing
−sc_min # min imize s i d e c h a i n s d u r i n g dock ing
−p a r s e r : p r o t o c o l i n p u t _ f i l e s / t h r e a d i n g _ d e s i g n . xml
−ex1 # Rotmer l i b r a r y 1
−ex2 # Rotmer l i b r a r y 2
−e x1 a r o # Rotamer a r o m a t i c 1
−o u t : p a t h
−pdb . / o u t p u t _ f i l e s /
−s c o r e / dev / n u l l /
Each option is explained with a # comment.
Residue File
The residue file tells the packer how to design the protein. The first line lets the packer
use the side chains of the input PDB even if they are not in the rotamer libraries. The
“NATAA” lines tells the packer to use input amino acid for everything not defined un-
der start. In other words it will only design everything under start. The first column
is the residue number, the second is the chain, and “ALLAA” tells the packer to use all
amino acid identities at this position. For complete documentation of the resfile, visit
https://www.rosettacommons.org/docs/latest/resfiles.html
USE_INPUT_SC
NATAA
EX 1 EX 2
s t a r t
96 H ALLAA
97 H ALLAA
98 H ALLAA
99 H ALLAA
100 H ALLAA
101 H ALLAA
102 H ALLAA
103 H ALLAA
104 H ALLAA
105 H ALLAA
106 H ALLAA
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107 H ALLAA
108 H ALLAA
109 H ALLAA
110 H ALLAA
111 H ALLAA
112 H ALLAA
113 H ALLAA
114 H ALLAA
115 H ALLAA
116 H ALLAA
117 H ALLAA
118 H ALLAA
119 H ALLAA
120 H ALLAA
121 H ALLAA
122 H ALLAA
123 H ALLAA
124 H ALLAA
125 H ALLAA
Constraint File
The constraint file ensures that the glycan’s are involved in binding. The torsional angles
of the glycan can cause major structural perturbations.
AtomPair NZ 57H O31 29G BOUNDED 0 2 . 5 7 0 . 2 0 . 5 t a g
AtomPair O 54H O32 29G BOUNDED 0 3 . 7 1 0 . 2 0 . 5 t a g
AtomPair O 55H OS1 29G BOUNDED 0 4 . 3 0 0 . 2 0 . 5 t a g
AtomPair ND2 73H O71 29G BOUNDED 0 4 . 0 2 0 . 2 0 . 5 t a g
AtomPair OD1 52L O81 33G BOUNDED 0 . 5 2 . 9 6 0 . 2 0 . 5 t a g
AtomPair OG 34L O81 33G BOUNDED 0 . 5 2 . 2 8 0 . 2 0 . 5 t a g
AtomPair NH2 30H NZ 41G BOUNDED 0 4 . 8 5 0 . 2 0 . 5 t a g
The constrain file syntax is found in the documentation -
(https://www.rosettacommons.org/docs/latest/constraint-file.html). Briefly, I define two atoms
with the input crystal structure distances. If these are violated, then there is an energetic
penalty.
VI.5.3.2 Running ROSETTA
To run ROSETTA, I use an application called ROSETTASCRIPTS (Fleishman et al., 2011a).
Since we have defined all the input files. Running the application only requires passing the
options file.
my / p a t h / t o / r o s e t t a / s o u r c e / b i n / r o s e t t a _ s c r i p t s .
m y o p e r a t i n g s y s t e m @ i n p u t _ f i l e s / t h r e a d i n g . t x t −d a t a b a s e my
/ p a t h / t o / r o s e t t a / d a t a b a s e /
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This protocol generates 200 models each taking approximately 1 hour to complete. It is
best to run this protocol on a computational cluster with each node producing a separate
model (-nstruct 1). All files are output into a directory output models/. There are 200 pre-
generated models for analysis.
VI.5.3.3 Analyzing Models
There are three scripts in the /analysis folder that are used to analyze the mutations. Score_-
vs_rmsd full.py will give all the models energies as well as how much they deviated from
the original structure. Get_per_ddg.py will give all of the binding energies decomposed by
residues. Scores_decomposed_by_resfile.py will decompose the energies of HCDR3 loop.
They are each run using the following.
s c o r e _ v s _ r m s d _ f u l l . py âL´Šm âL´Šn . . / i n p u t _ f i l e s / p g 9 _ i n p u t . pdb
âL´Šo s_v_rmsd âL´Šr . . / i n p u t _ f i l e s / n o r m a l _ d e s i g n . r e s f i l e
. . / o u t p u t _ f i l e s / âL´U˚ . pdb
g e t _ p e r _ d d g . py −m −o per_ddg . . / o u t p u t _ f i l e s / âL´U˚ . pdb
s c o r e s _ d e c o m p o s e _ b y _ r e s f i l e . py âL´Šm âL´Šo HCDR3 âL´Šr . . /
i n p u t _ f i l e s / n o r m a l _ d e s i g n . r e s
These will yield a series of data files that can be uploaded to a database or in a spreadsheet
viewer. The complex queries I used to check energies between wt and mutations are beyond
the scope of a protocol capture. But you can contact jwillis0720@gmail.com if you need
additional guidance.
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